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Abstract 
Antimicrobial Peptide Gene Expression in Human Tonsils 
The human palatine tonsils play important roles in host immunity and provide a barrier against 
invading pathogens. However the Gram-positive bacterium, Streptococcus pyogenes often 
penetrates their defences. This results in tonsillitis, in which sufferers present with swollen and 
painful palatine tonsils. Moreover tonsillitis is often recurrent. Despite tonsillitis being 
relatively common, the immunological factors that allow this infection to perpetuate remain 
obscure. Antimicrobial peptides (AMPs), expressed at epithelial and mucosal surfaces, provide 
a first-line of defence against potential pathogens. Moreover these molecules have also been 
reported to be up-regulated in response to infection, but their roles in the defence of the human 
palatine tonsils are not well known. Studies were therefore initiated to test the hypothesis that a 
defect in the innate immune response involving host AMPs, is a cause or contributory factor to 
recurrent acute tonsillitis (RAT). 
The first study investigated and compared AMP gene expression patterns in palatine tonsils 
excised from patients undergoing tonsillectomy for RAT to those of control subjects whose 
tonsils were excised for conditions such as snoring. To date it was the largest investigation of 
its kind using over ninety tonsils. The levels of LL-37, HBDl, HBD2 and LEAP-2 AMP 
mRNA expression were quantified by real-time PCR assays developed and optimised 
specifically for the study. The data indicated that all AMP genes examined were expressed, that 
considerable variability was detected between the AMP expression levels of individual subjects 
but that the mean AMP expression levels between the RAT and control groups were not 
statistically different. This study was conducted using tonsils excised from RAT patients at the 
time of their surgery when they were probably not suffering a streptococcal infection. To 
answer the question of whether RAT was due to a failure of the AMPs to up-regulate in 
response to infection, an in vitro model was adopted. 
HaCaT cells were used as the in vitro model of the tonsil and challenged with Group A 
streptococci. Quantitative real-time expression data suggested that in response to the S. 
pyogenes MI serotype, HBDI gene expression was decreased, suggesting that GAS down 
regulates the expression of this gene, whereas that of LEAP-2 was induced. The results of 
challenge experiments performed using pili-defective mutants also suggested that such changes 
in the host response occurred in the absence of streptococcal binding. The HaCaT cells were 
not however derived from tonsil. Thus to further investigate streptococcal-tonsil AMP 
responses an ex vivo tonsil model was used. 
Following challenge of the control (non-RAT) and RAT tonsil sections with S. pyogenes, a 
statistically significant increase in HBDI gene expression and a decrease in HBD2 gene 
expression were observed in the control (non-RAT) tonsils. No comparable statistically 
significant changes were identified in the RAT tonsils. These data therefore highlighted 
differences between the AMP expression profiles of the control (non-RAT) and RAT tonsils in 
response to a S. pyogenes M I challenge. Although speculative these data indicate that the RAT 
tonsils were less able to respond to the S. pyogenes challenge, which in part may help to explain 
the susceptibility of RAT patients to infection. 
I 
Abbreviations 
A260 
AMP 
ANOVA 
ATCC 
AU 
BLAST 
bp 
BSA 
cDNA 
CE 
Cfu 
Cfu/ml 
CL 
COREC 
Cp 
CRAMP 
Cys 
D3 
DRS 
FCS 
FITC 
FRET 
G 
GAPDH 
GFP 
GRAB 
GTC 
h 
H 
HAMP 
HBD 
HBDI 
HBD2 
HBD3 
hCAP18 
HD5 
HEp-2 
HNP 
Ig 
IL 
IPTG 
Kb 
Kr-Ar 
Absorbance 260 
Antimicrobial Peptide 
Analysis of Variance 
American Type Culture Collection 
Arbitrary unit 
Basic Local Alignment Search Tool 
Base pair 
Bovine Serum Albumin 
Copy or Complementary Deoxyribronucleic Acid 
Control Epithelium 
Colony forming unit 
Colony forming unit per millilitre 
Control Lymphoid 
Central Office for Ethics Committees 
Crossing Point 
Cathelicidin related AMP 
Cysteine 
1,25 dihydroxyvitamin-D3 
Distantly Related to SIC 
Foetal Calf Serum 
Fluorescein isothiocyanate 
Fluorescence Resonance Energy Transfer 
Group A Streptococcus 
Glyceraldehyde-3-Phosphate Dehydrogenase 
Green Fluorescent Protein 
G- related a-2 macroglobulin binding protein 
Guanidium isothiocyanate 
Hour 
Hour 
Hepcidin Antimicrobial Peptide 
Human beta-defensin 
Human beta-defensins 1 
Human beta-defensin 2 
Human beta-defensin 3 
Human cathelicidin protein 
Human alpha defensin 5 
Human Epithelial Cell Line-2 
Human Neutrophil Peptide 
Immunoglobulin 
Interleukin 
Isopropyl ~-D-l Thioglactopyranoside 
Kilobase 
Krypton-Argon 
II 
LB 
LC480 
LEAP-I 
LEAP-2 
LPS 
LREC 
LTA 
LUX 
M 
MAPK 
MHC 
Min 
MMLV 
mRNA 
NCBI 
NOD 
OD 
OSA 
PAMPs 
PBS 
PCR 
PFA 
PMA 
RAT 
RE 
RL 
rRNA 
RT 
RT-PCR 
s 
S. pyogenes 
Sbjct 
SD 
SEM 
SIC 
SIgA 
SLO 
SLPI 
SLS 
Spe 
SpeB 
Strep 
THB 
THYB 
TLR 
Tm 
TNF-a 
TRITC 
Luria- Bertani 
LightCycler 480 
Liver Expressed Antimicrobial Peptide 1 
Liver Expressed Antimicrobial Peptide 2 
Lipopolysaccharide 
Local and Regional Ethics Committee 
Lipoteichoic Acid 
Light Upon Extension 
Size Marker 
Mitogen Activated Kinase 
Major Histocompatability Complex 
Minutes 
Murine Molony Leukemia Virus 
Messenger RNA 
National Centre For Biotechnology Information 
Nucleotide binding oligomerisation domain 
Optical density 
Obstructive Sleep Aponea 
Pathogen Associated Molecular Patterns 
Phosphate Buffered Saline 
Polymerase Chain Reaction 
Paraformaldehyde 
Phorbol I2-myristate I3-acetate 
Recurrent Acute Tonsillitis 
RAT Epithelium 
RAT Lymphoid 
Ribosomal Ribonucleic Acid 
Reverse Transcription 
Reverse transcription-Polymerase Chain Reaction 
Seconds 
Streptococcus pyogenes 
Subject 
Standard Deviation 
Standard Error or the Mean 
Streptococcal Inhibitor of Complement 
Secretory Immunoglobulin 
Streptolysis 0 
Secretory Leukocyte Protease Inhibitor 
Streptolysin S 
Streptococcal Pyrogenic Endotoxin 
Streptococcal Cysteine Protease Endotoxin B 
Streptococci 
Todd Hewitt Broth 
Todd Hewitt Yeast Broth 
Toll-Like Receptor 
Melting Temperature 
Tumour Necrosis Factor Alpha 
Tetramethyl rhodamine isothiocyanate 
III 
UPL 
UV 
VDRE 
Vitamin D3 
VITD3 
a-helical 
Universal Probe Library 
Ultra Violet 
Vitamin D Response Element 
1,25 dihydroxyvitamin-D3 
1, 25-dihydroxyvitamin-D3 
Alpha-helical 
IV 
Table of Contents 
llllstract ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 1 
illJre"iatiolls ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 11 
Chapter 1 ..................................................................................................................... 1 
Introduction ................................................................................................................ 1 
1.1 Tonsils .................................................................................................................... 2 
1.1.1 Morphology and function ........................................... " ................... 2 
1.2 Tonsillitis ................................................................................................................ 4 
1.2.1 Clinical implications ........................................................................................... 4 
1.2.2 Pathology ............................................................................................................. 5 
1.3 Group A Streptococcus .......................................................................................... 6 
1.3.1 Introduction ......................................................................................................... 6 
, 
1.3.2 Identification and classification .......................................................................... 6 
1.3.3 Pathogenesis ........................................................................................................ 7 
1.3.4 Adhesion ........................................................................................................... 12 
104 Host Defense Peptides: Cationic Antimicrobial peptides .................................... 14 
1.4.1 Introduction ....................................................................................................... 14 
1.4.2 Cathelicidins ...................................................................................................... 16 
1.4.3 Defensins ........................................................................................................... 19 
1.4.4 Hepcidin ............................................................................................................ 21 
104.5 Liver Expressed Antimicrobial Peptide-2 (LEAP-2) ........................................ 23 
1.4.6 AMP killing mechanisms .................................................................................. 23 
1.4.6i Barrel-stave mechanism ............................................................................... 25 
1.4.6ii Carpet mechanism ....................................................................................... 25 
lA.6iii The 'toroidal-pore' mechanism ................................................................. 26 
104.7 Regulation of AMP gene expression ................................................................. 27 
V 
1.4.8 AMPs and tonsil ................................................................................................ 29 
1.4.9 Antimicrobial peptide- streptococcal interactions ............................................ 30 
1.4.9i AMPs prevent GAS infections in the skin ................................................... 30 
1.4.9ii Interaction with Streptococcus salivarius ................................................... 31 
1.4.10 GAS defence mechanisms ............................................................................... 32 
1.4.10i SpeB - cysteine proteinase ........................................................................ 32 
1.4.10ii SIC and DRS ....................................................................... 33 
1.5 Hypothesis and Aims ........................................................................................... 34 
Chapter 2 ................................................................................................................... 35 
Materials and Methods ......................................... _ ................................................. 35 
2.1 Bacterial Strains ................................................................................................... 36 
2.1.1 Streptococcus pyogenes strains ......................................................................... 36 
2.1.1 i Culture and maintenance of Streptococcus pyogenes strains ........................... 36 
2.1.2 Escherichia coli ................................................................................................. 37 
2.2 Hwnan Tonsils ..................................................................................................... 38 
2.2.1 Ethical approval ................................................................................................ 38 
2.2.2 Tonsil collection and processing ....................................................................... 38 
2.2.3 Tonsil: ex vivo model ........................................................................................ 39 
2.2.4 Streptococcus pyogenes bacterial challenge experiments ................................. 39 
2.2.5 Binding controls .................................................................................. : ............. 40 
2.2.6 Immunohistochemical analysis oftonsil.. .......................................... .40 
2.3 HaCaT Cells ......................................................................................................... 41 
2.3.1 Origin ................................................................................................................ 41 
2.3.2 Tissue culture .................................................................................................... 41 
2.3.3 HaCaT: cell challenge assays ............................................................................ 41 
2.3.4 HaCaT cells: bacterial challenge ....................................................................... 42 
2.3.5 HaCaT cell binding controls ............................................................................. 42 
VI 
2.4 HEp-2 Cells .......................................................................................................... 43 
2.4.1 Origin ................................................................................................................ 43 
2.4.2 Tissue culture .................................................................................................... 43 
2.4.3 Immunocytochemical staining ofHEp-2 cells .................................................. 43 
2.5 RNA Extraction .................................................................................................... 45 
2.5.1 RNA extraction from tonsil. .............................................................................. 45 
2.5.2 RNA extraction from cultured cells .................................................................. 46 
2.5.3 Analyses of RNA concentration and purity ...................................................... 46 
2.5.4 RNA integrity: denaturing RNA gel electrophoresis ....................................... .47 
2.6 Reverse Transcription - Polymerase Chain Reaction (RT-PCR) ......................... 48 
• 
2.6.1 DNase treatment of RNA .................................................................................. 48 
2.6.2 Reverse transcription (RT) ................................................................................ 48 
2.6.3 End-point polymerase chain reaction ................................................................ 49 
2.6.4 Agarose gel electrophoresis .............................................................................. 50 
2.6.5 Densitometry ..................................................................................................... 50 
2.7 DNA Cloning ....................................................................................................... 51 
2.7.1 DNA extraction ................................................................................................. 51 
2.7.2 PCR product clean-up and purification ............................................................. 51 
2.7.3 DNA cloning in pGEM-T-Easy Vector System ................................................ 52 
2.7.4 DNA ligation ..................................................................................................... 52 
2.7.5 Transformation and plasmid selection .............................................................. 53 
2.7.6 Plasmid preparation ............................................................................. : ............. 53 
2.7.7 DNA restriction enzyme analyses ..................................................................... 54 
2.7.8 DNA sequencing ............................................................................................... 55 
2.8 Real-Time PCR .................................................................................................... 55 
2.9 Statistical Analyses .............................................................................................. 55 
VII 
Chapter 3 ................................................................................................................... 56 
Optimisation and Development of Quantitative Real-Time peR Assays for the 
Antimicrobial Peptides LL-37, HDDt, HDD2, HDD3, Hepcidin and LEAP-2 and 
the Housekeeping Gene GAPDH ............................................................................ 56 
3.1 Introduction .......................................................................................................... 57 
3.1.1 Real-time PCR .................................................................................................. 57 
3.2 Assay development: an overview ......................................................................... 58 
3.2.1 Template preparation ........................................................................................ 58 
3.2.2 Selection of detection format ............................................................................ 58 
3.2.2i Non-specific detection formats ........................................................................ 59 
3.2.2ii Specific detection formats ............................................................................... 59 
3.2.3 Primer design and confirmation of specificity .................................................. 60 
3.2.4 Optimisation of PCR conditions ....................................................................... 61 
3.2.5 Standard curve formation .................................................................................. 61 
3.3 Optimisation of template preparation ................................................................... 62 
3.3.1 Storage and handling of human tonsil samples ................................................. 62 
3.3.li Comparison oftissue storage in liquid nitrogen vs. chemical preservative ..... 62 
3.3 . Iii Homogenisation of human tonsil samples .................................. '" ................. 62 
3.3.1iia Manual homogenisation ................................................................................ 63 
3.3.1iib Rotor-stator homogeniser .............................................................................. 63 
3.3.2 Extraction of RNA from human tonsil homogenates ........................................ 63 
3.3.3 Extraction of RNA from HEp-2 cells ................................................................ 64 
3.3.4 Extraction of RNA from HaCaT cells ............................................................... 65 
3.3.5 Optimisation of reverse transcription ................................................................ 65 
3.4 LL-37 Assay Development .................................................................................. 67 
3.4.1 Oligonucleotide primer and probe design ......................................................... 67 
3.4.2 Test of probe based assays for LL-37 mRNA quantification ........................... 67 
3.4.3 Assay development with Primer Set 3 and Sybr-green detection on the 
LightCycler 1.2 .......................................................................................................... 68 
3.4.4 Assay development with Primer Set 4 .............................................................. 69 
VIII 
3.4.4i peR optimisation ............................................................................................. 69 
3.4.4ii Development of concentration standards and standard curve optimisation .... 70 
3.4.4iii Reliability and reproducibility determination of coefficient of variation ...... 71 
3.4.5 Summary ofLL-37 assay .................................................................................. 71 
3.5 HBDI Assay Development .................................................................................. 72 
3.5.1 Oligonucleotide primer design .......................................................................... 72 
3.5.2 Primer Set 1 ....................................................................................................... 72 
3.5.3 Primer Set 2 ....................................................................................................... 73 
3.5.4 Summary ofHBDl assay .................................................................................. 74 
3.6 HBD2 assay development .................................................................................... 75 
3.6.1 Oligonucleotide primer and probe design ......................................................... 75 
3.6.2 Assay optimisation ............................................................................................ 75 
3.6.3 Summary ofHBD2 assay .................................................................................. 76 
3.7 HBD3 Assay Development .................................................................................. 77 
3.7.1 Oligonucleotide primer and probe design ......................................................... 77 
3.7.2 Assay optimisation ............................................................................................ 77 
3.8 Hepcidin Assay Development .............................................................................. 78 
3.8.1 Oligonucleotide primer and probe design ......................................................... 78 
3.8.2 Assay development ........................................................................................... 78 
3.9 LEAP-2 Assay Development ................................................................................ 80 
3.9.1 Oligonucleotide primer and probe design ......................................................... 80 
3.9.2 Assay optimisation ............................................................................................ 80 
3.9.3 Summary ofLEAP-2 assay ............................................................................... 81 
3.10 GAPDH Assay Development ............................................................................. 82 
3.10.1 Oligonucleotide primer and probe design ....................................................... 82 
3.10.2 Assay optimisation .......................................................................................... 82 
3.10.3 Summary of GAPDH assay ............................................................................ 83 
IX 
3. Figures and Tables ................................................................................................. 84 
Chapter 4 ................................................................................................................. 129 
In Vivo Expression of Antimicrobial Peptides in Human Tonsils from Control 
and Tonsillitis Patients ........................................................................................... 129 
4.1 Introduction ........................................................................................................ 130 
4.2 Subjects and Methods ........................................................................................ 131 
4.2i Sample size ....................................................................................................... 131 
4.3 Quantitative Real-Time PCR Analysis of Control Subjects and Tonsillitis Patients, 
Measuring LL-37, HBD1, HBD2 and LEAP-2 mRNA ........................................... 132 
4.3.1 All patient samples .......................................................................................... 133 
4.3.li Epithelial and lymphoid tissues ..................................................................... 133 
4.3.2 Tissue type and disease state ........................................................................... 135 
4.3.3 Gender ............................................................................................................. 136 
4.3.3i Intra-gender differences ................................................................................. 136 
4.3.3ii Gender and disease state ............................................................................... 137 
4.3.4 Age of subject and disease state ...................................................................... 137 
4.3.4i Expression of AMP mRNA in children <10 ye¥s old .................................. 137 
4.3.4ii Expression of AMP mRNA in under 45s compared to the over 45s ............ 139 
4.3.5 Previous or current infections ......................................................................... 140 
4.4 Discussion .......................................................................................................... 141 
4. Figures ................................................................................................................. 147 
x 
Chapter 5 ................................................................................................................. 161 
Antimicrobial Peptide Gene Expression in an In Vitro HaCaT Cell Model .•••• 161 
5.1 Introduction ........................................................................................................ 162 
5.1.1 Aims of investigation ...................................................................................... 163 
5.2 Consideration ofHEp-2 Cells as a Tonsil Model .............................................. 163 
5.3 Consideration of HaC aT Cells as a Model for Tonsil.. ...................................... 164 
5.4 AMP Gene Expression in HaCaT cells Treated with Bacterial and Environmental 
Agents ...................................................................................................................... 165 
5.4.1 End-point PCR studies of AMP mRNA expression in HaCaT cells treated with 
Bacterial and Environmental Components ............................................................... 165 
5.4.2 Treatment of HaCaT cells with 1,25 dihydroxyvitamin-D3 ........................... 166 
5.5 Expression of Antimicrobial Peptides Genes in HaCaT Cells Infected with S. 
pyogenes Ml Serotype ............................................................................................. 167 
5.5.1 HaCaT infection at 2, 4 and 6 hours: Semi-quantitative studies ..................... 168 
5.5.2 HaCaT infection at 2,4 and 6 hours: Quantitative studies (Real-time PCR) .169 
5.5.3 HaCaT infection at 5, 15,30,60 minutes of infection with S. pyogenes ........ 172 
5.5.4 Quantitative studies at 5, 15, 30 and 60 minutes of infection ......................... 172 
5.6 Gene Expression in HaCaT Cells Infected with S. pyogenes (Wild-type), M2 
Serotype .................................................................................................................... 173 
5.6.2 Quantitative studies ......................................................................................... 174 
5.7 Gene Expression of HBDI and LEAP-2 in HaCaT Cells Infected with Pili-
defective S. pyogenes Ml Serotype ......................................................................... 175 
5.7.1 Expression patterns ......................................................................................... 175 
5.8 Discussion .......................................................................................................... 177 
XI 
5. Figures .................................................................................................................. 186 
Chapter 6 ................................................................................................................. 208 
Antimicrobial Peptide Gene Expression in Human Palatine Tonsils •.••••.••••••••• 208 
6.1 Introduction ........................................................................................................ 209 
6.2 AMP Gene Expression in Human Tonsils Treated With Environmental Agents 
.................................................................................................................................. 210 
6.3 Expression of Antimicrobial Peptide Genes in Human Tonsils Infected with S. 
pyogenes Ml Serotype (Wild-type) ......................................................................... 212 
6.3.1 Real-time PCRdata: all samples ..................................................................... 213 
6.4 Expression of Antimicrobial Peptide Genes in Human Tonsils Infected with S. 
pyogenes M2 Serotype (Wild-type) ......................................................................... 215 
6.4.1 Real-time PCR- all samples ............................................................................ 216 
6.5 Discussion .......................................................................................................... 218 
6. Figures .................................................................................................................. 223 
Cha pter 7 ................................................................................................................. 248 
Final Discussion ...................................................................................................... 248 
Chapter 8 ................................................................................................................. 254 
References ............................................................................................................... 254 
APPENDIX A: Information sheet for participants 
APPENDIX B: Consent form 
APPENDIX C: Short questionnaire for participants 
XII 
List of Figures 
Figure 1.1: Human palatine tonsils ............................................................... 2 
Figure 1.2: Waldeyer's ring ....................................................................... 3 
Figure 1.3: LL-37 structure ..................................................................... 17 
Figure 1.4: HBD structure ...................................................................... 20 
Figure 1.5: Barrel-stave and carpet mechanisms ............................................ 26 
Figure 1.6: A representative TLR signalling pathway ....................................... 29 
Figure 3.1: Steps in real-time PCR assay development. .................................... 84 
Figure 3.2: Denaturing gel electrophoresis of RNA extracted from human tonsil tissue 
preserved and stored in a) liquid nitrogen or b) RNA Later ................................. 85 
Figure 3.3: Representative denaturing gel electrophoresis of human tonsil RNA 
extracted using a) the SV Total RNA Extraction kit rotor-stator homogenisation and b) 
the Micro-Midi Pure-Link RNA Purification System ........................................ 86 
Figure 3.4: Representative HEp-2 cell and HaCaT cell RNA .............................. 90 
Figure 3.5: Agarose gel electrophoresis of PCR products amplified from a) HEp-2 and 
b) HaCaT cell cDNA with LL-37 Primer Set 3 ................................................ 92 
Figure 3.6: Sequence of the PCR product amplified from HEp-2 cell cDNA with LL-
37 Primer Set 3 aligned to the LL-37 cDNA sequence ....................................... 93 
Figure 3.7: Agarose gel electrophoresis of PCR products amplified from the cloned 
sequence ofLL-37 with Primer Set 4 ........................................................... 95 
Figure 3.8: Melt peak analysis of products generated in real-time PCR using Primer 
Set 4 with cloned LL-37 PCR product as template on the LightCycler 1.2 ............... 95 
Figure 3.9: Melt peak analysis of LL-37 PCR products .................................... 99 
Figure 3.10: A representative LL-37 standard curve using standards 1-4 shown in 
Table 3.13 .......................................................................................... 99 
Figure 3.11: Agarose gel electrophoresis of a) HEp-2 cell and b) HaCaT cell PCR 
products amplified using HBD 1 Primer Set 1. .............................................. .1 02 
XIII 
Figure 3.12: Melt peak analysis from real-time PCR generated from human tonsil 
cDNA using HBD1 Primer Set 1 and human tonsil cDNA ................................ .102 
Figure 3.13: Sequence of PCR product from human tonsil amplified using HBD 1 
Primer Set 2 ....................................................................................... 103 
Figure 3.14: HBD1 standard curve plotted from dilution series shown in Table 
3.23 ................................................................................................ 106 
Figure 3.15: Melt peak analysis ofHBDl standards ...................................... 106 
Figure 3.16: Melt peak analysis of PCR products generated from human tonsil cDNA 
with HBD2 Primer Set 1 ........................................................................ 1 09 
Figure 3.17: a) Agarose gel electrophoresis of PCR products amplified using HBD2 
Primer Set 2 from HaCa T cell ................................................................. 110 
Figure 3.18: Melt peak analysis of PCR products generated from human tonsil cDNA 
with HBD2 specific primers ................................................................... 111 
Figure 3.19: A representative HBD2 standard curve from standards 1-5 .............. 112 
Figure 3.20. Analysis of HBD3 PCR products ............................................. 116 
Figure 3.21: Melt peak analysis of PCR products generated from human tonsil cDNA 
with HBD3 Primer Set 2 ........................................................................ 117 
Figure 3.22. Analysis ofhepcidin PCR products ......................................... ~ 118 
Figure 3.23: Analysis of real-time PCR products generated form the cloned hepcidin 
target sequence amplified with hepcidin specific primers .................................. 119 
Figure 3.24: Analysis of PCR products amplified with LEAP-2 specific 
primers ............................................................................................. 121 
Figure 3.25: Melt peak: analysis of PCR products generated from HaCaT cDNA with 
LEAP-2 Primer Set 1 ............................................................................ 122 
XIV 
Figure 3.26: A representative LEAP-2 standard curve from standards 1-5 of the 
dilution series shown in Table 3.34 ............................................................ 123 
Figure 3.27: GAPDH sequence analysis ..................................................... 125 
Figure 3.28: Melt peak analysis of PCR products generated from three HaCaT cDNA 
samples 1-3 with GAPDH Primer Set 1 ...................................................... 125 
Figure 3.29: GAPDH standard curve from dilution series shown in Table 3.38 ...... .126 
Figure 3.30: Melt peak analysis of PCR products with GAPDH Primer Set 1 .......... 127 
Figure 4.1: Expression of LL-37, LEAP-2, HBD1 and HBD2 mRNA adjusted to 
GAPDH (AU) in all subjects, classified in terms of epithelial and lymphoid 
samples ............................................................................................ 147 
Figure 4.2: Localisation ofLEAP-2 in tonsil.. .............................................. 148 
Figure 4.3: Expression of LL-37, LEAP-2, HBD1 and HBD2 mRNA adjusted to 
GAPDH (AU) in all subjects, classified in terms of tissue type and disease state ...... 149 
Figure 4.4a-b: Expression of LL-37 and LEAP-2 mRNA: adjusted to GAPDH (AU) in 
all male subjects .................................................................................. 150 
Figure 4.4c-d: Expression of HBDI and HBD2 mRNA: adjusted to GAPDH (AU) in 
all male subjects .................................................................................. 151 
Figure 4.5a-b: Expression ofLL-37 and LEAP-2 mRNA: adjusted to GAPDH (AU) in 
all female subjects ............................................................................... 152 
Figure 4.5c-d: Expression of HBD1 and HBD2 mRNA: adjusted to GAPDH (AU) in 
all female subjects .............................................................................. .153 
Figure 4.6a-b: Expression of LL-37 and LEAP-2: mRNA adjusted to GAPDH (AU) in 
all patient subjects, classified in terms of gender ............................................ 154 
Figure 4.6c-d: Expression of HBD1 and HBD2 mRNA: adjusted to GAPDH (AU) in 
all patient subjects, classified in terms of gender ............................................ 155 
Figure 4.7a-b: Expression ofLL-37 and LEAP-2 mRNA: adjusted to GAPDH (AU) in 
all subjects < ten years old ...................................................................... 156 
Figure 4.7c-d: Expression of HBDI and HBD2 mRNA: adjusted to GAPDH (AU) in 
all subjects < ten years old ...................................................................... 157 
xv 
Figure 4.8a-d: Expression of LL-37, LEAP2, HBDI and HBD2 mRNA: adjusted to 
GAPDH (AU) in all subjects over and under 45 years of age excluding all samples from 
subjects :::;10 years old ........................................................................... 158 
Figure 4.9a-b: Expression ofLL-37 and LEAP -2 mRNA: adjusted to GAPDH (AU) in 
all patient subjects, classified in terms oflast sore throat .................................. 159 
Figure 4.9c-d: Expression of HBDI and HBD2 mRNA: adjusted to GAPDH (AU) in 
all patient subjects, classified in terms oflast sore throat .................................. 160 
Figure 5.1: HEp-2 cells ......................................................................... 186 
Figure 5.2: Agarose gel results showing PCR products amplified from cDNA reverse 
transcribed from HEp-2 cell RNA with HBD3 (lane 1) and HBDI (lane 2-3) specific 
primers ............................................................................................. 187 
Figure 5.3: Agarose gel results showing PCR products amplified from cDNA reverse 
transcribed from 10 HEp-2 cells ............................................................... 188 
Figure 5.4: GAPDH, LL-37, LEAP-2 expression in HaCaT cells ............................ 189 
Figure 5.5: Representative RT-PCR results following challenge of HaCaT cells with 
D3 ......................................................................................................... 190 
Figure 5.6: Densitometry analysis of AMP gene expression ............................. 191 
Figure 5.7: S. pyogenes binding control showing HaCaT cells after 2 hours of infection 
with S. pyogenes, Ml serotype (wild-type) ........................................................ 192 
Figure 5.8: LL-37 expression in S. pyogenes infected HaCaT cells ..................... 193 
Figure 5.9: HBDI expression in S. pyogenes infected HaCaT cells ..................... 194 
Figure 5.10: HBD2 expression in S. pyogenes infected HaCaT cells .................... 195 
Figure 5.11: HBD3 expression in S. pyogenes infected HaCaT cells .................... 196 
Figure 5.12: Hepcidin expression in S. pyogenes infected HaCaT cells ................. 197 
Figure 5.13: LEAP-2 expression in S. pyogenes infected HaCaT cells .................. 198 
Figure 5.14: AMP gene expression patterns of control cells and cells treated with 1,25 
dihydroxyvitamin-D3 for 2 hours ............................................................. 199 
Figure 5.15: Expression ofLL-37 mRNA in HaCaT cells infected with S. pyogenes for 
2, 4 and 6 hours and treated with 1,25 dihydroxyvitamin-
D3 ................................................................................................. 200 
XVI 
Figure 5.16: Expression ofHBDl, HBD2 and LEAP-2 mRNA in HaeaT cells infected 
for 2, 4 and 6 hours with S. pyogenes, Ml serotype (wild-
type) .............................................................................................. 201 
Figure 5.17: Binding control results showing HaeaT cells after 5, 15, 30 and 60 
minutes of infection with S. pyogenes, Ml serotype (wild-
type) .............................................................................................. 202 
Figure 5.18: Real-time peR results showing expression ofHBDl, HBD2 and LEAP-2 
mRNA in HaeaT cells infected with S. pyogenes, Ml serotype (wild-
type) .............................................................................................. 203 
Figure 5.19: Binding control results showing HaeaT cells after 5,30 and 60 minutes, 2, 
4 and 6 hours of infection with S. pyogenes M2 serotype (wild-type) .................. .204 
Figure 5.20: Real-time peR data showing expression ofHBD1, HBD2 and LEAP-2 in 
HaeaT cells infected with S. pyogenes M2 serotype (wild-type) ......................... 205 
Figure 5.21: Binding control results showing HaeaT cells after 6 hours of infection 
with S. pyogenes Ml serotype wild-type and pili-defective mutants ~spyl29 and 
~spy 1154 .......................................................................................... 206 
Figure 5.22: Real-time peR results for a six hour incubation of HaeaT cell with 
control cells (e), and the S. pyogenes Ml strain, wild-type (wt) and pili-defective 
mutants ~spy129 (129) and ~spyl154 (1154) .............................................. 207 
Figure 6.1: LL-37 Gene Expression: Real-time peR data showing LL-37 mRNA 
expression in human tonsil sections incubated for two hours with D3 (VITAMIN D3), 
L T A, LPS and PMA using the ex vivo tonsil model.. ...................................... 223 
Figure 6.2: HBDI Gene Expression: Real-time peR data showing HBDI mRNA 
expression in human tonsil tissue sections incubated for two hours with D3 (VITAMIN 
D3), LTA, LPS and PMA using the ex vivo tonsil model.. ............................... .224 
Figure 6.3: HBD2 Gene Expression: Real-time peR data showing HBD2 mRNA 
expression in human tonsil tissue sections incubated for two hours with D3 (VITAMIN 
D3), L T A, LPS and PMA using the ex vivo tonsil model.. ................. , .............. 225 
Figure 6.4: LEAP-2 Gene Expression: Real-time peR data showing LEAP-2 mRNA 
expression in human tonsil tissue sections incubated for two hours with D3 (VITAMIN 
D3), LTA, LPS and PMA using the ex vivo tonsil model.. ................................ 226 
Figure 6.5: 1,25 dihydroxyvitamin-D3: Real-time peR data showing LL-37, HBD1, 
HBD2 and LEAP-2 mRNA expression in individual human tonsils incubated for 2 
hours with D3 using the ex vivo model ....................................................... 227 
XVII 
Figure 6.6: LTA: Real-time PCR data showing LL-37, HBD1, HBD2 and LEAP-2 
mRNA expression in individual human tonsils incubated for 2 hours with L T A using 
the ex vivo model. ................................................... " ...... '" ................. 228 
Figure 6.7: LPS: Real-time PCR data showing LL-37, HBD1, HBD2 and LEAP-2 
mRNA expression in individual human tonsils incubated for 2 hours with LPS using the 
ex vivo modeL .................................................................................... 229 
Figure 6.8: PMA: Real-time PCR data showing LL-37, HBD1, HBD2 and LEAP-2 
mRNA expression in individual human tonsils incubated for 2 hours with PMA using 
the ex vivo modeL ................................................................................ 230 
Figure 6.9: Binding control results showing control (non-RAT TA-C) and RAT tonsil 
(T A-J) tissue after two hours of infection with S. pyogenes Ml serotype ............... 231 
Figure 6.10: LL-37 Gene Expression: Real-time PCR data showing LL-37 mRNA 
expression in human tonsil incubated for two, four and six hours with S. pyogenes Ml 
serotype using the ex vivo tonsil modeL ..................................................... 233 
Figure 6.11: HBDI Gene Expression: Real-time PCR data showing HBDI mRNA 
expression in human tonsil incubated for two, four and six hours with S. pyogenes MI 
serotype using the ex vivo tonsil model.. ..................................................... 234 
Figure 6.12: HBD2 Gene Expression: Real-time PCR data showing HBD2 mRNA 
expression in human tonsil incubated for two, four and six hours with S. pyogenes MI 
serotype using the ex vivo tonsil modeL ...................................................... 235 
Figure 6.13: LEAP-2 Gene Expression: Real-time PCR data showing LEAP-2 mRNA 
expression in human tonsil incubated for two, four and six hours with S. pyogenes MI 
serotype using the ex vivo tonsil model ....................................................... 236 
Figure 6.14: LL-37 Gene Expression: Real-time PCR data showing LL-37 mRNA 
expression in human tonsil incubated for two, four and six hours with S. pyogenes Ml 
serotype using the ex vivo model. .............................................................. 237 
Figure 6.15: HBD 1 Gene Expression: Real-time PCR data showing HBD 1 mRNA 
expression in human tonsil incubated for two, four and six hours with S. pyogenes Ml 
serotype using the ex vivo model. ............................................................. 23 8 
Figure 6.16: HBD2 Gene Expression: Real-time PCR data showing HBD2 mRNA 
expression in human tonsil incubated for two, four and six hours with S. pyogenes Ml 
serotype using the ex vivo model. ............................................................. 239 
Figure 6.17: LEAP-2 Gene Expression: Real-time PCR data showing LEAP-2 mRNA 
expression in human tonsil incubated for two, four and six hours with S. pyogenes MI 
serotype using the ex vivo model. ............................................................. 240 
Figure 6.18: Binding control results for four control tonsils (M2TCI-4) showing tonsil 
tissue after two hours of infection with S. pyogenes M2 serotype ........................ 241 
XVIII 
Figure 6.19: LL-37 Gene Expression: Real-time peR data showing (a) LL-37 and (b) 
LEAP-2 mRNA expression in all human tonsils incubated for 2 and 4 hours with S. 
pyogenes, M2 serotype (wild-type) using the ex vivo tonsil model. ....................... 242 
Figure 6.20: Real-time peR data showing (a) HBDI and (b) HBD2 mRNA expression 
in all human tonsils incubated for 2 and 4 hours (2H and 4H) with S. pyogenes M2 
serotype (wild-type) using the ex vivo tonsil model.. ........................................ 243 
Figure 6.21: LL-37 Gene Expression: Real-time peR data showing LL-37 mRNA 
expression in human tonsil incubated for (a) two and (b) four hours with S. pyogenes 
M2 serotype using the ex vivo model.. ....................................................... 244 
Figure 6.22: HBDI Gene Expression: Real-time peR data showing HBDI mRNA 
expression in human tonsil incubated for (a) two and (b) four hours with S. pyogenes 
M2 serotype using the ex vivo model.. ....................................................... 245 
Figure 6.23: HBD2 Gene Expression: Real-time peR data showing HBD2 mRNA 
expression in human tonsil incubated for (a) two and (b) four hours with S. pyogenes 
M2 serotype using the ex vivo model.. ....................................................... 246 
Figure 6.24: LEAP-2 Gene Expression: Real-time peR data showing LEAP-2 mRNA 
expression in human tonsil incubated for (a) two and (b) four hours with S. pyogenes 
M2 serotype using the ex vivo model.. ....................................................... 247 
XIX 
List of Tables 
Table 2.1: Streptococcus pyogenes wild-type and recombinant strains ................ .36 
Table 2.2: Determining volume of RNA lysis solution required per sample .......... .45 
Table 2.3: A typical end-point PCR reaction .............................................. .49 
Table 3.1: Representative spectroscopy results from RNA extracted from human 
tonsil samples with either a) SV Total RNA Isolation kit or b) Micro-Midi Pure-Link 
RNA Purification System ..................................................................... 87 
Table 3.2: Spectroscopy results from a representative set of eleven HEp-2 cell RNA 
samples .......................................................................................... 88 
Table 3.3: Spectroscopy results from a representative set of eleven HaCaT cell RNA 
samples ........................................................................................... 89 
Table 3.4: List of primer sets designed to amplify regions of the mRNA sequence 
encoding human LL-37 ........................................................................ 91 
Table 3.5: Cp values from primer titration in an LL-37 specific PCR using Primer Set 
3 and Sybr-green detection on the LightCycler 1.2 ......................................... 94 
Table 3.6: Cp values from MgCh titration in an LL-37 specific PCR using Primer 
Set 3 and Sybr-green detection on the LightCycler 1.2 .................................... 94 
Table 3.7: Cp values from cDNA titration in an LL-37 specific PCR using Primer Set 
3 and Sybr-green detection on the LightCycler 1.2 ........................................ 94 
Table 3.8: Cp values of six human tonsil cDNA samples from an LL-37 specific 
PCR using Primer Set 4 on the LightCycler 1.2 ............................................ 96 
Table 3.9: Cps from LL-37 specific real-time PCR using Primer Set 4 on the 
LightCycler 1.2 showing the effect of primer concentration ........................... 96 
Table 3.10: Cp values from LL-37 specific real-time PCR using Primer Set 4 on the 
LightCycler 1.2 showing the effect of MgCh concentration ........................... 96 
Table 3.11: Cp values from LL-37 specific PCRs using Primer Set 4, conducted at 
annealing temperatures of 55, 56, 58 and 60°C on the LightCycler 1.2 ................. 97 
Table 3.12: Cp values from LL-37 specific PCRs using Primer Set 4 with varying 
amounts (2111 each of a 1:2 dilution series) of human tonsil RT product added ........ 97 
Table 3.13: Cp values from a dilution series of cloned LL-37 sequence fragment, 
amplified with Primer Set 4 on the LightCycler 480 ....................................... 98 
xx 
Table 3.14: Cp values of standards 1-4 from six independent PCRs from which the 
coefficient of variation of the assay was calculated ....................................... 1 00 
Table 3.15: Summary ofLL-37 assay ...................................................... 100 
Table 3.16: List of primer sets designed to amplify regions of the mRNA sequence 
encoding HBD 1 ................................................................................ 1 0 1 
Table 3.17: Cp values of six human tonsil samples from an HBD 1 specific PCR using 
Primer Set 2 on the LightCycler 1.2 ......................................................... 103 
Table 3.18: Cp values from a single human tonsil sample amplified with HBDI 
Primer Set 2 on the LightCycler 1.2 in reactions with varying primer 
concentration ........................................................ , .......................... 1 04 
Table 3.19: Cp values from a single human tonsil sample amplified with HBDI 
Primer Set 2 on the LightCycler 1.2 in reactions with varying MgCh 
concentration ................................................................................... 1 04 
Table 3.20: Cp values from a single human tonsil sample amplified with HBDI 
Primer Set 2 on the LightCycler 1.2 in reactions with varying annealing 
temperature ................................................................................................................. 1 04 
Table 3.21: Cp values of four tonsil samples from an HBDI specific PCR using 
Primer Set 2 on the LightCycler 480 ........................................................ 1 05 
Table 3.22: Cp values of four HaCaT cell samples from an HBDI specific PCR using 
Primer Set 2 on the LightCycler 480 ....................................................... .1 05 
Table 3.23: Cp values from a dilution series of cloned HBDI PCR product, amplified 
with Primer Set 2 on the LightCycler 480 .................................................. 105 
Table 3.24: Cp values from six independent PCR reactions from which the 
coefficient of variation of the assay was calculated ....................................... 1 07 
Table 3.25: Summary ofHBDI assay .................................................... .107 
Table 3.26: List of primer sets designed to amplify regions of the mRNA sequence 
encoding HBD2 ................................................................................ 108 
Table 3.27: Cp values from a dilution series of cloned HBD2 PCR product, amplified 
with Primer Set 2 on the LightCycler 480. For each standard the dilution of starting 
DNA stock and assigned arbitrary concentrations are shown ........................... II2 
Table 3.28: Cp values of three human tonsil samples from an HBD2 specific PCR 
using Primer Set 2 ............................................................................. 113 
Table 3.29: Cp values of HBD2 standards 1-4 from six independent PCR reactions 
from which the coefficient of variation for each was calculated ....................... .l13 
XXI 
Table 3.30: Summary ofHBD2 assay ..................................................... 114 
Table 3.31: List of primer sets designed to amplify regions of the mRNA sequence 
encoding HBD3 ............................................................................... .115 
Table 3.32: Sequence of oligonucleotide primers used to amplify a region of the 
mRNA sequence encoding human hepcidin .............................................. .118 
Table 3.33: Sequence of oligonucleotide primers designed to amplify regions of the 
mRNA sequence encoding human LEAP-2 ............................................... .119 
Table 3.34: Cp values from a dilution series of cloned LEAP-2 PCR product, 
amplified with Primer Set 1 on the LightCycler 480 ...................................... 122 
Table 3.35: Cp values of LEAP-2 standards 1-4 from six independent PCR reactions 
from which the coefficient of variation for each was calculated ........................ 123 
Table 3.36: Summary ofLEAP-2 assay ................................................... 124 
Table 3.37: Sequence of oligonucleotide primers designed to amplify a fragment of 
the mRNA sequence encoding human GAPDH .......................................... 125 
Table 3.38: Cp values from a dilution of GAPDH cDNA, amplified with Primer Set 1 
on the LightCycler 480) ...................................................................... 126 
Table 3.39: Cp values from six independent PCR reactions from which the 
coefficient of variation was calculated ...................................................... 127 
Table 3.40: Summary ofGAPDH assay .................................................. 128 
Table 5.1: Summary of semi-quantitative PCR data after two, four and six hours of 
infection with S. pyogenes Ml serotype ..................................................... 169 
Table 5.2: Summary of quantitative PCR data after two, four and six hours of 
infection with S. pyogenes ......... ........................................................... 171 
Table 5.3: Summary of quantitative PCR data after 5, 15, 30 and 60 minutes of 
infection with S. pyogenes Ml serotype .................................................... 173 
Table 5.4: Expression patterns of AMP mRNA with M2 serotype S. pyogenes ..... 174 
Table 6.1: Expression of AMPs in control (non-RAT) and RAT tonsils after 2,4 and 
6 hours of infection with S. pyogenes .. ..................................................... 215 
XXII 
Chapter 1 
Introduction 
1.1 Tonsils 
1.1.1 Morphology and Function 
Human palatine tonsils are lymphoepithelial organs ovoid in shape and situated in the 
pharynx at the opening of the gastrointestinal and respiratory tracts (Perry and Whyte 
1998) (Figure 1.1). They sit within the tonsillar fossa between the palatoglossal and the 
palapharyngeal arches (Nave, Gebert et al. 2001), and being secondary lymphoid organs 
function in the body's immune responses. Indeed in this position they encounter large 
numbers of respiratory and gastrointestinal antigens, and through activation of immune 
pathways help protect the body from infection. 
Figure 1.la&b: Human palatine tonsils: a) in-situ in the airways. The palatine tonsils can be observed 
at each side of the throat. b) A pair of human palatine tonsils immediately after excision. 
The tonsils are components of a ring structure consisting of lymphoid tissues, first 
described by, and subsequently named after Waldeyer in 1884 (cited by (Perry and 
Whyte 1998). Waldeyer's ring (Figure 1.2), comprises the palatine tonsils, paired tubal 
tonsils, nasopharyngeal tonsils (adenoids) and the lingual tonsil, all joined by smaller 
lymphoid tissues (Perry and Whyte 1998). This lymphoid ring is organised in a similar 
way to the lymphoid tissue in the gut and lung (Cebra, Periwal et al. 1998; Tschemig 
and Pabst 2000). 
2 
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Figure 1.2: Waldeyer's ring: This ring structure of lymphoid tissue comprises the adenoids, tubal tonsils, 
palatine tonsils and the lingual tonsil. This diagram is from (perry and Whyte 1998). 
The surface of each tonsil is covered by a stratified squamous non-keratinised 
epithelium. This epithelium contains a thick band of connective tissue containing a 
network of blood vessels, nerves and lymphatics (Perry and Whyte 1998; Nave, Gebert 
et al. 2001), and at certain sites invaginates to form crypts. At such sites the epithelial 
cells are reshaped and there is no connective tissue, which allows motile, non-epithelial 
cells to be incorporated. Indeed, this reticulated epithelium contains, primarily, cells of 
the immune system including T-cells, Immunoglobulin (Ig) - IgA, IgG, IgM- producing 
B-cells, macrophages, dendritic and Langerhan cells. Some of these cells have been 
observed to infiltrate the tonsillar crypts from as early as the 16th week of gestation (von 
Gaudecker and Muller-Hermelink 1982; Perry and Whyte 1998). It has been 
determined that the surface area of the oropharyngeal surface of the tonsils is 45cm2, 
however, when the surface area of the 10-30 crypts per tonsil is taken into account this 
is increased considerably to 295cm2 (Perry 1994; Perry and Whyte 1998). 
Below the surface epithelium are a number of primary and secondary lymphoid 
follicles. Lymphoid follicles are round or elliptical in shape and here T-Iymphocytes 
are activated and B-cells mature (Nave, Gebert et al. 2001). The secondary lymphoid 
follicles contain germinal centres and mantle zones. These are the sites of centroblast 
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proliferation and naIve B-cell storage (Banchereau, Briere et al. 1994; Brachtel, 
Washiyama et al. 1996). 
Within the tonsils the immune cells function to defend the organs and the body per se, 
from infection. In tonsils excised from both recurrent acute tonsillitis (RAT) sufferers 
and those with hypertrophic tonsils, neutrophils have been identified to migrate to and 
accumulate within the epithelial layers (Ebenfelt and Lundberg 1996; Ebenfelt, Ericson 
et al. 1998). Other immune effecters such SIgA and IgG are also active against 
pathogens; for example Streptococcus pyogenes (s. pyogenes), the major bacterial 
pathogen associated with recurrent acute tonsillitis (RAT), isolated from the tonsillar 
surface have been observed to be coated with these immunoglobulins (Lilja, Silvola et 
al. 1999). However, it is not surprising that the tonsils have a large number of active 
immune cells and molecules, as they have been identified as a reservoir for a number of 
potential pathogenic bacteria. Indeed the microbiota of the pharynx has been shown to 
include a-hemolytic and non-hemolytic streptococci, coagulase negative staphylococci, 
Neisseria jlavesceus, Corynebacterium diphtheriae and Neisseria gonorrhoea 
(Kielmovitch, Keleti et al. 1989). Recently the estimated probabilities of typical 
bacterial types being found on the tonsillar surface, as determined from tonsillar swabs, 
were Haemophilus Injluenza (27%), Staphylococcus aureus (38%), s. pneumoniae 66% 
and Group A Streptococcus (GAS) (62%) (Gul, Okur et al. 2007). 
1.2 Tonsillitis 
1.2.1 Clinical Implications 
Infection of the palatine tonsils usually presents as a sore throat. Although often 
dismissed as trivial complaints, such infections are painful with the victims requiring 
periods of absence from their employment or school. Moreover tonsillitis is often 
recurrent, occurring in some patients at least once per month. 
Diseased tonsils appear swollen and often accumulate debris within the crypts and pits 
(Caldas, Neves et al. 2007). Although in most cases the disease can be treated 
successfully with antibiotics, a tonsillectomy is recommended for severe cases of 
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recurrent acute tonsillitis (RAT) (Rosenfeld and Green 1990; Discolo, Darrow et al. 
2003). To qualify for a tonsillectomy the sufferer must have experienced seven 
episodes of tonsillitis in the year preceding tonsillectomy, five episodes over the two 
years, or three episodes over the two preceding years (SIGN 1999). The fact that 
tonsillectomy is the single most common operation in ENT units world-wide and costs 
the NHS >£60 million annually emphasises the seriousness of the infection (Little and 
Williamson 1996). Tonsillectomy is also often recommended for obstructive sleep 
apnoea (OSA) and sufferers of peritonsillar abscess, also know as quincy (Galioto 
2008). The procedure itself takes between 15 and 30 minutes to perform under a 
general anaesthetic, and involves removing the palatine tonsils. This procedure can be 
performed relatively easily with little risk to the patient and causes no deleterious 
effects on the immune system. 
1.2.2 Pathology 
Tonsillitis can be caused by viruses and/or bacteria (Putto 1987). Viral tonsillitis is 
common, with approximately 40% of all tonsillitis infections being caused by 
respiratory viruses, with adenovirus being the most common agent (Putto 1987). 
However Epstein-Barr, Influenza and Respiratory Syncytial Viruses have all been 
reported to be involved in the pathology of the infection (Putto 1987; Nokso-Koivisto, 
Hovi et al. 2006). As mentioned previously a number of bacteria including S. 
pneumoniae and S. aureus (Gul, Okur et al. 2007), inhabit the tonsillar surface 
asymptomatically. However S. pyogenes, a Gram-positive, facultative anaerobe is the 
major bacterium found in bacterial tonsillitis infections. 
It is of interest that tonsillar size has also been perceived to be a causal factor in the 
susceptibility to tonsillitis, and a connection between tonsillar hypertrophy and recurrent 
acute tonsillitis has long been held by those in the medical field, although never really 
proven. Some support for this link was provided in the late 1980s when a report was 
published that identified tonsillar size as being proportional to the mean bacterial colony 
forming units/g tonsil in both RAT and hypertrophic tonsils (Brodsky, Moore et al. 
1988). However further investigation of a potential link between tonsillar size and 
disease status has since determined that the number of follicles in the lymphoid centres 
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are equal in hypertrophic tonsils and those susceptible to bacterial tonsillitis, but that the 
follicles of the former are significantly enlarged. This in turn indicates that the immune 
mechanisms associated with the two conditions, hypertrophy and RAT, are probably 
different (Zhang, Pang et al. 2003). 
1.3 Group A Streptococcus 
1.3.1 Introduction 
Streptococcus pyogenes is a coccus shaped bacterium that forms chains and can 
colonise epithelial and mucosal tissues (Cunningham 2000). As mentioned previously 
Group A Streptococcus (GAS), a major causal factor in RAT, is not part of the normal 
flora of the human body, but can be carried asymptomatically (Cunningham 2000; 
Tyrrell, Lovgren et al. 2002). Moreover this opportunistic pathogen can, if unchecked, 
cause necrotizing lesions in skin (Taviloglu, Cabioglu et al. 2005), and pyrogenic 
infections (Cunningham 2000), both of which can be life-threatening. 
1.3.2 Identification and classification 
Classical microbiological techniques have been used routinely to identify GAS. The 
most common method is to grow the bacteria on 5% sheep blood agar. The GAS can be 
identified like most beta-haemolytic streptococci by halos around the cocci shaped 
colonies which are indicative of haemolysis. Other streptococci including alpha-
haemolytic streptococci and members of the normal flora will grow, but will cause 
partial or no halos i.e. they cause lysis few the red blood cells (Cunningham 2000). 
During the 20th century Rebecca Lancefield, working in the Rockefeller Institute in New 
York, investigated the cell wall composition of streptococci and classified them 
according to the carbohydrate composition of their bacterial cell wall. Classification of 
the streptococci in this manner requires the bacteria to be grown in Todd Hewitt broth 
and treated with boiling 0.1 M hydrochloric acid, which allows the bacterial wall 
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polysaccharides and M proteins (protein projections extending from the cell surface) to 
be extracted. Further analyses of the cell wall components by the Lancefield capillary 
precipitation technique and the slide agglutination procedure allows the streptococci to 
be typed into groups A, B, C, D, F and G respectively (Cunningham 2000). Each group 
is typified by a different cell wall polysaccharide composition, for example the major 
carbohydrate moieties of the GAS cell wall are N-acetylglucosamine and rhamnose. In 
addition the bacteria can also be typed through their T-proteins, which are protein 
markers on the bacterial cell surface, and identified via an agglutination test 
(Cunningham 2000). Indeed T proteins are often used as epidemiological markers. 
Today a molecular biological approach is usually taken to classify streptococci. One 
such method uses PCR and focuses on the emm gene sequence that encodes the variable 
region within the M protein. This approach has elucidated more than 95 M serotypes of 
streptococci (Beall, Facklam et al. 1996), and recently the genomes of some GAS 
strains have been published in their entirety, such as Ml (SF370) (Ferretti, McShan et 
al. 2001), M3 (MGAS315) (Beres, Sylva et al. 2002) and MI8 (MGAS8232) (Smoot, 
Barbian et al. 2002). 
The S. pyogenes Ml and M2 serotypes were used in the studies described in this thesis 
as they have been previously isolated from the area of focus i.e. the throat, although 
GAS have been isolated from other sites including the blood, the brain and the Cerebral 
Spinal Fluid (Tyrrell, Lovgren et al. 2002). However as discussed by Cunningham et al 
(2000), in their work reviewing Group A Streptococcus infections, certain S. pyogenes 
serotypes are more likely to cause a particular type of infection. For example S. 
pyogenes serotypes MI, M3, M5, M6, MI4, MI8, M19 and M24 are more likely to be 
associated with throat infections, whereas the S. pyogenes M serotypes M2, M49, M57, 
M59, M60 and M61 are more likely to be associated with pyodema skin infection and 
glomerulonephritis. 
1.3.3 Pathogenesis 
Streptococcus pyogenes Ml infection is the most common cause of bacterial tonsillitis 
(Stenfors, Bye et al. 2003), and it has been demonstrated that individuals retain GAS 
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intracellularly in their pharyngeal epithelial cells following an episode of tonsillitis 
(Osterlund and Engstrand 1997). Streptococci also specifically colonise epithelium 
such as keratinocytes and the pharynx (Osterlund and Engstrand 1997; Cunningham 
2000; Dorschner, Pestonjamasp et al. 2001), in the first instance causing erysipelas, 
cellulitis and impetigo in skin, and pharynxgitis or tonsillitis in the airways 
(Cunningham 2000). A GAS infection can also have severe consequences such as 
rheumatic fever, rheumatic heart disease, reactive arthritis and glomerulonephritis, and 
invasive diseases such as toxic shock syndrome, necrotising fasciitis sepsis and scarlet 
fever (Cunningham 2000). GAS are also implicated in stress induced psoriasis that 
interestingly, often follows a bacterial tonsillitis infection (England, Strachan et al. 
1997). 
Streptococci exert their deleterious effects and defend themselves via a number of 
virulence factors which can be broadly classified into two groups, cell surface factors 
and secreted exoproteins (Russell and Sriskandan 2008). The cell surface factors 
protein molecules which are anchored or attached to the cell surface, for example the 
M-protein, fibronectin binding proteins, the G-related a-2-macroglobulin binding 
protein (GRAB) and C5a peptidase. As well as cell wall components peptidoglycan, 
L T A, the hyaluronic acid capsule and carbohydrates (Russell and Sriskandan 2008). 
The secreted exoproteins are toxins such as streptolysin 0 (SLO) and streptolysin S 
(SLS) and superantigens (Russell and Sriskandan 2008). 
The M-protein, as mentioned previously in 1.3.2 are dimeric, coiled-coil fibrils, 
approximately 50-60nm in length, which confer the ability to resist phagocytosis by 
polymorphonuclear leukocytes in the absence of type specific antibodies (Fischetti 
1989). In a review by Fischetti et al (1989) it described the M-proteins to be highly 
variable in the N-terminal region, this area of the protein was the extracellular part 
which extended outside of the bacterial cell wall and is also the part of the molecule 
which is used for emm typing. The C-terminal of the protein is highly conserved and 
remains internalised within the bacterium. These M-proteins have been shown to 
facilitate adhere to cells (Cue, Lam et al. 2001) and bind through a variety of proteins on 
the host cell surface such as fibronectin (Schmidt and Wadstrom 1990; Courtney, Li et 
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al. 1994; Cue, Lam et al. 2001), sialic acid (Ryan, Pancholi et al. 2001), complement 
(Horstmann, Sievertsen et al. 1988), IgG and albumin (Schmidt and Wad strom 1990). 
Fibronectin binding proteins are also cell surface virulence factors. Fibronectin is an 
extracellular glycoprotein which is a large component of the connective tissue matrix 
and laminae (Hedman, Vaheri et al. 1978) and is common throughout many tissues in 
the human body, thus being a readily available target molecule for binding (Navarre and 
Schneewind 1999). These protein have been reviewed in the thesis by W.O. Smith 
(2004) and have found to be M-proteins, streptococcal surface GAPDH and surface 
endolase, SfbI, FBP54, Sfbll, protein F2, PFBP, FBalFbaA, FbaB and sfbX. 
GRAB is a protein which is found in most strains of S. pyogenes (Toppel, Rasmussen et 
al. 2003). It protects the bacterium and causes utilised a cysteine proteinase in order to 
exert deleterious effects on host cell immune defences, as described in 1.4.10. 
C5a peptidase is a bacterial cell wall associated protein which was analysed by sodium 
dodecyl-sulphate polyacrylamide electrophoresis to determine that this molecule is 
approximately 140 kDa in size (Cleary, Handley et al. 1992). This enzyme cleaves a 
chemotaxin C5a (involved in the complement cascade) in the polymorphonuclear 
leukocyte binding domain, thus affecting the immune response of the host cell (Cleary, 
Handley et al. 1992). 
A number of bacterial cell wall components have been observed to act as bacterial cell 
virulence factor such as L T A, which was first reported to be a molecule associated with 
bacterial cell adhesion to the host cell in 1976 (Beachey and Ofek 1976). It is presented 
in Ofek, Beachey et al (1982) that LTA is associated with the M-protein on the surface 
of S. pyogenes and can bind to fibronectin (Nealon, Beachey et al. 1986), thus acting as 
an adhesion and therefore encouraging colonization. The hyaluronic acid capsule is 
encoded by a three gene operon, containing the locus for hasA, hasB and hasC 
(DeAngelis, Papaconstantinou et al. 1993). This capsule causes extracellular matrix 
proteins to undergo paracellular translocation by binding CD44, thus indicating host 
defences are affected by hyaluronic acid binding (Fanning, Volkov et al. 2005). 
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The secreted exoproteins are toxins such as streptolysin 0 (SLO) and streptolysin S 
(SLS) (Fontaine, Lee et al. 2003). SLO is a thiol activated 571 amino acid secreted 
protein toxin which exerts cytolytic effects via pore formation in the cell membrane. 
SLO has a conserved core, with the variation seen at the N-terminal. This toxin has a 
cysteine 41 amino acid residues up-stream of the C-terminus which can be converted to 
disulphide structures with thiol compounds which can prevent the binding of the toxin 
to membranes (Palmer 2001). This molecule which targets cholesterol in eukaryotic 
cell membranes binds as a monomer via a conserved region close to the C-terminal. 
Proliferation of arc and ring structures can be observed surrounding the pores (Palmer, 
Vulicevic et al. 1998). SLS is also an extracellular, cytolytic toxin which is only active 
when bound to a carrier molecule (Theodore and Calandra 1981). This toxin was 
cloned and sequenced a research group in 2002 and it was discovered that the operon in 
which this toxin was encoded contained 9 genes sagA-l 
S. pyogenes has been seen to be a large producer of the superantigenic toxins (Proft and 
Fraser 2007), for instance the streptococcal pyrogenic exotoxin (Spe A, C, G-J, L, M); 
streptococcal superantigens (SSA) which are exotoxins that have interactions with 
antigen presenting cells, specifically with major histocompatibility complex class II 
molecules which leads to activation of T -cells (Russell and Sriskandan 2008) and 
streptococcal mitogenic exotoxin Z cause severe invasive infections and are the most 
powerful T-cell antigens found to-date (Proft and Fraser 2007). Since the completion of 
GAS genomes more superantigens have been discovered as database mining has 
elucidated these molecules (Proft and Fraser 2007). GAS has been seen to express the 
following superantigen genes speA, spec, speG, speH, spel, speJ, speK, speM, ssa and 
smeZ (Russell and Sriskandan 2008). These molecules approximately 25kDa in size, 
characteristically soluble and non-glycosylated (Russell and Sriskandan 2008). The 
molecules are secreted from the bacterium and the signal N-terminal is cleaved at the 
bacterial surface (Russell and Sriskandan 2008). 
The function of these molecules is reviewed in (Russell and Sriskandan 2008) and the 
main ways they use of interfering with the host immune responses and protective 
mechanisms are to inhibit the production of specific antibodies, to disrupt T-cell 
responses and to cause proliferation ofproimflammatory cytokines such as TNF-u. 
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They act on host antigen presenting cells, inducing an immune response via MHC class 
II molecules (Russell and Sriskandan 2008) which cause massive, non-antigen specific 
T-cell activation (Llewelyn and Cohen 2002). As reviewed in Russell and Sriskandan, 
(2008), this action has also been observed to be closely related to the structure of the 
molecule as crystallography studies have shown a common structure between all of the 
superantigens which have been crystallised and studied, these molecules are SPEA, 
SPEC, SPEH, SPEJ and SMEZ, which have all been identified as having two globular 
domains, the N-terrninal domain is a p-barrel and a C-terminal domain which is a p-
grasp domain. These domains have an alpha-helix between the two domains. 
It is known that superantigens and some other toxins can cause their virulent effects by 
the non-specific activation of T-cells resulting in cytokine release, through mechanisms 
involving major histocompatibility complex (MHC) class II molecules and some VP-
regions of the T -lymphocyte receptor (Fast, Schlievert et al. 1989; Hackett and Stevens 
1992; Norrby-Teglund, Norgren et al. 1994). Specifically with superantigens the 
conserved superantigenic structure interacts with specific regions of the major 
histocompatibility complex (MHC) class II molecules to elicit this response (Russell 
and Sriskandan 2008). 
Streptococcus pyogenes also secretes other exotoxins such as endoglycosidase (Collin 
and Olsen 2001), Immunoglobulin G degrading enzyme of S. pyogenes (von Pawel-
Rammingen, Johansson et al. 2002), DNases (Wannamaker 1958), as well as the 
cysteine protease (speB) further described in 1.4.10i and SIC (streptococcal inhibitor of 
complement) and DRS (distantly related to SIC) which are described in 1.4.lOii. 
Streptococcal virulence factors can often be identified post-infection, for example mice 
infected with S. pyogenes present with raised levels of antibody against the 
streptococcal extracellular cysteine protease, exotoxin B (Guzman, Talay et al. 1999; 
Cunningham 2000). 
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1.3.4 Adhesion 
Streptococci are known to adhere to host epithelial cells. Moreover, adherence is a 
two-way relationship where adhesins from both bacterial and host cells are 
monopolised. Originally M-proteins, projections extending from the streptococcal 
surface and discovered by electron microscopy, were thought to be the primary adhesins 
used by the bacteria (Ellen and Gibbons 1972). To date however at least eleven GAS 
adhesins have been identified including the aforementioned M-protein and LT A, as well 
as number of binding proteins that specifically target host cell proteins including 
collagen, vitronectin, galactose and serum opacity factor. Other proteins targeted on the 
host cell surface include fibronectin, fibrinogen, fucosylated glycoprotein and 
membrane proteins e.g. CD46 on keratinocytes (Cunningham 2000). 
Pili, which are typically found on the surface of Gram-negative bacteria, also function 
as adhesins and actually playa major role in adherence of the bacteria to the host cell 
(Wu and Fives-Taylor 2001). As discussed in Wu and Fives-Taylor (2001) many types 
of pili have been discovered and are grouped based in their modes of assembly and 
expression, for example Type I fimbria, Type 4 pili and Curli fimbriae. 
Until relatively recently (2003), pili were not identified in Gram-positive bacteria. They 
were discovered in Corne bacterium diptheria using electron microscopy and further 
investigations using deletions in the genome of this bacterium determined that the pili 
were made of three subunits encoded by there genes, SpaA, SpaB and SpaC (Ton-That 
and Schneewind 2003). Later more Gram-positive bacteria were shown to have pili, 
and these included S. agalacticae, a Group B streptococci which was discovered by 
screening multiple genomes of GAS, after the discovery of high molecular weight 
polymers. After this discovery immunogold electron microscopy was used to deduce 
that the polymers produced a pilus structure (Lauer, Rinaudo et al. 2005) and S. 
pyogenes, which were discovered in a similar manner, using a bioinformatic approach 
of genome scanning by comparing the DNA sequences of GAS strains using GcG 
Wisconsin 10.0 software.' This yielded the genes encoding pili in this organism. 
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Electron microscopy was then conducted to confirm the presence of pili (Mora, Bensi et 
al. 2005). 
Recently there has been extensive work conducted in Newcastle by Abbot, Smith et al 
(2007), looking at invasion and adhesion of GAS to both tonsils and skin. This study 
showed that after 5mins of incubation with a tissue sample S. pyogenes had already 
begun to bind to the tonsil. The study showed binding rate continued rapidly between 
30min and 2 hours of incubation and after this time continued at a slower rate. Abbot, 
Smith et al (2007) was also able to show using plate counts that after 2 hours of 
incubation with tonsil tissue 10-20% (> 1 06 cfu) S. pyogenes had adhered to the tissue; 
this adhesion also appeared to be the same in control (excised for apnoea or snoring) 
and RAT tonsils. Pili-defective mutants did not adhere to tonsil, even after an extended 
incubation time of 18 hours (Abbot Smith et al 2007). Using the pili-defective mutant 
S. pyogenes in adhesion experiments with all three genes encoding the pili subunits 
(tlspyl25 tlspyl28 and tlspyJ30) and the gene for pili assembly (tlspy129) all required 
for pili formation Abbot, Smith et al (2007) had established emphatically that pili are 
necessary to cause a GAS infection in human tonsils and keratinocytes. Two pili-
defective mutants have been used in the studies reported in this thesis. These are 
/).spyl29 that lacks pili and tlspyl154 that lacks pili and surface proteins such as 
adhesins. 
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1.4 Host Defense Peptides: Cationic Antimicrobial peptides 
1.4.1 Introduction 
Antimicrobial peptides (AMPs) are small, between 11 and 50 amino acids in length, 
hydrophobic, cationic peptides, with a positive net charge due to the presence of lysine 
and arginine amino acids (Hancock 1997; Hancock and Scott 2000). These peptides are 
host encoded and can kill a broad range of microorganisms such as Gram-positive and 
Gram-negative bacteria, fungi and enveloped viruses (Izadpanah and Gallo 2005). 
These peptides, being a fundamental part of the innate immune system are synthesised 
in both the plant and animal kingdoms and in the latter are found in mammals 
, 
amphibians, avian, fish and insects (Hancock and Chapple 1999; Wong, Xia et al. 2007' 
, 
van Dijk, Veldhuizen et al. 2008). In mammals they are localised at epithelial and 
mucosal surfaces, and within antigen presenting cells including neutrophils and 
macrophages (Huttner and Bevins 1999). 
Historically, the first AMPS were reported in 1962 by Kiss and Michl et al (cited by 
Hancock, Chapple et al. 1999), who reported the presence of these natural antibiotics in 
the skin of the frog Bombina Variegata. These host defence peptides were aptly named 
Bombinins. Later, in 1972, Melittin, an AMP derived from bee venom was reported 
(Habermann 1972). Mammalian AMPs were first reported in the mid 1960s in two 
papers, which described the antibacterial and enzymatic activities of cationic proteins 
isolated from the polymorphonuclear leukocyte lysosomes of guinea pigs (Zeya and 
Spitznagel 1966 (a); Zeya and Spitznagel 1966 (b); Habermann 1972). Since then many 
more AMPs have been documented and characterised. Moreover to facilitate studies 
involving AMPs, the peptides have been classified into families, usually on the basis of 
their structure and amino acid content. Currently there are well over 1000 AMPs 
documented in a number of databases, the largest of which can be accessed at 
http;llwww.bbcm.univ.trieste.itl-tossi/search.htm. 
There are at least four different families of AMPs; the alpha-helical (a-helical) AMPs 
without cysteine amino acids, of which the cathelicidin LL-37 is a member; AMPs with 
cysteines linked by disulphide bridges e.g. the a-defensin, Human Neutrophil Peptide 1 
(HNP-l); AMPs with an unusually high proportion of specific amino acid residues, e.g. 
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Histatins including His 1 and His 2; and AMPs with loop structures such as Bactenecin 
(Bals 2000; Koczulla and Bals 2003). The work presented in this study is focussed on 
two major families, the cathelicidins and the human beta-defensins (HBDs). 
The term host defence peptides has been used to describe small, cationic peptides often 
referred to in the literature as antimicrobial peptides as these biological molecules have 
been seen to have immunomodulatory properties e.g. acting as an inducer of 
chemokines or other immune effectors, as well as having antimicrobial functions. 
Recently, some research groups have begun to favour the term host defence peptides, 
rather than antimicrobial peptides as it fully describes their multiplicity of function 
(Devine and Hancock 2004; Devine and Cosseau 2008). This shift in terminology was 
proposed by Hancock and Devine in their 2004 editorial' Antimicrobial or Host defence 
peptides' this proposal has also been included in the recent review by (Devine and 
Hancock 2004; Devine and Cosseau 2008). This proposal states that the physiological 
concentrations at which these peptides are found in some biological tissues are not high 
enough to exhibit an antimicrobial effect and therefore their immunomodulatory role is 
the primary function. It is considered in the editorial that while some of these peptides 
do have an antimicrobial role at a particular site in the body they may have other host 
defence functions at many others. The Hancock and Devine (2004) editorial also 
suggested that antimicrobial ability of many AMPs has been measured in a 10mM 
phosphate buffer or growth medium which are not physiologically relevant and that salt 
concentration, cell surface factors and serum factors may affect antimicrobial activity in 
vivo. In particular salt concentration is considered and it is discussed that at 
physiological salt concentrations in blood (1 mM Mg2+ and 2mM Ca2+) the antimicrobial 
activity of most host defence peptides would be removed. 
The within the mouth a vast number of bacteria can be found, more than 700 types have 
been isolated (Devine and Cosseau 2008). As reviewed in Devine and Cosseau (2008), 
this number comprises both oral commensals e.g. Streptococcus mitis, Streptococcus 
oratis, some species of Prevotella and Fusobacterium nucleatum and some organisms 
associated with disease e.g Streptotoccus mutans, Streptococcus sobrinus and 
lactobacilli. As this environment is bacteria rich the mouth has developed complex 
defence mechanisms, including many molecules such as AMPs, lysozyme, lactoferrin, 
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lactoperoxidase, myeloperoxidase, Secretory IgA, Chitinase and von ebnerglands 
proteins (Devine and Cosseau 2008). 
Within the mouth AMP expression has seen to be within saliva, the gingival crevicular 
fluid, oral epithelial cells and neutrophils (Devine and Cosseau 2008). The AMPs 
expressed here are the Histatins (Oppenheim, Xu et al. 1988), alpha de fens ins (Dale and 
Fredericks 2005), beta defensins (Bonass, High et al. 1999) and the cathelicidins 
(Putsep, Carlsson et al. 2002). Within the mouth AMPs have been seen to be expressed 
at concentration which would be antimicrobial (Tao, Jurevic et al. 2005), the AMPs 
reported here were extracted from saliva samples from subjects, of which 92% were 
healthy, they were 0.31IJg/ml, 3.07IJg/ml and 0.8IJg/ml for HBD3, LL-37 and HNPI-3 
respectively (Tao, Jurevic et al. 2005). The physiological concentration of HBD2 was 
reported as being 0.04IJg/ml in oral epithelial tissue (Sawaki, Mizukawa et al. 2002). 
Tao, Jurevic et al (2005), also reported that HNP 1 -3 and LL-37 concentrations were 
higher in the groups of subjects without caries, suggesting a protective role of AMPs in 
the mouth. 
1.4.2 Cathelicidins 
The cathelicidin family of AMPs was discovered in the 1990s as a consequence of 
studies focussed originally on Bac 5, an AMP derived from bovine neutrophils (Zanetti, 
Del Sal et al. 1993; Gennaro and Zanetti 2000). In fact cathelicidin molecules were 
found to be synthesised at the myeloid and metamyeloid stages of maturation of the 
neutrophil cells, and packaged into azurophil granules for storage (Gabay, Heiple et al. 
1986; Sorensen, Arnljots et al. 1997). 
Cathelicidins, are not specific to mammals as they are also found in birds (Xiao, Cai et 
al. 2006; van Dijk, Veldhuizen et al. 2008) and fish (Chang, Zhang et al. 2006; Maier, 
Dorn et al. 2008). In humans there is one cathelicidin called hCAP 18 (Gudmundsson, 
Magnusson et al. 1995; Nizet, Ohtake et al. 2001). Although the human genome 
contains only one cathelicidin gene (Duff, Sudheendra et al. 2006), multiple genes have 
been found in other species such as horse, pig and cow (Lee, Ohtake et al. 2005). It is 
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hypothesized that evolution of multiple cathelicidin genes provides these species with 
enhanced resistance to infection (Lee, Ohtake et al. 2005). The human cathelicidin gene 
(Figure 1.3), positioned on chromosome 3p21, is composed of four exons and three 
introns (Agerberth, Gunne et al. 1995; Gennaro and Zanetti 2000; Elloumi and Holland 
2008); (Sorensen, Follin et al. 2001). The encoded protein is synthesised as an 18 kDa 
precursor molecule, with a conserved N-terminal domain and a variable C-terminal 
sequence (Figure 1.3). The prepropeptide, known originally as either Profall-39, 
hCAP18 or cathelin-LL-37, was discovered by three different groups simultaneously, 
(Agerberth, Gunne et al. 1995; Cowland, Johnsen et al. 1995; Larrick, Hirata et al. 
1995), although it is now routinely referred to as hCAPI8. The precursor protein is 
cleaved enzymatically to release the mature C-terminus (4.5kDa), which has 
antimicrobial activity (Putsep, Carlsson et al. 2002). In vitro three serine proteinases, 
cathepsin G, elastase and proteinase 3 have all been shown to cleave hCAP-18, although 
proteinase 3 is believed to function in vivo (Zanetti, Gennaro et al. 1995). 
The mature antimicrobial peptide is called LL-37. This name is based on the structure 
of the peptide that contains 37-amino acids with the amino acid leucine at positions 1 
and 2 respectively (Putsep, Carlsson et al. 2002). The peptide sequence is: 
LLGDFFRKSK EKIGKEFKRI VQRIKDFLRN L VPRTES (Tjabringa, Aarbiou et al. 
2003). 
Exonl Exons2,3 Exon4 
D S'UTR 
• Signal sequence • Prosequence D Mature peptide 
• 3' Um 
Signal Pro Mature N-,f-----------1r 
Figure 1.3: LL-37 Structure: Gene to mature peptide. Schematic representation. Adapted from 
(Koczulla and Bals 2003). 
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Expression of LL-37 has been reported in a number of tissues in humans including the 
tonsils (Song, Hwang et aI. 2006; Ball, Siou et aI. 2007), sweat glands (Murakami, 
Ohtake et aI. 2002), the lungs and airway epithelium (Bals, Wang et aI. 1998), 
keratinocytes (Frohm, Agerberth et aI. 1997) and breast tissue (Heilborn, Nilsson et aI. 
2005). In body fluids such as serum and airway surface fluid a LL-37 concentration of 
0.2 - I f.lM has been reported (Sorensen, Cowland et aI. 1997; Schaller-Bals, Schulze et 
aI. 2002). 
LL-37 has both killing and signalling roles in the protection of the host from infection 
(Dorschner, Pestonjamasp et aI. 2001; Nizet, Ohtake et aI. 2001). As regards signalling 
the molecule has been shown to have chemotactic effects on monocytes, neutrophils, T-
lymphocytes and mast cells (Yang, Chertov et aI. 2001; Niyonsaba, Iwabuchi et aI. 
2002), and to stimulate the differentiation of dendritic cells (Davidson, Currie et aI. 
2004). Moreover in relation to mast cells, which are among the first inflammatory cells 
to encounter invading pathogens, LL-37 has been shown to induce intracellular calcium 
mobilisation and histamine release (Niyonsaba, Someya et aI. 2001). The peptide, 
through mitogen activated kinase (MAPK) signalling pathways also induces IL-8, IL-18 
and IL-20 production in primary keratinocytes (Niyonsaba, Ushio et aI. 2005). Other 
non-microbial roles for this peptide have been reported, and include wound healing and 
angiogenesis (Steinstraesser, Ring et aI. 2006), as well as cell apoptosis (Okumura, Itoh 
et aI. 2004; Barlow, Li et aI. 2006). 
In fact gene expression profiling studies by Scott, Davidson et al (2002), indicated that 
LL-37 treatment of macrophages was associated with the up-regulation of 29 genes, 
encoding cytokines, chemokines including those for monocyte chemoattractant protein 
I (MCP-I) and IL-8, and chemokine receptors (Scott, Davidson et aI. 2002). 
Interestingly, LL-37 treatment was also associated with the down-regulation of at least 
20 genes involved in immune response and repair mechanisms, for example IL-12, 
macrophage-inflammatory protein, oncostatin and DNA repair proteins (Scott, 
Davidson et aI. 2002). These findings support the hypothesis that LL-37 contributes to 
the immune response by not only killing bacteria, but also by limiting the damage 
caused by bacterial products and by recruiting immune cells to the infection site so they 
can clear the infection. 
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1.4.3 Defensins 
The de fens ins, like cathelicidin, function to protect the host from a microbial assault. In 
humans there is more than one defensin gene, and defensin genes are expressed and 
peptides synthesised in a broad range of tissues and cells. Defensins are subdivided into 
three main classes in vertebrate, the a-defensins, the ~-defensins and the 9-defensins. 
They are classified according to the arrangement of the disulphide bridges between the 
six conserved cysteine residues (Hollox, Armour et al. 2003). 
The a-defensins are a major constituent of granulocytes and neutrophils (Lehrer and 
Ganz 2002), and the genes are expressed in a limited number of epithelial tissues that 
include the gut epithelium, the endocervix and the vagina (Hollox, Armour et al. 2003). 
They are between 29-35 amino acid residues in length, and characterised by three 
disulphide bonds with the following pairing Cysl-Cys6, Cys2-Cys4 and Cys3-Cys5 
(Lehrer and Ganz 2002). There are six known a-defensins; these include four human 
neutrophil peptides that are primarily expressed by granulocytes and neutrophils, and 
HD5 and HD6 that are expressed by the Paneth cells in the intestine (Lehrer and Ganz 
2002). The alpha-defensins can kill a wide range of Gram-positive and Gram-negative 
bacteria including both intracellular and extracellular organisms. For example the gut 
a-de fens in HD5, displays activity against Escherichia coli, Listeria monocytogenes, 
Salmonella typhimurium as well as Candida albicans, with minimal inhibitory 
concentrations in the nanomolar range (Porter, van Dam et al. 1997). 
The main human ~-defensin locus is 8p22-p23 (Semple, Rolfe et al. 2003), and the 
genes are characterised by two exons flanking one intron (Figure 1.4) (Koczulla and 
Bals 2003). Through in silico analyses over 40 open reading frames with DNA 
sequences, potentially encoding ~-defensins, have been identified in the human genome 
although many appear to encode transcripts with premature stop codons, and are 
thought to be pseudogenes (Pazgier, Hoover et al. 2006). The activities of HBD 1-4 
have however been well characterised and mRNA expression of the HBDl-4 genes has 
been shown in numerous tissues including skin (Harder, Meyer-Hoffert et al. 2004), 
intestine (Fahlgren, Hammarstrom et al. 2004), tonsil (Harder, Bartels et al. 2001; Ball, 
Siou et al. 2007) and cartilage (Varoga, Pufe et al. 2005). 
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The p-defensin family peptides are 38-42 amino acid residues long and structurally, are 
similar to the a-defensins, except for the different pairing of the six cysteines. In p-
defensins the pairing is Cysl-Cys5, Cys2-Cys4, Cys3-Cys6 (Yang, Chertov et al. 2001). 
The human p-defensins exhibit antimicrobial activity against numerous pathogens 
including Gram-negatives e.g. E. coli and P. aeruginosa (Harder, Bartels et al. 1997) 
and Gram-positives e.g. S. pyogenes (Fernie-King, Seilly et al. 2004; Fernie-King, 
Seilly et al. 2006). 
Exon 1 Exon2 
Signal Pro Mature 
N C 
D S'UTR 
• Signal sequence 
• Prosequence 
D Mature peptide 
• 3' UTR 
Figure 1.4: HBD Structure: Gene to mature peptide. Schematic representation. Adapted from 
(Koczulla and Bals 2003). 
The work in this thesis is focussed particularly on the human p-defensins 1-3. There 
are, in the public domain, many excellent reviews describing the defensins, including 
those by (Schneider, Unholzer et al. 2005; Pazgier, Hoover et al. 2006; Menendez and 
Finlay 2007) and (Devine and Cosseau 2008). Because of this information in this thesis 
relating to HBDI-3 will be summarised in a few paragraphs. 
HBDI (also referred to as hDEFB1), was first identified in the mid 1990s in plasma 
(Bensch, Raida et al. 1995). The gene is classically recognised as being constitutively 
expressed in most cells including those derived from the trachea, bronchi, gingiva 
(Zhao, Wang et al. 1996; Krisanaprakornkit, Weinberg et al. 1998; Mathews, Jia et al. 
20 
1999; Proud, Sanders et al. 2004), although it has been shown to be up-regulated in 
Acne Vulgaris, a potentially microbial infection (Chronnell, Ghali et al. 2001). Gram-
negative bacteria are particularly susceptible to the antimicrobial effects of HBD 1. 
HBD2 (hDEFB4), was isolated originally from psoriatic skin lesions where it is found 
in high concentrations (Harder, Bartels et al. 1997). In vitro this AMP is known to 
exhibit antimicrobial activities against Gram-negative bacteria including E. coli and P. 
aeruginosa (Harder, Bartels et al. 2001), but at high concentrations 1001lg/ml can also 
exhibit bactericidal activity against Gram-positive bacteria (Schneider, Unholzer et al. 
2005). HBD2 gene expression is induced by a range of stimuli such as lL-B, TNF-a, 
Lipopolysaccharide (LPS) as well as Gram-positive and negative bacteria. 
HBD3 (hDEF103) was isolated by three groups independently (Garcia, Jaumann et al. 
2001; Harder, Bartels et al. 2001; Jia, Schutte et al. 2001). In fact two of the groups, 
Jia, Schutte et al (2001) and Garcia, Jaumann et al (2001), discovered the AMP using a 
genomics based approach by searching the human genome for a sequence with 
homology to HBD2. The peptide is inducible and in vitro HBD3 has been shown to 
have antimicrobial activities against Gram-positive bacteria including GAS, and Gram-
negative bacteria such as E. coli (Harder, Bartels et al. 2001). 
The defensins, like LL-37, are also proposed to have non-microbial functions. For 
example in keratinocytes, HBD2 and HBD3 have been shown to promote the 
production and release of inflammatory mediators such as cytokines (Niyonsaba, Ushio 
et al. 2007). HBD2 has been reported to induce histamine release in mast cells 
(Niyonsaba, Someya et al. 2001), while HBD3 has been suggested to play a role in 
wound healing (Varoga, Pufe et al. 2005). There is also evidence to show that the 
HBDs influence cell differentiation (Shiba, Mouri et al. 2003), as well as acting as 
chemoattractant agents (Yang, Chertov et al. 1999). 
1.4.4 Hepcidin 
Hepcidin is found in mammals and insects (Park, Val ore et al. 2001), and the 
mammalian peptide has been shown to have antimicrobial activity against Bacillus sp., 
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Micrococcus lute us and Staphylococcus carnosus (Krause, Neitz et al. 2000). Like the 
human ~-defensins hepcidin is cysteine rich, but the peptide has eight, rather than six, 
cysteine amino acids which form four disulphide bonds (Park, Valore et al. 2001). 
The primary amino acid structure of the active form of hepcidin IS 
DTHFPICIFCCGCCHRSKCGMCCKT, and the secondary structure as determined by 
two-dimensional HNMR spectroscopy comprises a beta-sheet structure with a hairpin 
loop (Hunter, Fulton et al. 2002). The active peptide is 2-3 kDa in size with a positive 
charge of 3 at neutral pH. It is synthesised as a 84 amino acid prepropeptide and like 
other AMPS, mature hepcidin is cleaved in this case by propeptide convertases. 
Hepcidin was discovered almost simultaneously by two research groups. In 2001, Park 
and colleagues, reported a peptide with antimicrobial activity in human urine (Park, 
Valore et al. 2001), while Krause and co-workers, identified the same peptide (also 
known as LEAP-I) in a human plasma ultrafiltrate (Krause, Neitz et al. 2000). 
Interestingly in the study by Park, Valore et al (2001), three Hepcidin molecules were 
reported, Hepc20, Hepc22 and Hepc25, the former two being processed forms. In fact 
in silico analysis has revealed that more than one active peptide is possible from the 
single precursor protein due to various possible cleavage sites (Park, Valore et al. 2001). 
Park and colleagues demonstrated elevated hepcidin expression in fetal and adult livers, 
although they were unable to detect gene expression in tissues such as the prostate, 
testes, ovary, small intestine or colon (Park, Val ore et al. 2001). This result was 
supported by the studies of Krause, Neitz et al (2000), who using real-time PCR 
indicated that the liver expression of hepcidin, was comparable to that of the house-
keeping gene, GAPDH. 
Although the hepcidin, or LEAP-l molecule, was identified originally as an AMP it 
actually plays a key role in iron homeostasis. Indeed injection of synthetic hepcidin into 
mice induces hypoferremia within one hour (Rivera, Nemeth et al. 2005). The roles of 
hepcidin in iron homeostasis were actually established through transgenic mice models 
and investigation of genetic defects that result in iron deficiency (Nicolas, Bennoun et 
al. 2001; Roetto, Papanikolaou et al. 2003; Viatte, Lesbordes-Brion et al. 2005) or 
extreme peptide production (Nicolas, Bennoun et al. 2002) in humans. The induction of 
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hepcidin expression by inflammatory stimuli and the resulting hypoferraemia is 
proposed to playa role in host defences against microbial infection (Ganz 2007). 
1.4.5 Liver Expressed Antimicrobial Peptide-2 (LEAP-2) 
Liver Expressed Antimicrobial Peptide-2 (LEAP-2) was, like hepcidin, isolated from 
human blood ultrafiltrate. This LEAP-2 peptide was characterised by Krause, Sillard et 
al (2003), and is known to be synthesised as a 77-residue precursor molecule, which is 
processed, probably by furin, to release the mature peptide. LEAP-2 is again cysteine 
rich with four cysteine residues forming two disulphide bonds binding in the 
conformation Cys l-Cys3 and Cys2-Cys4. Studies carried out by this group identified 
LEAP-2 gene expression in many epithelial tissues including the liver, kidney, colon, 
lung, trachea and heart (Krause, Sillard et al. 2003). The mature LEAP-2 peptide has 
been shown to have antimicrobial activity against Gram-positive and Gram-negative 
bacteria (Krause et al. 2003; Townes, Michailidis et al. 2004). 
1.4.6 AMP killing mechanisms 
It is widely recognised that cationic AMPs neutralize and kill both Gram-negative and 
Gram-positive bacteria as well as fungi, parasites, cancer cells and enveloped viruses, 
e.g. Herpes simplex virus and HIV; however the usual targets of the AMPs microbial 
rather than eukaryotic (Hancock and Scott 2000). Some of the exact mechanisms by 
which this killing occurs are debated but it is widely agreed that killing is linked to the 
charge and hydrophobicity of the peptides, and the formation of pores in the microbial 
membranes. 
A good general explanation of actions of AMPs on membrane can be found in a review 
by Brogden et al (2005). This review outlines how attraction between the peptide and 
the cell membrane through electrostatic bonding allows the AMP to attach to the 
membrane. Generally AMPs are cationic and are attracted to the negatively charged 
outer membrane of bacteria, in Gram-negative bacteria the net negative charge is 
generated by anionic phosholipids and phosphate groups. In Gram-positive bacteria this 
is generated by the teichoic acids. The AMPs then attach to the membrane by adsorbing 
and embedding into it, the lipid head groups then stretch the membrane. This review 
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also details that in a low peptide:lipid situation peptide molecules will bind to the 
membrane and in a high peptide:lipid situation pores will be formed. 
The mode of action against Gram-negative bacteria is widely accepted basically as 1) 
interaction with cell membranes, 2) crossing of the cell membrane and 3) killing of cells 
(Hancock and Scott 2000). Initially, the AMPs interact with the membrane surface, 
specifically the polyanionic surface LPS, next the divalent cations which bridge and 
partly neutralise LPS. This disruption of the outer bacterial cell membrane allows the 
AMP to pass through the membrane (Hancock and Scott 2000). In a review on killing 
mechanism of this type this entrance to the membrane by electrostatic interactions with 
itself has been termed 'self promotion of their own uptake', this review by Hancock and 
Scott (2000) suggests this term which they once used to described the uptake of 
polycationic antibiotics across the outer membrane (Hancock and Chapple 1999). The 
next stage of AMP action on Gram-negative bacteria is to integrate into the membrane 
via associating with negatively charged phospholipids so that the AMPs become 
orientated parallel to the membrane (Hancock and Scott 2000). At this stage of 
membrane disruption it is understood that at a particular concentration the peptide 
molecules form transmembrane channels in the membrane, these are also know as 
aggregate channels, supramolecular peptide/lipid complexes or toroidal channels 
(Hancock and Scott 2000). There is debate around mechanisms of cell death at this 
stage, as to whether the depolarisation of the membrane by disruption of the proton 
motive force is enough to cause leakage of the contents of the cell, therefore the 
departure of molecules essential for the live of the cell, or as to whether this pore 
formation is just an 'intermediate step' in the process of cell death and that the 
inhibition of a vital function of the cell such as DNA synthesis causes the death of the 
cell (Hancock and Scott 2000). 
The mode of action of AMPs on Gram-positive is not agreed on in literature and the 
method of action is still not resolved to-date. It is proposed in some studies that 
interactions with cytoplasmic membranes are voltage dependant (Falla, Karunaratne et 
al. 1996) but in other studies transmembrane potential for AMP interactions have been 
seen to vary between peptides (Koo, Yeaman et al. 1997 ; Yeaman, Bayer et al. 1998). 
In the study by Koo, Yeaman et al (1997), when defensin transmembrane potential was 
compared to thrombin-induced platelet microbicidal protein 1, the defensins appeared to 
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have potentially independent or very low membrane potential in comparison. This 
variation in membrane potential and permeablisation was also observed after analysis 
with flow cytometry by Yeaman, Bayer et al (1998) as here as HNP-l was observed to 
depolarise and permeablise the membrane, whereas thrombin-induced platelet 
microbicidal protein 1 permeabilised but did not depolarise (Yeaman, Bayer et aI. 
1998). These articles suggest that membrane perturbation is required for killing but is 
not essential; leading to the suggestion that killing may be due to the inhibition of an 
intracellular target. 
The membrane disrupting properties of AMPs have been analysed using model systems 
involving the lipid bilayers of artificial liposomes (Jelinek and Kolusheva 2005), and 
three main models of pore formation have been proposed: the barrel-stave mechanism 
(Rapaport and Shai 1992), the carpet mechanism or the Shai-Matsuzakul method 
(Matsuzaki 1999; Zasloff 2002), and the toroidal pore mechanism (Brogden 2005). It 
has also been observed that the AMPs differentiate between the membranes of higher 
eukaryotes and prokaryotes including bacteria, through the different compositions of the 
membranes, including the absence or presence of cholesterol (Schroder 1999). 
1.4.Gi Barrel-stave mechanism 
A representation of this killing mechanism is shown in Figure l.5. Essentially, a-helical 
cationic peptides form bundle-like structures, which target the bacterial membrane via 
the alignment of their hydrophobic regions with the lipid core of the membrane. This 
results in a membrane pore and further AMP monomers, recruited to the site, enlarge 
the pore (Oren and Shai 1998; Brogden 2005). 
1.4.Gii Carpet mechanism 
In the carpet mechanism the cationic AMPs bind to the negatively charged surface 
membrane of the bacteria and 'carpet it' i.e. the bacterial membrane is covered with a 
layer of AMPs. The peptides then permeate the membrane causing the negatively 
charged membrane lipid heads to rotate and make contact with the positively charged 
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cationic peptides, which subsequently results in the formation of micelles and 
membrane disruption (Oren and Shai 1998; Brogden 2005). 
1.4.6iii The 'toroidal-pore' mechanism 
The AMPs LL-37 and magainin are proposed to function through a toroidal pore or 
'aggregate channel' killing mechanism (Huang, Chen et al. 2004). This involves AMP 
helices inserting into the lipid bilayer leading to the dynamic formation of pores. The 
peptides are believed to induce bending of the lipid mono I ayers continuously through 
the pore, resulting in the pore being lined with both the AMP and the lipid head groups 
of the bilayer. The toroidal-pore model differs from the barrel-stave model in that the 
AMPs are always associated with the lipid head groups. 
"carpet" mechanism 
,J.;1 ~ / J ~barr.I.S"V<>. mechanism 
A 
B 
c 
Figure 1.5: Barrel-stave and carpet mechanisms are represented as above. This schematic representation 
was adapted from (Oren and Shai 1998). The orientation of AMP molecules and their ability to form 
pores in the bacterial membranes is shown. The cationic AMPs initiate contact with the lipid bilayer of 
cell membranes in A for both mechanisms. In the carpet mechanism B the membrane is disrupted by the 
movement of the negatively charged lipid heads to be in contact with the cationic peptides, forming 
micelles and thus breaking down the membrane C. The a-helical cationic peptides depicted in the barrel 
stave mechanism form a bundle and permeate the lipid bilayer using their charges to align the 
hydrophobic core regions with the hydrophilic peptides B allowing pore formation and further 
internalisation of AMPs. 
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In each case these interactions lead to a loss of membrane function including breakdown 
of membrane potential, loss of cell metabolites and ions, and alteration of membrane 
permeability, all of which result in bacterial cell killing. The ability of a peptide to 
cause bacterial cell death through a number of different mechanisms is termed the 
'multi-hit process' and may be responsible for the success, in evolutionary terms, of 
AMPs in host defence (Zhang, Dhillon et al. 2000). Many AMPs have intracellular 
targets once they are inside the membrane. Some have been seen to inhibit vital cellular 
processes such as cell wall synthesis, nucleic acid synthesis, protein synthesis and 
enzymatic activity (Brogden 2005). 
Interestingly PR-39, a proline rich AMP identified in the pig intestine is also reported to 
inhibit DNA synthesis in E. coli (Boman, Agerberth et al. 1993; Schroder 1999). 
To date the actual kiIling mechanisms of the HBDs are not well defined (Zasloff2002). 
Moreover the mechanisms by which the LEAP molecules kill bacteria are not known. 
1.4.7 Regulation of AMP Gene Expression 
The stimuli and signalling pathways that activate and control the expression of the AMP 
genes are an active area of research. However it is recognised that the Toll-Like 
Receptors (TLRs), which are situated in the surface of host cells, play important roles in 
AMP gene expression. To date ten human TLR proteins have been identified (TLRI-
10) and the receptors, found on epithelial cells and mononuclear phagocytes including 
monocytes and macrophages, and are activated through binding to specific P AMPs 
(pathogen associated molecular patterns) on bacterial surfaces (Li 2004; Froy 2005). 
The PAMPs include lipopolysaccharide, peptidoglycan and bacterial flagellin. It must 
be acknowledged that the term P AMP is not the most accurate term for describing these 
molecular patterns which activate TLRs, as often they are not derived from pathogens in 
source, whereas PAMP implies only pathogen associated molecular patterns would 
active TLRs. 
Activation of a TLR, following the binding of an appropriate ligand, generates a 
signalling cascade, which ultimately results in the nuclear translocation of NF-KB 
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(Figure 1.6). This transcription factor then binds to the promoters of genes enc d' 
o Ing a 
number of pro-inflammatory molecules, including the cytokines, TNFa IL-1 IL 6 
' ,- and 
IL-8 (Cook, Pisetsky et al. 2004) as well as AMPs (Lu, Kurago et al. 2006). In addition 
TLRs can also activate pathways involving mitogen activated protein kinase (MAPK) 
leading to the nuclear translocation of the AP-1 transcription factor (Froy 2005). 
The TLRs 2-6 and 9 have been shown to mediate an increase in defensin gene 
expression. For example HBD2 gene expression is mediated through TLR4 Signalling in 
gut epithelia, but TLR2 and TLR6 signalling in airway epithelia (Froy 2005). HBD2 
gene expression has also been shown to be up-regulated by Salmonella flagellin (FliC) 
via TLR5 in the immortalised Caco-2 cell line (Ogushi, Wada et al. 2001). 
In addition to the TLRs, mammals are typified by a family of intracellular receptors 
known as NOD (nucleotide binding oligomerisation domain) proteins. Binding of NOD 
proteins to intracellular bacterial components via a C terminal LRR (leucine-rich 
repeat) domain leads to activation of both NF-KB and MAPK pathways. NOD is found 
in intestinal cells and has been implicated in the regulation of HBD2 gene expression 
(Voss, Wehkamp et al. 2006). Recently it has been shown, at least in oral epithelial 
cells, that the combination of signalling through TLRs and NODs leads to the 
synergistic activation of antibacterial responses (Uehara and Takada 2008). 
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Bacterial cell 
Epithelial Host cell 
Figure 1.6: A representative TLR signalling pathway. 
1.4.8 AMPs and tonsil 
Compared to the literature relating to host defence peptides, in particular, the number of 
articles focussed on AMPs and tonsils is limited. 
The first references relating to defensin gene expression in tonsil were published seven 
years ago by Chae, Lee et al (2001), and Harder, Bartels et al (2001), and these studies 
used RT-PCR analyses to identify the expression of HBDI and HBD3 mRNA 
transcripts in tonsil. The groups of Weise, Meyer et al (2002), and Wang, Dong et al 
(2004), then published research papers in which the authors used RT-PCR analyses, to 
investigate and compare AMP gene expression profiles in control (non-RAT) and RAT 
tonsils. In the study by Weise, Meyer et al (2002), a cohort of 49 hyperplastic tonsils 
and RAT tonsils were analysed and compared for HBD1, HBD2, HNPI and HNP4 
mRNA expression and the results indicated constitutive expression of HBDI mRNA, 
but an up-regulation of HBD2 mRNA in the chronically diseased groups. Similarly in 
the study conducted by Wang, Dong et al (2004), involving a sample cohort of 18, 
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constitutive expression of HBD I was reported in both control (non-RAT) and RAT 
tissues. 
The first paper describing the expreSSIOn of cathelicidin LL-37 mRNA in palatine 
tonsils was published in mid 2000s, (Song, Hwang et al. 2006). This study, using RT-
PCR, reported that the expression of LL-37 mRNA was significantly higher in tonsils 
excised from chronic tonsillitis sufferers when compared to control (non-RAT) patients, 
who were undergoing tonsillectomy for hypertrophic tonsils. In fact in this study the 
amount of LL-37 mRNA detected in control (non-RAT) tonsils was negligible. 
Work by Ball, Siou et al (2007), using semi-quantitative RT-PCR confirmed the 
expression of the LL-37, HBDI, HBD2, HBD3 genes in tonsils, and moreover reported 
for the first time the gene expression of hepcidin (LEAP-I) and LEAP-2. Moreover the 
RT-PCR data indicated that the expression of the cathelicidin gene encoding LL-37 was 
detectable in tonsils from control subjects and moreover the levels appeared comparable 
in control and RAT patient tonsils, although it was acknowledged that the control (non-
RA T) data was from two subjects only. 
1.4.9 Antimicrobial peptide- streptococcal interactions 
In comparison to the wealth of literature focussed on host defence peptides and cationic 
antimicrobial peptides in particular, there are again relatively few papers documenting 
the interactions between AMPs and streptococci. Moreover of those published the 
majority are focused on the interactions between streptococci and the cathelicidins. 
1.4.9i AMPs prevent GAS infections in the skin 
Studies conducted in vitro and in vivo have shown the importance of the cathelicidins in 
protecting the mammalian host against streptococcal infections. For example an in vivo 
study carried out in a murine model (Dorschner, Pestonjamasp et al. 2001), showed the 
protective effects of CRAMP, the murine analogue of LL-37. In normal skin the levels 
of CRAMP were not able to be detected, whereas after wounding and inoculation with 
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GAS, the expression of this gene was up-regulated and an increase in peptide h' 
synt eSIS 
was recorded. Indeed it was estimated that the wounds in the mice resulting c: 1 
' lrom cm 
incisions, contained up to 0.1 Ilg CRAMP (cathelicidin related antimicrobial peptide) per 
mg total protein (Dorschner, Pestonjamasp et al. 2001). Moreover CRAMP kn k 
oc -out 
mice were observed to experience greater necrotising skin lesions than their wild-type 
siblings when challenged with GAS (Nizet, Ohtake et al. 2001). Recently th 
, e up-
regulation of LL-37 in response to GAS has also been documented in human skin 
(Johansson, Thulin et al. 2008), and a unique murine 28 amino acid cathelicidin peptide, 
which protects against Gram-positive infection of the mouse skin has been identified in 
mast cells (Di Nardo, Yamasaki et al. 2008). 
As stated previously it has been proposed that multiple cathelicidin genes provide an 
organism with an increased resistance to infection. This has been shown quite elegantly 
in studies using transgenic mice (Lee, Ohtake et al. 2005). In these studies transgenic 
mice, engineered to express either the porcine cathelicidin gene PR-39 or over express 
the endogenous cathelicidin CRAMP, were challenged with GAS. The mice expressing 
PR-39 and endogenous CRAMP, showed increased resistance to GAS skin infections 
when compared to those expressing CRAMP alone. Indeed up to 50% fewer necrotic 
ulcers and 60% fewer surviving bacteria were observed in the mice synthesising the two 
different cathelicidins. Whether the added protection was due to direct killing activities 
of the peptides or to the PR-39 inducing cytokines, chemokines and potentially other 
AMPs is not however known. 
1.4.9ii Interaction with Streptococcus salivarius 
While the host innate responses function to eliminate potential pathogens there is a 
paradigm in that some bacterial species evade these systems and actually function as 
probiotic commensals. Streptococcus salivarius is one such organism. It colonises 
epithelial surfaces in the human mouth and naso-pharynx and is reported to be 
protective against pathogens such as S. pyogenes. It has been proposed recently that S. 
salivarius achieves this by modulating genes associated with adhesion to the epithelial 
layer and by inhibiting host inflammatory responses through down-regulation of the 
NFKB pathway. Indeed S. salivarius was shown to suppress IL-8 secretion in bronchial 
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cells stimulated with LL-37 (Cosseau, Devine et al. 2008). This suggests that the 
organism not only functions directly against pathogens, S. salivarius synthesises its own 
antimicrobial peptides, but protects the host tissues from potential damage caused by 
immunostimulatory cells and products. 
1.4.10 GAS Defence mechanisms 
In order to be successful, as S. pyogenes obviously is, micro-organisms must evolve 
mechanisms to protect themselves from host innate defences, including AMPs. The 
mechanisms employed are numerous and many have been discussed in a number of 
review articles including one by Peschel, (2002). One common bacterial mechanism 
employed by bacteria to avoid killing by AMPs is the binding and/or neutralisation of 
the AMP. Examples of this includes the staphylokinase of S. aureus that binds a-
defensins (Jin, Bokarewa et al. 2004), and proteases synthesised by many human 
pathogens which are able to degrade LL-37 (Schmidtchen, Frick et al. 2002), and thus 
inactivate the peptide before it reaches the bacterial membrane. Bacteria may also 
undergo cell surface modifications to reduce their charge and hence reduce the 
electrostatic interactions between the AMPs and the bacterial surface. Indeed the 
incorporation of D-alanine into the Gram-positive cell wall generates a more positive 
charged microbial surface (Peschel 2002). 
Many streptococcal proteins including GRAB, streptococcal cysteine protease, 
streptococcal endotoxin B (SpeB), streptococcal inhibitor of complement (SIC) and 
Distantly related to SIC (DRS) have been identified as factors which protect GAS from 
the effects of AMPs. Of these SpeB and SIC are particularly protective against LL-37. 
1.4.10i SpeS - Cysteine proteinase 
S. pyogenes secretes the extracellular cysteine protease SpeB as a 40kDa zymogen that 
is cleaved to the mature 28kDa active proteinase (Hauser and Schlievert 1990). The 
proteinase has broad proteolytic activity and cleaves a large number of human proteins 
including fibrin and fibronectin (Kapur, Topouzis et al. 1993). Proteoglycan is also 
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degraded by SpeB, which leads to the release of dermatan sulphate, which in turn 
inactivates a-defensins and LL-37 (Schmidtchen, Frick et al. 2002). 
A link between the GAS surface protein GRAB and SpeB in bacterial resistance to 
AMPs has been proposed following experiments in which different concentrations and 
combinations of a-2-macroglobulin, SpeB, an Spe inhibitor and LL-37 were added to 
GAS (Nyberg, Rasmussen et al. 2004). It was shown in vitro that SpeB is actually 
trapped by GRAB and while in this complex SpeB cannot degrade large proteins, the 
small LL-37 peptides can permeate the complex, where they are degraded. It is 
assumed therefore that in vivo GRAB secures SpeB at the bacterial surface and hence 
protects GAS from killing by LL-37. 
1.4.10ii SIC and DRS 
SIC, a 31 kDa extracellular protein synthesised by GAS, particularly the M 1 and M57 
serotypes was so named because it was first identified as a protein that inactivates 
complement (Akesson, Sjoholm et al. 1996). It is essential for GAS virulence as /).sic 
mutants were shown not to colonise the mouse throat (Lukomski, Hoe et al. 2000). SIC 
protein has been shown to inhibit lysozyme and SLPI, (Secretory Leukocyte Protease 
Inhibitor), two major components of the innate immune system. Indeed binding to the 
latter protects GAS from killing by SLPI (Fernie-King, Seilly et al. 2004). In addition 
SIC and a related molecule, DRS, exert their protective effects by also binding to LL-
37, and physically inhibiting its action. Binding is in a ratio of one molecule of SIC to 
two molecules of LL-37 while DRS binds LL-37 in a 1: 1 ratio (Fernie-King, Seilly et al. 
2006). 
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1.5 Hypothesis and Aims 
Although the human palatine tonsils play important roles in host immunity and provide 
a barrier against invading pathogens, the Gram-positive bacterium, S. pyogenes often 
penetrates their defences. This results in tonsillitis, in which sufferers present with 
swollen and painful palatine tonsils. However despite tonsillitis being relatively 
common, the physiological and immunological factors that allow this infection to 
perpetuate remain obscure. AMPs, expressed at epithelial and mucosal surfaces, 
provide a first-line of defence against potential pathogens. Moreover these molecules 
have also been reported to be up-regulated in response to infection. However the roles 
of AMPs in the defence of the human palatine tonsils are not well known. 
The hypothesis was therefore proposed that a defect in the innate immune response 
involving host AMPs, such as a deficiency in AMP expression at the epithelial surface 
and/or a failure of the AMPs to up-regulate in response to infection, is a cause or 
contributory factor to recurrent acute tonsillitis. 
The aims of this study were: 
(i) To investigate and compare the AMP gene expression patterns of palatine tonsils 
excised from patients undergoing tonsillectomy for RAT to those of control subjects 
whose tonsils were excised for conditions such as snoring or sleep apnoea. 
(ii) To identify an immortalised cell line that modelled the tonsil epithelium in vitro, to 
describe its AMP expression profile, and to challenge the cells in vitro with S. pyogenes, 
and determine the effects of binding and infection on AMP gene expression. 
(iii) To use the ex vivo tonsil model, to investigate and compare the effects of S. 
pyogenes challenges on the AMP expression patterns in human tonsils excised from 
control (non-RAT) subjects and RAT patients. 
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Chapter 2 
Materials and Methods 
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2.1 Bacterial Strains 
2.1.1 Streptococcus pyogenes strains 
Streptococcus pyogenes Ml and M2 serotypes and mutants thereof were used. These 
are detailed in Table 2.1 
Table 2.1: Streptococcus pyogenes wild-type and recombinant strains. 
M Serotype Strain Source/ Reference 
S. pyogenes M I wild-type SF370 A TCC 7002941 (Suvorov and 
Ferretti 1996). 
S. pyogenes MIl1spy129 (pilus mutant) SF370 Engineered from S. pyogenes 
M I wild-type, (Abbot, Smith et 
al. 2007). 
S. pyogenes M I I1spy 1 J 54 (surface protein mutant) SF370 Engineered from S. pyogenes 
MI wild-type, (Abbot, Smith et 
al. 2007). 
S. pyogenes M2 wild-type Ncl75245 Clinical Isolate, Newcastle 
upon Tyne. 
The wild-type and recombinant strains where appropriate were transfected with the 
pCM18 plasmid expressing green fluorescent protein (GFP) as described in Section 
2.2.4. Transfections were performed by Dr Wendy D. Smith (lCaMB). 
2.1.1 i Culture and maintenance of Streptococcus pyogenes 
strains 
Streptococcus pyogenes were grown without shaking in either Todd-Hewitt Broth 
(THB, Difco) supplemented with 0.5% (w/v) Bacto-yeast extract (Difco), or on 
blood agar plates (Todd-Hewitt Yeast Broth (THYB) with 1.5% (w/v) Bacto-agar 
(Difco», at 3rC and 5% CO2• Where selection for plasmids was required, 
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erythromycin dissolved in 100% ethanol was added to a final concentration of 
1.Oflg/ml. Glycerol stocks of S. pyogenes were produced by adding one bacterial 
colony to Sml THYB, culturing the bacteria overnight at 37°C in a static incubator in 
the presence of S% CO2, and then adding sterile glycerol to lml of the culture to give 
a final concentration of20% (v/v). Glycerol stocks were stored at -80°C. 
2.1.2 Escherichia coli 
JM109 competent cells were purchased as part of the p-GEM-T Easy Vector System 
kit (Promega). Genotype: endAl, recAl, gyrA96, thi, hsdR17 (rk-, mk+), relAl, 
supE44, ~( lac-proAB), [F' traD36, proAB, laqIqZ~M15]. E. coli were cultured as 
described in 2.7.S. 
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2.2 Human Tonsils 
2.2.1 Ethical approval 
The Local and Regional Ethics Committee (LREC), Newcastle upon Tyne was 
consulted prior to the study and ethical approval was granted to allow collection of 
human tonsil tissue. The information sheets and consent forms distributed to 
potential volunteers (Appendix A and Appendix B respectively), were designed to 
comply with current Central Office for Ethics Committees (COREC) regulations. 
Patients were informed of the study at their pre-admissions appointment, which 
provided a 'cooling off period' to allow them time to decide whether or not they 
wished to take part in the study. 
2.2.2 Tonsil collection and processing 
Human tonsils were collected from patients undergoing tonsillectomy at the Freeman 
Hospital, Newcastle upon Tyne. Before excision patients were asked to complete a 
short questionnaire detailing their gender, age and last sore throat (Appendix C). 
Tonsils were excised for conditions including recurrent acute tonsillitis (RAT), 
obstructive sleep apnoea, enlarged tonsils and tonsillar crypts, and snoring. In most 
cases both tonsils were obtained from the patient. Tissues from patients with 
exceptionally scarred tonsils or those which had undergone trauma during surgery, 
and in which the epithelia could not be differentiated from the lymphoid interior, 
were not used. Scarred tonsils from which epithelium and lymphoid tissues could be 
differentiated were used as many of the tonsils from RAT sufferers had this 
appearance. 
Tonsils collected for RNA extraction were dissected immediately after excision. 
Whole tonsil dissection involved the intact epithelial surface being separated from 
the lymphoid interior of the tonsils and samples of both being taken. The samples 
were either snap frozen in liquid nitrogen or preserved in RNA Later (Ambion). For 
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the ex vivo challenge experiments the tonsils were transported to the laboratory in 
sterile polypropylene tubes. 
2.2.3 Tonsil: ex vivo model 
Within an hour of excision intact tonsil epithelium was dissected from the whole 
tonsils and divided into segments approximately 3mm x 3mm in size. Each segment 
was placed apical side up in a 12mm diameter well (Corning), and incubated at 37°C 
and 5% CO2 for three hours in RPMI-1640 (Sigma) culture medium supplemented 
with 2% (v/v) non-essential amino acids (NEAA, Sigma) and 200ng/ml gentamycin 
(Sigma), the latter to kill surface bacteria from the pharyngeal cavity. After washing 
three times in phosphate buffered saline (PBS) the samples were transferred to the 
upper chamber of a Transwell (O.4I-1M pore size, CoStar) containing antibiotic free 
culture medium in the lower chamber. Tissue samples were submerged in either 
2001-11 of culture medium (control) or culture medium containing appropriate 
challenge reagents (test) before incubation for a pre-determined time period. For 
investigations involving a bacterial challenge, binding controls, described in Section 
2.2.5 were included. Following incubation the tissue samples were washed three 
times in PBS and analysed as appropriate. 
2.2.4 Streptococcus pyogenes bacterial challenge experiments 
Streptococcus pyogenes contained pCM18, a low copy number plasmid which is 8.2 
kb in size including a 1.8kb cloned gfPmut3* gene from a constitutive lactococcal 
promoter CP25 which it expressed (Hansen, Palmer et al. 2001). The plasmid also 
includes an erythromycin resistance gene. S. pyogenes was grown to an optical 
densitY600 (OD600) of 0.5 (l08 cfulml; (Abbot, Smith et al. 2007), washed three times 
in distilled water and re-suspended in the antibiotic free RPMI-1640 culture medium. 
An aliquot of the bacterial suspension (2001-11) was added directly to each tissue 
(equivalent to a multipl~city of infection of approximately 200: 1; (Abbot, Smith et al. 
2007) and the tissues incubated at 37°C and 5% CO2 for pre-determined time periods. 
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Following the bacterial challenge weakly adhering bacteria were removed by 
washing three times with PBS, and the tissues fixed as described in Section 2.2.5 
(binding controls) or the RNA extracted as described in Sections 2.5.1 or 2.5.2 for 
use in the gene expression analyses. 
2.2.5 Binding controls 
To check for the binding of the streptococci during the tonsil infections binding 
controls were employed. For such controls tissue samples were challenged as above 
with bacteria, but after the appropriate incubation periods the samples were fixed in 
100% (v/v) ice-cold methanol for 15min, blocked at room temperature for 30min in 
3% (v/v) goat serum (Sigma) and stained with a murine anti-cytokeratin-14 
monoclonal antibody (Sigma) diluted I :200 in PBS with 3% (v/v) goat serum for I h 
at room temperature. After washing in PBS the tonsil samples were incubated with 
goat anti-mouse Alexa-fluor 568, diluted I: 1 00 in PBS with 3% (v/v) goat serum, for 
1 h at room temperature. Tissue samples were again washed in PBS before being 
mounted and imaged by confocal laser scanning microscopy (TCS-NT Leica with 
Kr-Ar laser). Using appropriate excitation and emission filter sets, Z-series images 
were collected. 
2.2.6 Immunohistochemical analysis of tonsil 
Frozen human tonsil sections were fixed in 2% Paraformaldehyde (PF A, Sigma) in 
PBS for 30min on ice. After PF A fixation tonsil sections were permeablised with 
0.1 % Triton X-I 00 for 30min at room temperature. All tissue sections were blocked 
in 10% goat serum in PBS (Sigma) for I h on ice before incubation with anti-human 
LEAP-2 purified IgG (l: 100 in PBS) over night at 4°C. The sections were then 
incubated with goat anti-rabbit antibody-FITC (Chemicon), 1 : 50 in PBS for 3h 
before being mounted on slides with Vectashield. LEAP-2 expression was shown in 
bright green after visualisation with a confocal laser scanning microscope. Control 
sections were performed alongside test sections; these were prepared without 
primary antibody. 
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2.3 HaCaT cells 
2.3.1 Origin 
The HaCaT cells are an immortalised keratinocyte cell line, originally derived from 
human skin (Boukamp, Petrussevska et al. 1988) and were obtained from Dr Carol 
Todd (Dermatological Sciences, Newcastle University). 
2.3.2 Tissue culture 
To establish the HaCaTs from frozen a vial of cells (106/ml) was thawed gently at 
3JOC in a water bath before being added to a 25cm3 flask (Coming) containing 10ml 
of cell culture medium (Dulbecco's Modified Eagle's Medium (Sigma) including 
glucose 4.5g/1 and L-glutamine 584mg/ml supplemented with sodium pyruvate 
IIOl-lg/ml (Sigma), 10% (v/v) FCS (Sigma) and 1 % (v/v) penicillin/streptomycin 
(Sigma 100ull-ll penicillin/lOOI-lg/ml streptomycin in 0.9% sodium chloride)). 
To passage the HaCaT cells, the culture medium was decanted off, the cells washed 
in PBS and 5ml Trypsin-EDT A (Sigma) was added to the cells. After approximately 
lOmin at 37°C and 5% CO2 the detached cells were resuspended in 25ml of fresh 
medium, dispersed by passing through a large gauge needle, and cell numbers 
determined using a cell counter (Coulter). For maintenance of the cell line the 
HaCaT cells were split at a ratio of 1: 1 0 and cells were passaged every seven days. 
2.3.3 HaCaT: cell challenge assays 
The cultured HaCaT cells were subjected to either bacterial and/or environmental 
challenges. For such experiments the cells were counted, seeded into 12 well plates 
(12mm diameter), at a density of 106 cells per well and cultured in 1 ml growth 
medium at 37°C and 5% C02 until confluent. Prior to challenge, the HaCaT cells 
were incubated for 3h at 37°C and 5% CO2 in cell culture medium lacking FCS and 
antibiotics. This medium was removed and replaced by either Iml control medium or 
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medium containing the appropriate challenge (bacterial and/or en . 
vlronmental) 
reagents. These reagents were Lipoteichoic acid (L T A, from S. pyog . 
enes, SIgma, 
final concentration 2Jlg/ml), Lipopolysaccharide (LPS, Sigma, final c . 
oncentratlOn 
O.2Jlg/ml), Phorbol 12-myristate 13-acetate (PMA, Sigma, final concentrat' 2 
Ion OJlM) 
and 1,25 dihydroxyvitamin-D3 (D3, Fluka, final concentration 200nM) Aft 
. er a pre-
determined incubation period the medium was removed, the cells washed th . 
ree tImes 
with PBS and RNA extracted from the cells as described in Section 2.5.2. 
2.3.4 HaCaT cells: bacterial challenge 
For the bacterial challenge of HaCaT cells S. pyogenes was grown to an OD
600 
of 0.5 
(108 cfu/ml) and prepared as described in Section 2.2.4. 1 5ml f b 
. 0 acterial 
suspension was added per well; cells and bacteria were incubated at 37°C with 5% 
CO2 for an appropriate pre-determined incubation period. 
2.3.5 HaCaT cell binding controls 
To check for the binding of the streptococci to HaCaT cells binding controls were 
performed. For such controls the HaCaT cells were seeded and cultured to 
confluence on pre-sterilised (ethanol) 10mm coverslips (VWR) placed in the wells of 
a 12 well plate. Following bacterial challenge the HaCaT cells were fixed in 2% 
paraformaldehyde for 15min on ice, washed three times with PBS, permeabilised 
with 0.1 % Triton-X100 (Sigma) at room temperature and incubated with Phalloidin-
Rhodamine (Sigma), a stain of filamentous actin, diluted 1 :200 in PBS for 1h at 
room temperature before mounting and imaging as described in Section 2.2.5. 
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2.4 HEp-2 Cells 
2.4.1 Origin 
The HEp-2 (Human Epithelial Cell line 2) immortalised cell line was purchased from 
ATCC (CCL-23). This cell line was derived originally from an epidermoid 
carcinoma of the larynx but has since been found to have been contaminated with 
HeLa cells derived from a cervical cancer cell line (www.lgcpromochem-atcc.com). 
2.4.2 Tissue culture 
HEp-2 cell monolayers were established from frozen using the same procedures as 
described for HaCaT cells (Section 2.3.2) and maintained in cell culture medium 
containing Dulbecco's Modified Eagle's Medium, supplemented with 2mM L-
glutamine, 10% (v/v) FCS, 2% (v/v) NEAA and 1 % (v/v) penicillin/streptomycin 
(Sigma 100ullll penicillin/lOOllg/ml streptomycin in 0.9% sodium chloride). 
HEp-2 cells were maintained routinely in 175cm3 flasks. To passage the cells, the 
culture medium was decanted off, the cells washed in PBS and 5ml Trypsin-EDT A 
(Sigma) added. After approximately lOmin at 37°C and 5% CO2 the detached cells 
were transferred to a 30ml universal, dispersed by passing through a large gauge 
needle, centrifuged at 5,000g for 3min at room temperature, resuspended in 10ml of 
medium and cell numbers determined using a cell counter (Coulter). For 
maintenance of the cell line 2xl 06 HEp-2 cells were seeded per 175cm3 flask with the 
addition of 30ml cell growth medium. Cells were passaged every seven days. 
2.4.3 Immunocytochemical staining of HEp-2 cells 
For immunocytochemical staining 105 cells were seeded onto 10mm sterile 
covers lips positioned in each well of a 24 weII plate (Corning). 1ml of HEp-2 
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culture medium was added per well and cells were cultured at 37°C and 5% C02. 
Once confluent the cells were washed three times in PBS, fixed and permeabilised as 
described in Section 2.3.5. The cells were incubated with Phalloidin (Sigma) diluted 
1:4 for Ih at 4°C before washing three times with PBS. The coverslips were 
removed from the wells mounted on slides (VWR) with Vectashield and visualised at 
xlOO magnification using a confocal microscope and TRITC filters as described in 
Section 2.2.5. 
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2.5 RNA Extraction 
2.5.1 RNA extraction from tonsil 
Extraction of RNA from human tonsil was performed using a 'Pure Link Micro-to-
Midi Total RNA Purification System' (Invitrogen). Essentially, the tissue samples 
were weighed and the appropriate amount of lysis solution, supplied with the kit and 
containing guanidinium isothiocyanate (GTe) and 1 % (v/v) 2-mercaptoethanol, 
required for the extraction was calculated according to the manufacturer's 
instructions (Table 2.2). 
Table 2.2: Detennining volume of RNA lysis solution required per sample 
Amount of tissue (mg) RNA lysis solution (ml) 
::;10 0.5 
10-60 0.6 
60-100 1.2 
100-200 2.4 
.. (Table adapted from Invitrogen Pure Lmk MIcro-MIdI RNA PunficatJon System manual p12) 
Fresh tonsil tissue or tissue preserved in 'RNA Later' (Ambion) was dissected into 
small pieces; frozen tissue was crushed to a fine powder using a pestle and mortar. 
The tissue was added to a pre-cooled polypropylene tube containing the appropriate 
amount of lysis solution and homogenised on medium setting for approximately 45s 
until a smooth suspension was observed. Homogenisation was performed using a 
rotor-stator style homogeniser, a TissueRupter (Qiagen), with disposable probes. 
Between samples the rotor-stator probe was rinsed in 100% ethanol and PBS to 
prevent cross contamination of the samples. Following homogenisation, the tissue 
samples were centrifuged at 2600g for 5min and room temperature, to remove any 
remaining cellular debris. The supernatants containing the nucleic acids were 
transferred to sterile 15ml polypropylene tubes and one volume 100% ethanol was 
added to each. Any precipitate formed was dispersed by vortexing and each sample 
was added in 700f.l1 aliquots to a fresh spin cartridge. After centrifugation at 12,000g 
for 15s a series of wash steps were performed using wash buffers I and II from the kit 
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(constituents not provided by manufacturer), which removed any impurities from the 
RNA preparations. The RNA was finally eluted in 2 x 30j.l1 volumes of nuclease-
free water and stored at -80°C. 
2.5.2 RNA extraction from cultured cells 
To isolate RNA from HaCaT cells and HEp-2 cells the SV Total RNA Isolation 
System (Promega) was used. As recommended by the manufacturer, 175 j.ll of lysis 
solution (4M guanidinium isothiocyanate, O.OlM Tris, 0.97% ~-mercaptoethanol) 
was added directly to cells cultured in a 12mm diameter well. A sterile pipette tip 
was used to scrape the cells from the plastic and the cells were sheared by passing 
through a 20-gauge needle. Following centrifugation of the cell lysate at 12000g for 
10min, the supernatant was collected and the nucleic acid precipitated by the addition 
of 250j.l1 of 95% ethanol. For purification of the RNA the nucleic acid was bound to 
silica contained within a column provided with the kit, washed to remove proteins 
with buffer containing 60mM potassium acetate, 10mM Tris-HCI and 60% ethanol 
(using a vacuum manifold fitted with spin column adapters (Promega)), DNase 1 
treated as recommended by the manufacturer and the RNA eluted in 100j.ll of 
nuclease-free water. The purified RNA was stored at -80°C. 
2.5.3 Analyses of RNA concentration and purity 
The concentrations of RNA extracted from the tissue samples and cells were 
determined spectrophotometrically. Essentially, RNA samples were diluted 1: 1 0 or 
1: 1 00 in nuclease-free water and the absorption of RNA measured at 260nm. The 
conversion factor 40j.lg/ml per 1 unit OD26onm was used to calculate RNA 
concentration. For initial calibration of the spectrophotometer nuclease-free water 
was used. Absorbance was also measured at 280nm and 230nm to check for 
contamination of the sample with protein (A2601A28o) and guanidine isothiocyanate 
(A2601 A23o). In both cases ratios of 1.8-2.2 indicated that the sample was within an 
acceptable purity range and was free from protein and lor chemical contamination. 
46 
2.5.4 RNA integrity: denaturing RNA gel electrophoresis 
The RNA quality of the samples was also investigated by gel electrophoresis. This 
provided separation and visualisation of the 18S and 28S ribosomal RNA (rRNA) 
subunits and allowed an assessment of the integrity of the nucleic acid. 
For such analyses, a 1 % (w/v) denaturing RNA gel was used. This was prepared by 
gently dissolving molecular biology grade agarose (Sigma) in a solution of 86% (v/v) 
distilled water, 5% (v/v) 20x MOPS buffer (400mM MOPS (Sigma), 100mM sodium 
acetate (NaAc, BDH), 20mM EDTA (Sigma)) and 7.5% (v/v) formaldehyde (BDH). 
The molten gel was poured into a gel casting tray in a fume hood, left to set and then 
positioned in a gel electrophoresis tank. Illg of each RNA sample diluted in 
nuclease-free water to a volume of 10111 was incubated for 5min at 45°C with 14111 
formamide (Sigma). To each sample formaldehyde (38% concentrated), MOPS 
buffer, ethidium bromide and bromophenol blue loading dye (Sigma) was added in 
the ratio 4.3:1.4:1:4 to give a final total sample volume of 20.7111. The samples were 
incubated for 5min at 65°C and loaded onto the denaturing RNA gel submerged in a 
Ix MOPS running buffer containing 75ml formaldehyde per litre. Electrophoresis 
was performed at 110V for 90min. The molecular weight markers were RNA 
Millenium Markers (Ambion). For good quality RNA both the 28S and 18S rRNA 
bands were visible and the 28S rRNA band was twice as bright as the 18S rRNA 
band. 
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2.6 Reverse Transcription - Polymerase Chain Reaction (RT-
PCR) 
2.6.1 DNase treatment of RNA 
To eliminate any genomic DNA contamination of the RNA samples DNAse 
treatments were performed. The HaCaT RNA, as described in Section 2.5.2, was 
DNAse treated on the column as part of the RNA extraction process. All human 
tonsil RNA samples were subjected to DNAse treatment using a DNase treatment kit 
(Promega), containing DNAse (1 ullll). 
For DNAse treatment, 3.51lg RNA was diluted with nuclease-free water to a final 
volume of 24.5111. DNAse prepared in reaction buffer (400mM Tris-HC1, 100mM 
MgS04 and 10mM CaC}z) was added at 1 u per Ilg RNA and the solution incubated 
for 30min at 37°C. The DNAse treatment was halted by the addition of stop solution 
(200mM EGT A, 1I10th of the final reaction volume) and heat inactivated for lOmin 
at 65°C. 
2.6.2 Reverse transcription (RT) 
Total RNA was reverse transcribed into complementary or copy DNA (cDNA) for 
use in end-point and real-time PCR analyses. For such reactions Illg of total RNA 
was resuspended in 25.5111 nuclease-free water, 1111 of random hexamers (stock 
O.5mg/ml: GE Healthcare UK Ltd), was added and the solution incubated at 65°C for 
5min before being rapidly cooled on ice. This denatured any secondary structure and 
allowed the hexamers to anneal to the single-stranded RNA. Following the 
incubation step, 12.5111 of 5x reaction buffer (stock 50mM Tris-HCI, 75mM KCI, 
3mM MgC}z and IOmM DTT), 10111 of dNTPs (stock 2mM), 0.1111 Human Placental 
RNAse inhibitor (stock RNasin (4 Oullll) , Promega) and 1111 of M-MLV RNaseH 
reverse transcriptase (stock 200ullll) (Promega) were added. This was mixed and 
the solution incubated for 2h at 42°C in a Thermo Px2 thermal cycler followed by a 
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final 70°C step to inactivate the enzyme prior to polymerase chain reaction. Sample 
incubations included no template and no reverse transcriptase enzyme controls. 
2.6.3 End-point polymerase chain reaction 
Polymerase chain reaction (PCR) was used to replicate cDNA exponentially by an 
enzymatic reaction using DNA polymerase. The DNA polymerase used was Taq 
polymerase, a "hot start" enzyme requiring an initial period of high temperature for 
activation. Typical PCR reactions were set-up as shown in Table 2.3 in a final 
volume of2S)l1. 
Table 2.3: A typical end-point PCR reaction 
Reagent Amount Added 
Template cDNA 2J.tl 
Nuclease-free water To a final volume of2S)l1 
Reaction buffer (200mM Tris-HCL, SOOmM KCI), 2.S )ll 
dNTP (Invitrogen) 2.S Jll 
(dATP, dGTP, dTTP, dCTP each at 2mM) 
MgCI2+ (SOJlM) 1 JlI 
Target specific primers (IO)lM) O.S JlI of each 
(Forward and Reverse) 
Platinum Taq DNA Polymerase (Invitrogen) SulJlI 0.2SJlI 
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Each PCR was perfonned in a Thenno Px2 thennal cycler as follows: 
1 cycle at 95°C for 15min to activate the Taq DNA polymerase 
40 cycles of: 
95°C for 30s, 55 or 58°C (dependent on gene of interest) for 30s, 72°C for 45s 
Followed by 1 cycle of 72°C for 10min and a holding stage at 4°C. 
No template controls, with nuclease-free water as a substitute for cDNA, were 
perfonned with each PCR reaction to ensure the specificity of PCR product. 
2.6.4 Agarose gel electrophoresis 
cDNA products from end-point PCR were separated based on their size and 
visualised on an agarose electrophoresis gel (1.2%). An agarose gel was prepared by 
melting the appropriate amount of electrophoresis grade agarose (l.2g of agarose in a 
100ml gel) in Ix TBE buffer (54g Tris, 27.5g Boric Acid, 20ml 0.5M EDTA per 
litre) containing a final concentration of 2.5x 1O-3Ilg/ml ethidium bromide. This was 
allowed to set in a gel-casting tray of the appropriate size, transferred to a gel tank 
(Thistle Scientific Ltd) and submerged in xI TBE electrophoresis buffer. The 
samples containing loading dye (0.25% bromophenol blue / 50% glycerol) added in a 
1:5 dye to sample ratio were loaded into the wells of the gel and electrophoresed at 
110V for 90min. Visualisation of the DNA was performed using a UV 
transilluminator (302nm, AlphaImager 1200 gel documentation and analysis system, 
Flowgen). Various DNA ladders including a 100 base pair (bp) DNA ladder and a 
lKb DNA ladder (All from NEB) were used as appropriate. 
2.6.5 Densitometry 
Densitometry was perfonned using software provided as part of the AlphaImager 
1200 gel documentation system. 
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2.7 DNA Cloning 
2.7.1 DNA extraction 
To extract DNA from agarose gels for further analyses including DNA cloning, the 
gels were first visualised under UV light and the required DNA bands excised using 
a scalpel blade. The bands were weighed and the DNA recovered using a GenE lute 
Gel Extraction kit (Sigma). 
For this procedure a volume of gel solubilisation solution was added to each sample 
according to the weight of the agarose gel (311I1mg). This was incubated at 50-60°C 
for 1 Omin with regular vortexing to dissolve the gel slice, and then 100% isopropanol 
(1I1I1ml) was added. During this period, a spin column was inserted into a collection 
tube and primed by the addition of 500111 of column preparation solution followed by 
centrifugation at 13000g for I min. The flow-through was discarded from the 
collection tube and the solution containing the melted agarose gel was passed 
through the column in 700111 aliquots to allow the DNA to bind to the membrane. 
Sample impurities were removed by treating the column with an ethanol-based wash 
solution and the purified DNA was eluted from the column in 50111 of 10mM Tris-
HCI. 
2.7.2 peR product clean-up and purification 
PCR products contain impurities such as primers and unincorporated dNTPs that 
have been carried over from the amplification reaction. Purification of these 
products was undertaken by either gel purification, as described in Section 2.7.1, or 
by using an Amicon Microcon-PCR Centrifugal Filter Device (Millipore). This 
device was used according to manufacturer's instructions. 
Essentially, the PCR product to be purified was diluted to a final volume of 500111 
with nuclease-free water and forced through a 'clean-up' filtration column by 
centrifugation in a microfuge at 1500g for lOmin. 20111 of nuclease-free water was 
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then added to the column, which was inverted, placed into a second collection tube 
and subjected to a second centrifugation at 1500g for 2min. The eluate containing the 
concentrated, purified PCR product was collected. 
2.7.3 DNA cloning in pGEM-T-Easy Vector System 
Recombinant DNA clones were engineered by ligation of the appropriate PCR 
products into the pGEM-T-Easy vector. 
2.7.4 DNA ligation 
Initially, a PCR reaction was performed as described in Section 2.6.3. A 
characteristic of the Taq polymerase enzyme is that following amplification 
adenosine triphosphate residues are added to the 3' ends of the double-stranded PCR 
product. This property can be exploited by cloning the product into a linearised 
vector, such as the pGEM-T Easy vector, with complementary 3' T overhangs. The 
amount of insert required per reaction was determined using the equation: 
ng of vector x Kb size of insert 
ng of insert to be used = x insert to vector molar ratio (3: 1) 
-------------------
Kb size of the vector 
For cloning ligation reactions were set-up as follows in a final volume of IOIlI: 
3111 PCR product (purified by column or gel) 
5111 Ix rapid ligation buffer (Promega) 
I III pGEM-T Easy Vector (50ng/lll) 
I III T4 DNA ligase (Promega) (3u/lll) 
Positive control inserts were provided with the kit and for negative controls the PCR 
product was replaced with 3111 nuclease-free water. Ligations were performed 
Overnight at 4°C to yield the maximum number of transform ants. 
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2.7.5 Transformation and plasmid selection 
To produce recombinant clones the ligated DNA was transformed into JMI09 
competent cells. These high efficiency competent cells were provided with the 
pGEM-T Easy system. 
Essentially, SOIlI of competent cells were added to 2111 of the ligation reaction and 
incubated on ice for 20min. This was 'shocked' at 42°C for 4S-S0s and 9S01l1 of 
SOC medium (2% (w/v) Bacto-tryptone (BD Biosciences), 0.5% (w/v) Bacto-yeast 
extract (BD Biosciences), 1% (v/v) 1M NaCI (Sigma), 0.25% (v/v) 1M KCI (Sigma), 
1 % (v/v) MgCh (filter sterilised, Sigma), 1 % (v/v) 2M glucose (filter sterilised, 
Sigma», was added and the culture incubated for l.Sh at 37°C in a shaking incubator. 
The culture was plated on Luria-Bertani (LB, 10% (w/v) Bacto-tryptone, S% (w/v) 
Bacto-yeast extract, 5% NaCI (Sigma) in nuclease-free water) agar plates containing 
a final concentration of 100 Ilg/ml ampicillin and spread with 40111 Isopropyl ~-D-l­
thiogalactopyranoside (IPTG, stock: 24mg/ml) and 40111 5-Bromo-3-indolyl-~-D­
Galactopyranoside (Stock: 2Smg/ml in dimethylformamide, Sigma) and grown 
overnight at 37°C. Blue-white selection was used to indicate which transformants 
had incorporated the pG EM -T Easy vector. Bacteria containing vectors and insert 
were white colonies and bacteria containing only the vector were blue. 
Propagation of the bacteria with the insert was achieved by selecting white colonies 
and culturing each for approximately 12-16 hours in Sml LB broth containing 100 
Ilg/ml ampicillin (Sigma) in a shaking incubator at 37°C. 
2.7.6 Plasmid preparation 
For plasmid preparation a Wizard Plus SV Miniprep DNA Purification System 
(Promega) was used. 
Essentially, cells were pelleted from the Sml culture by centrifugation at 10,000g for 
Smin. The pellet was resuspended in 2S01l1 cell resuspension solution (SOmM Tris-
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HC1, lOmM EDTA, 1001lg/ml RNase A) by vortexing, the cells lysed with 250lll cell 
lysis solution (O.2M NaOH, 1% SDS) and 10111 of an alkaline protease solution 
added to digest unwanted proteins from the bacterial cells. This was followed by 
350lll of a neutralisation solution (4.09M guanidine hydrochloride, 0.759M 
potassium acetate, 2.12M glacial acetic acid). The cellular suspension was 
centrifuged at 13,000g for 10min to separate unwanted bacterial chromosomal DNA 
from the plasmid DNA. Plasmid DNA was isolated and purified using a spin 
column; essentially 750111 of column wash solution (60% ethanol, 60mM potassium 
acetate, 8.3mM Tris-HCI, 0.04mM EDTA) was forced through the column by 
centrifugation at 13,OOOg for Imin, this was repeated using 250lll of column wash 
solution before a 2min spin at 13,000g to dry the column. The plasmid DNA was 
eluted in lOOlll of nuclease-free water. 
2.7.7 DNA restriction enzyme analyses 
Restriction enzyme digests were used to excise and identify potential inserts in the 
recombinant plasmids. The restriction enzyme used was EcoRI. 
For restriction analysis reactions were set-up as follows in a final volume of 20IlI: 
8111 of plasmid DNA (250ng/1l1) 
21ll lOx reaction buffer 'H' (provided with enzyme) 
0.81l1 BSA (Bovine Serum Albumin) (provided with enzyme 10mg/ml) 
I III EcoRI (Promega, 12u11l1) 
The reaction was incubated for 1-3h at 37°C before electrophoresis on a 1.2% 
agarose gel. DNA samples that were seen to contain an insert of the correct size 
were sequenced to confirm identity as described in Section 2.7.8. 
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2.7.8 DNA sequencing 
DNA sequencmg of the recombinant clones was performed at the Pinnacle 
Laboratory based m Newcastle University usmg M13 forward (5'-
tgtaaaacgaccggccagt-3') and reverse primers (5' -caggaaacagctatgacc-3') using an 
Applied Biosystems Sequencer. Sequences returned were compared to GENBANK 
sequences and identified using BLAST (Basic Local Alignment Search Tool) 
available on the NCB I (National Centre for Biotechnology Information) website 
(http://www.ncbi .nlm.nih.gov I). 
2.8 Real-Time peR 
Real-time PCR methods were developed to quantify the expreSSIOn of genes 
encoding LL-37, HBD1, HBD2 and LEAP-2. The development and optimisation of 
these methods is described in detail in Chapter 3 and the final method for each assay 
can be found in Table 3.15 (LL-37 assay), Table 3.25 (HBDI assay), Table 3.30 
(HBD2 assay), Table 3.36 (LEAP-2 assay) and Table 3.40 (GAPDH assay). 
2.9 Statistical Analyses 
Analyses were performed using Graph Pad Prism 4. T-tests and ANOVA statistical 
tests were performed and suitable post-tests applied when appropriate. Dunnett's 
post-tests were applied when treatments compared to control were being considered. 
Bonferroni post-tests were used when more than one group of data were being 
compared. For the patient, studies Dr Tom Chadwick (School of Population and 
Health Sciences, Newcastle University) advised on the power calculations and 
samples size; these are described further in Chapter 4. 
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Chapter 3 
Optimisation and Development of Quantitative 
Real-Time peR Assays for the Antimicrobial 
Peptides LL-37, HBD1, HBD2, HBD3, Hepcidin and 
LEAP-2 and the Housekeeping Gene GAPDH 
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3.1 Introduction 
In previous studies semi-quantitative end-point PCR assays were developed and used to 
investigate the expression of the AMPs LL-37, HBDl, HBD2, HBD3, hepcidin and LEAP-
2 in human palatine tonsil and HEp-2 cells (Ball, Siou et al. 2007). These assays have 
limited sensitivity, are time consuming and expensive and thus not suited to the larger scale 
study of AMP gene regulation required for the current work. This chapter describes the 
development of assays to quantify these AMPs using a more sensitive technique with a 
large dynamic range: real-time PCR. Optimisation of RNA extraction from cells and 
human palatine tonsils and reverse transcription of the RNA to cDNA is also described. In 
subsequent chapters the assays are used to compare expression of AMPs in the cDNA 
samples extracted from human tonsil samples and the immortalised keratinocyte cell line, 
HaCaT following manipulation or challenge. 
3.1.1 Real-time peR 
Real-time PCR uses fluorescent reporter molecules to quantify the amount of product 
generated throughout the reaction. The fluorescence generated is proportional to the 
quantity of the specific mRNA, determined by the choice of oligonucleotide primers, in the 
starting sample. Fluorescence is detected and measured by a fluorimeter incorporated into 
the thermal cycler; a measurement is taken in each cycle of amplification and the data 
obtained manipUlated through the relevant software to allow determination of mRNA 
quantity. This requires determination of the background level of fluorescence, a threshold 
level of fluorescence and cycle number, known as the crossing point (Cp), for each sample 
at which its fluorescence surpasses the threshold. In the case of the Roche LightCycler 1.2 
or 480, the two real-time PCR instruments used in this study, background fluorescence is 
determined for each sample during the early cycles of PCR when fluorescence from 
reaction products is negligible. The software provided with the instrument uses this in an 
algorithm to determine the respective threshold value and reports the Cp for each sample. 
Additionally if concentration standards are included in the assay, the concentration of the 
specific mRNA in the starting sample is also reported. 
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The Cp of a particular sample can be used to determine the efficiency of a PCR and also 
gives an indication of the relative expression level of a particular mRNA in a sample. An 
efficient, exponential PCR reaction is defined by a one cycle increase in Cp when template 
concentration is reduced by 50%. A high Cp indicates either a low level of gene expression 
or inefficient amplification. When optimising an assay, a reduction in Cp of a specific 
sample is taken to indicate an increase in the efficiency of the PCR and therefore to result 
from a beneficial alteration. 
3.2 Assay development: an overview 
The main stages of assay development are outlined in Figure 3. I. 
3.2.1 Template preparation 
RNA extracted from tissues or cultured cell lines was reverse transcribed into cDNA for 
PCR. The quality of the template added to the PCR reaction can affect the quantification of 
the gene of interest, therefore optimisation of the RNA extraction and the reverse 
transcription (RT) method was undertaken. An important aspect in the selection of RT 
reagents is the carryover of factors into the PCR which can result in inhibition of the DNA 
polymerase. One example is dithiothreitol (OTT), used as a stabilising reagent in the 
buffer. Products of RT were required to be used directly in the PCR reactions without any 
purification, so it was necessary to determine if this was the case and also to investigate the 
effect of dilution of RT products o~ PCR efficiency; dilution of the cDNA can dilute out 
such impurities, reducing their effect and resulting in increased PCR efficiency. Therefore 
a dilution series of RT products was tested in each PCR. 
3.2.2 Selection of detection format 
The selection of detection format depends on many factors such as PCR instrumentation, 
template concentration, level of expression of the gene of interest and specific assay design 
58 
choices, for example, mUltiplexing. Both specific (oligonucleotide probe based detection) 
and non-specific (intercalating DNA dyes) detection formats are available for use. The 
suitability of these for each AMP assay was assessed in this investigation and the preferable 
set of conditions chosen. 
3.2.2i Non-specific detection formats 
These are methods based on the use of intercalating dyes such as Sybr-green 1 that bind to 
double-stranded nucleic acids and on excitation with a laser, fluoresce. The proportion of 
double-stranded product in a peR reaction is directly proportional to fluorescence. 
Non-specific detection formats have been used longer than other methods; which is 
advantageous as procedures for assay development are readily available. These detection 
formats may also be more sensitive than probes as multiple reporter molecules are 
intercalated per product, and therefore generate higher fluorescence levels. However, the 
non-specific nature of the intercalating dyes can be problematic as any double-stranded 
nucleic acids, including primer-dimer, PCR artefacts or misprimed products will be 
detected and may affect quantification of the target gene. To overcome this, melting 
temperature analysis of the PCR products is performed. Different products or artefacts melt 
at different temperatures and are detected as changes in fluorescence, plotted as either a 
melt curve (fluorescence vs. temperature) or the rate of change of fluorescence (first 
derivative) vs. temperature (commonly called melt peaks). Melt curve analysis was 
performed for all assays using Sybr-green in this work. Only data showing a single major 
peak, i.e. representative of the single correct product, was used in analysis. 
3.2.2ii Specific detection formats 
Specific detection formats usually involve primers and an oligonucleotide probe which 
hybridises to a specific complementary sequence within the amplicon giving a second level 
of specificity to the assay. The use of mUltiple probes each labelled with a different 
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fluorophore also gives the ability to quantify more than one gene in a sample, known as 
multiplexing. Specific detection formats are usually based on fluorescence resonance 
energy transfer (FRET) or donor and quencher based mechanisms such as the Universal 
Probe Library (UPL, Roche) assays which were attempted here. In these assays, design 
software provided by Roche is used to determine the primer and probe combinations 
required for each gene (http://www.exiqon.com/uploadslUniversal_ProbeLibrary.pdt). 
In contrast, LUX or Light Upon Extension assays, use labelled primers (Kusser 2006). 
Each gene specific primer pair has one labelled primer holding a quenched fluorophore 
within a hairpin conformation and one unlabelled primer. Fluorescence is generated when 
the labelled primer anneals to a complementary sequence releasing the fluorophore from 
the hairpin structure surrounding it. When the primer is extended the fluorophore is 
unquenched and emits fluorescence of a specific wavelength. LUX assays require only a 
single fluorescent label per assay thus are generally cheaper than probe based methods and 
retain the simplicity of design of Sybr-green type assays. As with probe based detection 
methods, they also allow multiplex reactions to be performed. For mUltiplexing, each set of 
primers is labelled with a different fluorophore, emitting fluorescence at discrete 
wavelengths. Compared to Sybr-green type assays, the LUX system is also advantageous 
as only double-stranded cDNA structures containing the labelled primer are detected and 
quantified. However, primer-dimer and mis-primed products containing the labelled primer 
would also fluoresce; therefore melt curve analysis was used in all LUX assays. 
3.2.3 Primer design and confirmation of specificity 
Primers were designed following general peR requirements, i.e. approximately 20-25 bases 
long with 50-60% GC content and no obvious secondary structure or GC runs at the 3' 
terminus, with some further specialisation for real-time PCR. As PCR works more 
efficiently with shorter products, primers were designed to generate products of between 
IOO-200bp, to minimise the effect of any genomic DNA contamination of samples, primers 
were designed either to cross exon-exon boundaries or with the hybridisation sites for each 
primer in a pair located on separate exons. 
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To confirm the specificity of the primers and determine that they amplified the required 
region of the target gene, peR products were purified by agarose gel electrophoresis 
(Section 2.6.4) and characterised either by direct sequencing (Section 2.7.8); cloning in 
pGem-T -easy and sequencing of multiple clones (Section 2.7) or determination of the 
melting temperature of the peR product (Section 3.2.2i). 
3.2.4 Optimisation of peR conditions 
After an initial trial of a basic peR reaction with each gene, optimisation of peR 
conditions such as cycle number, incubation times and temperatures, primer and 
magnesium chloride concentration, and annealing temperature was performed to improve 
the reaction. 
3.2.5 Standard curve formation 
The usual methods of cDNA quantification by real-time peR are either use of a standard 
concentration curve or peR based efficiency calculations (Gentle, Anastasopoulos et al. 
200 I; Livak and Schmittgen 200 I; Pfaffl 200 I; Liu and Saint 2002; Muller, Janovjak et al. 
2002; Peirson, Butler et al. 2003; Huggett, Dheda et al. 2005; Larionov, Krause et al. 
2005). Most commonly the peR efficiency method is used. However, the use of standard 
curves has some advantages, including simplicity and reliability, when compared to 
efficiency calculations. Inclusion of a standard curve in each peR also allows the assay to 
be validated each time it is run (Larionov, Krause et al. 2005). This method was chosen for 
the current study. Standard curves were obtained by serial dilutions of a concentrated stock 
of the peR target, in most cases a 'miniprep' of the cloned peR product or eDNA. 
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3.3 Optimisation of template preparation 
3.3.1 Storage and handling of human tonsil samples 
3.3.1 i Comparison of tissue storage in liquid nitrogen vs. chemical 
preservative 
Tonsil samples were collected fresh at surgery, transported to the laboratory and stored 
prior to RNA extraction. As RNA is susceptible to degradation it was necessary to 
determine the preferred method of tissue storage between collection and extraction. Two 
preservation methods, liquid nitrogen and a chemical preservative, RNA Later (Ambion) 
were compared. The RNA extraction method described in Section 2.5.1 was used and the 
isolated RNA compared using denaturing gel electrophoresis. Results (Figure 3.2) showed 
that tissue stored in either RNA Later or in liquid nitrogen was good quality, indicated by 
the presence of strong bands for both 28S and 18S rRNA, therefore allowing the use of 
both tissue preservation methods throughout the study. 
3.3.1 ii Homogenisation of human tonsil samples 
In the first step of processing, tonsils were mechanically disrupted to allow efficient lysis of 
cells and release of nucleic acids during subsequent extraction steps. The use of manual 
and rotor-stator style homogenisers was compared. Prior to homogenisation, frozen tonsil 
was ground into a fine powder using a pestle and mortar under liquid nitrogen and samples 
stored in RNA Later were finely dissected. 
62 
3.3.1 iia Manual homogenisation 
A plastic homogeniser (SchUtterlabor) was used to grind (approximately 30mg) tissue in 
(I 75fll) lysis buffer in a J .5ml microfuge tube. Subsequent processing resulted in low yield 
of poor quality RNA. It was observed that during homogenisation tough, connective tissue 
could not be dispersed and remained in the sample. This may have clogged the column 
based down-stream steps resulting in poor RNA purification and this method was therefore 
deemed unsuitable for further use. 
3.3.1 iib Rotor-stator homogeniser 
The Tissue Rupter (Qiagen), a rotor-stator style homogeniser was used with a disposable 
probe to mechanically disrupt tissue (Section 2.5. J). Tissue (approximately 100mg) in 
(O.5ml) lysis solution was dispersed into a thick suspension with no obvious clumps of 
connective tissue. It was concluded that mechanical disruption of tissue with the rotor-
stator was preferred for homogenate production. This method required greater starting 
amounts of tonsil tissue, but the amount of tissue was not a limiting factor and allowed use 
of this method in all cases. 
3.3.2 Extraction of RNA from human tonsil homogenates 
RNA extracted from human tonsil homogenates using the SV RNA Isolation kit (Promega), 
the Micro-Midi Pure-Link RNA Purification System (Invitrogen) and Side-Step reagent 
(Stratagene) was compared. 
RNA extracted using either the SV total RNA kit was found to be of low quality (Figure 
3.3a) although purity and yield were good (Table 3.Ja). Similar results were obtained with 
Side-Step reagent (results not shown). In contrast, that obtained using the Micro-Midi 
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Pure-Link RNA Purification System was of high quality (Figure 3.3b), purity and yield 
(Table 3.1 b). 
In conclusion, RNA extraction using the Invitrogen Micro-Midi Pure-Link RNA 
Purification System resulted in the best quality RNA. Therefore this was used for all 
subsequent RNA extractions from human tonsil. 
3.3.3 Extraction of RNA from HEp-2 cells 
HEp-2 cells (5 x 105 cells seeded) were grown on 12-well plates until confluent, before 
RNA extraction using the Promega SV Total RNA extraction kit. The resulting RNA was 
eluted in a 1001l1 volume and yield and concentration was assessed as described in Sections 
2.5.3 and 2.5.4 respectively. Using this method, the concentration of RNA in the final 
eluate was within the concentration range of 100-400ngllll. Representative results from a 
single experiment with II samples are shown in Table 3.2. An assessment of RNA purity 
was made by examining absorbance at 230, 260 and 280nm and absorbance ratios 
calculated; a value of 2 for A26o/A23o and A26o/A28o indicated pure RNA. As ratios for 
A2601 A230 were obtained in the range 2.05 to 2.44 and A2601 A280 in the range 2.04 to 2.14 
(Table 3.2), RNA was deemed to be free from any substantial contamination. 
The integrity of RNA was investigated using denaturing gel electrophoresis as described in 
Section 2.5.4. 18S and 28S rRNA subunits were clearly visible (Figure 3.4a). The 28S 
rRNA subunit was seen to be twice as bright as the 18S rRNA subunit indicating RNA was 
intact and suitable for use in peR analysis. As the concentration, purity and integrity of 
RNA extracted from HEp-2 cells was sufficient, no further optimisation of this extraction 
protocol was required. 
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3.3.4 Extraction of RNA from HaCaT cells 
HaCaT cell RNA was extracted and analysed as described for HEp-2 cells. Usually RNA 
concentration was in the range of 30-31 Ong/,..LI. This was a suitable concentration range for 
reverse transcription and PCR. RNA purity was also found to be suitable (usually 1.5-2 for 
A2601 A280 ratios and a lower but still suitable range of values for A2601 A230 ratios). Results 
from a representative experiment with II samples are shown in Table 3.3. 
Integrity of RNA was investigated by subjecting samples to electrophoresis on a denaturing 
gel, as described in Section 2.5.4. 28S and 18S rRNA bands could be clearly seen and the 
28S band was twice as bright as the 18S band, indicating intact RNA of good quality 
(Figure 3.4b). 
3.3.5 Optimisation of reverse transcription 
Reverse transcription (RT) using either MML V RNaseH+ Reverse Transcriptase (Prom ega) 
or Transcriptor (Roche), an enzyme engineered specifically for real-time PCR applications 
from Roche, was compared. The use of a reverse transcriptase with RNAseH+ is 
advantageous for real-time PCR as the RNAseH+ activity destroys the RNA template, 
which can interfere with PCR efficiency, when it is formed into a DNA:RNA hybrid with 
the nascent cDNA (Gerard and Grandgenett 1975). Transcriptor, which is a modified 
MML V Reverse Transcriptase, also has endogenous RNaseH+ activity. 
l)lg of human tonsil RNA from the same sample was reverse transcribed with each enzyme 
using the recommended conditions (Section 2.6.2) and a 1:2 dilution series in nuclease-free 
water (from 1:4 to 1 :64) was made and amplified in real-time PCR with LL-37 primers. 
Data showed that dilution had less of an effect on reverse transcriptase products generated 
with the Prom ega MMLV RNAseH+ (Cp range 32.98-35.21) than those synthesised with 
the Roche enzyme (32.56-36.66). Using Transcriptor, lower Cp values were found with the 
more dilute cDNA, indicating dilution of inhibitors present in the RT product. As there 
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may be slight variation in the amount of RT buffer and RNA present between samples, a 
reverse transcriptase that has less effect on peR was most suitable, indicating use of the 
Promega reagents. 
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3.4 LL-37 Assay Development 
Assay development for quantification of LL-37 mRNA involved the testing of 
oligonucleotide probe, Sybr-green and LUX detection and two real-time PCR instruments: 
the LightCyclers ].2 and 480. 
3.4.1 Oligonucleotide primer and probe design 
Four sets of primers were used in the development of the LL-37 assay. These are listed in 
Table 3.4. Primers were tested by amplifying human tonsil, HEp-2 cell or HaCaT cell 
cDNA. 
3.4.2 Test of probe based assays for LL-37 mRNA quantification 
Two oligonucleotide primer and probe combinations were tested. The Universal Probe 
Library (UPL; Roche) consists of ninety oligonucleotide probes which together are able to 
detect all human genes. Primers specific to the sequence of interest are selected to amplify 
a small region which contains the hybridisation site for one of the 9 bp probes. 
The UPL online design software (Section 3.2.2ii) was used to design probe and primer 
combinations for human LL-37. From these, the combinations identified as best and 
second best, probe no. 85 with Primer Set] and probe no. 79 with Primer Set 2 (Table 3.4), 
were selected for testing. Reactions were set-up as directed in the UPL guide (Roche). 
However, neither probe and primer combination worked; each resulted in very low 
fluorescence and no products were detected. Despite attempts to optimise the assays by 
varying annealing temperature and time, they remained unsuccessful and use of this system 
was not investigated further. 
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3.4.3 Assay development with Primer Set 3 and Sybr-green detection 
on the LightCycler 1.2 
Primer Set 3 was used in semi-quantitative RT-PCR assays as described in Chapter 2. It 
had been previously shown to amplify a single product of 518bp from human tonsil cDNA 
which was confirmed to be LL-37 by direct sequencing (Ball, Siou et at. 2007). In the 
current work, amplification of HEp-2 cell and HaCaT cell cDNA by end-point PCR with 
these primers gave a single product of approximately 500bp (Figure 3.5). Sequencing of 
HEp-2 products showed them to be >99% identical to the human LL-37 sequence 
(Genbank accession number NM_004345) between bases 140 - 657 (Figure 3.6). The 
mismatched bases were located towards the 3' end of the sequence, most likely indicating 
errors introduced during the sequencing reaction and caused by factors such as reduced 
enzyme stringency, shortage of dNTPs or the accumulation of inhibitory by-products. 
Other possible causes of these errors are mis-incorporation of bases during PCR and allelic 
differences between individuals. The polymerase used for the amplification was a Taq 
DNA polymerase which has an error rate of no more than 4% (U.S Patent no. 7384739, 
issued 10th June 2008). The individuals from which the tonsil was obtained and from which 
HEp-2 and HaCaT cells were originally transformed may have a genomic sequence that 
differs by one or two bases, e.g. single nucleotide polymorphisms, from that used to derive 
the Genbank sequence. 
An initial attempt to amplify two human tonsil cDNA samples in real-time PCR using 
Primer Set 3, x I Sybr-green Taq Ready Mix (Sigma) and I /!M of each primer following the 
manufacturers protocols resulted in low levels of product with a T m of -89°C for each 
sample. The amount of product was below the level required to generate a reliable Cp 
value. To optimise the assay, PCRs were performed in which the concentration of primers 
and MgCIz. and the amount of RT product added to the reaction were varied. Increasing 
primer concentration from 0.5/!M to 2/!M reduced Cp from 33.52 cycles to 27.61 cycles 
(Table 3.5), whereas increasing MgCIz concentration above that contained in the ready-mix 
(7mM) had no effect on Cp (Table 3.6). Reducing the volume of RT product added also 
improved PCR performance; using I/JI of RT product (added as 2/J1 of a 1:2 dilution in 
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ultra-pure water) resulted in a Cp of 36.41 whereas O.S III of RT product (2111 of a 1:4 
dilution) resulted in a Cp of 33.S2 (Table 3.7). 
Primer Set 3 was designed to measure LL-37 expression in a semi-quantitative PCR assay 
and generated a product of Sl8bp, which is greater than the preferred amplicon size for 
real-time PCR (l00-200bp). Despite the improvements obtained by altering primer 
concentration and reducing the amount of RT product added, the Cp values recorded for 
tonsil samples remained high (-30 cycles), therefore it was decided not to proceed further 
with this primer pair and to design new primers which better fitted the requirements of real-
time PCR. 
3.4.4 Assay development with Primer Set 4 
3.4.4i peR optimisation 
Primer Set 4 was designed to amplify a 104bp product, suitable for real-time PCR, and 
included a fluorescently labelled primer allowing product detection by the LUX mechanism 
(Invitrogen, Section 3.2.2ii). Initially these reactions were performed in Platinum TAq 
Supermix (Invitrogen) following the manufacturer's protocols. The primers were designed 
to lie within the region of the human LL-37 cDNA delineated by Primer Set 3 and, when 
used to amplify that cloned sequence, generated a product of approximately 100bp (Figure 
3.7) with a T m of 86°C (Figure 3.8). 
When used to amplify human tonsil cDNA these primers also produced a product with T m 
of 86°C, confirming amplification of LL-37 from these samples. However, the Cps for 
each of a series of six samples were all high, >30 cycles (Table 3.8), indicating either 
inefficient amplification or low expression of this AMP in human tonsil. Despite attempts 
to improve the PCR, the Cp was not reduced by altering primer or MgCIz concentration 
(Tables 3.9 and 3.10, respectively) or the annealing temperature of the reaction (Table 
3.11). At this time, a new instrument for real-time PCR, the LightCycler 480 (Roche), 
became available. This uses a 96-well plate format instead of the 36-glass capillary format 
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of the LightCycler 1.2. Advantages of this instrument include higher throughput and 
increased ease of reaction set-up. Therefore it was decided to perform further optimisation 
on the LightCycler 480. Initial observation showed that Platinum TAq SuperMix was not 
suitable for use on the LightCycler 480 as it resulted in considerable well-to-well variation; 
therefore further assays were performed in LC480 Probes Master Mix (Roche) following 
the manufacturer's instructions. 
To test the effect of RT product concentration on real-time PCR a sample of human tonsil 
cDNA was serially diluted and a fixed volume (Sill) of each dilution included in a series of 
real-time PCRs. This showed that the Cp of the sample was lower when the cDNA was 
more concentrated, therefore a 1:2 dilution of RT product was selected for future assays 
(Table 3.12). 
3.4.4ii Development of concentration standards and standard curve 
optimisation 
Human tonsil cDNAs amplified with Primer Set 4 produced a Cp range of 32-37 cycles 
(Section 3.4.4); therefore, a standard curve was developed to cover this range. Starting 
with the master stock of cloned LL-37 PCR product (Figure 3.6), a 1 in 107 dilution was 
made and from this a 1:5 dilution series generated (Table 3.13). These were amplified 
following the protocols determined during optimisation (Table 3.13). Melt curve analysis 
(Figure 3.9) of the reaction products showed that while standards 1-4 generated single 
products with T m of -88°C, standard 5 produced two products, the major with T m of -82°C 
and likely representative of primer-dimer, and standard 6 did not generate any products, 
suggesting that the concentration of target sequence in standards 5 and 6 is so low that 
amplification does not result in detectable quantities of product. The Cps for standards 1-4 
ranged from 30-39 cycles (Table 3.13), which was appropriate for the predicted Cp of 
human tonsil samples. Arbitrary concentration values were assigned to standards 1-4 and 
plotted against measured Cp (Figure 3.10). This generated a standard curve with a 
calculated efficiency for the reaction of 1.85 (for an ideal exponential reaction the 
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efficiency, which is determined from the slope of the curve, is 2) and an error of 0.0491. 
Serial dilutions were prepared, assayed alongside the cDNA samples and a standard curve 
was plotted each time the assay was used. 
3.4.4iii Reliability and reproducibility determination of coefficient 
of variation 
A comparison of Cp values of standards 1-4 from six PCRs performed at different times 
was conducted. The coefficient of variation was calculated by: 
Average Cp value of the six experiments 
_______________ X 100 = Coefficient of variation (%) 
Standard deviation of the six experiments 
Calculations were performed in Microsoft Excel. The coefficient of variation was in the 
range 5-15% (Table 3.14). Due to the high level of variation between PCR runs, it was 
decided to include a series of standards and generate a standard curve each time a PCR was 
performed. This would validate the assay on each occasion. It was also decided that each 
sample should be assayed in quadruplicate to ensure the greatest possible accuracy. 
3.4.5 Summary of LL-37 Assay 
Optimisation of real-time PCR assays for LL-37 used a variety of instruments and 
chemistries. Compared to the LightCycler 1.2 the LightCycler 480 offered the advantage 
of high throughput, therefore it was chosen for sample analyses. Data described in 
subsequent chapters were all obtained from the LightCycler 480 using the LUX assay. The 
final preparation and conditions required for the analysis of the LL-37 expression in human 
tonsil and HaCaT cells are described in Table 3.15. 
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3.5 HBD1 Assay Development 
Assay development for the quantification of HBDI mRNA included the testing of different 
detection formats (SYBR green and LUX), use of the LightCyclers 1.2 and 480 and 
optimisation of PCR conditions. 
3.5.1 Oligonucleotide primer design 
Two sets of primers were used in the development of the HBD 1 assay. These are listed in 
Table 3.16. Primers were tested by amplifying human tonsil or HaCaT cell cDNA and 
sequencing of the products. 
3.5.2 Primer Set 1 
As with LL-37 Primer Set 1, these primers were available from a previous study. In that 
study a product of 221 bp amplified from human tonsil was confirmed to be HBDI by direct 
sequencing (Ball, Siou et al. 2007). In this study, products of similar size were generated 
from both HEp-2 and HaCaT cell cDNA using Primer Set 1 (Figure 3.11). In real-time 
PCR using 1 x Sybr-green Taq Ready Mix (Sigma) and 1 flM of each primer on the 
LightCycler 1.2 and following the manufacturer's protocol, a single human tonsil sample 
gave a Cp of 25.02 with a Tm of -85°C (Figure 3.12). Although these results indicated 
that this primer set would be suitable for the development of a real-time assay for HBD 1 
using Sybr-green detection, at this time a problem beyond my control was encountered; due 
to production problems the manufacturers withdrew Sybr-green Taq Ready Mix from sale. 
A few alternatives were tested but did not give similar signal strength therefore, because of 
the success of LUX assay development with LL-37, it was decided to develop a LUX assay 
for HBD l. However, having shown the suitability of these primers for detection of HBD 1, 
they were used for the semi-quantitative PCR assays described in Chapter 2. 
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3.5.3 Primer Set 2 
This primer set was specifically designed to generate short amplicons of 87bp suitable for 
real-time PCR and used LUX detection. Products from amplification of human tonsil and 
HaCaT cells were cloned using the p-GEM-T -Easy vector system and sequenced. The 
sequence of clones from both templates was 100% identical to the HBD I sequence in 
Genbank (Accession No. NM_0052 18.3) (Figure 3.13). 
Initially the LightCycler 1.2 was used for assay optimisation. Using standard conditions 
(20111 reaction containing 1 x Platinum Taq Supermix (Invitrogen) and 111M each primer), a 
series of six tonsil samples gave a Cp range of 27.78-33.68 cycles (Table 3.17). This was 
not improved by altering primer or MgCIz concentration (Tables 3.18 and 3.19). The 
optimal annealing temperature was determined to be 60°C (Table 3.20). 
The assay was then transferred to the LightCycler 480 and, because of similar problems in 
well-to-well variation as encountered during LL-37 assay optimisation when using 
Platinum Taq Supermix, to LC480 Probes Master Mix (Roche). Using these reagents, a 
series of four tonsil samples gave a Cp range of 27.35-28.17 cycles (Table 3.21). However, 
when a series of HaCaT cell cDNA samples were amplified these were found to give a 
much higher Cp range (33.01- 35.05 cycles; Table 3.22). Therefore to cover the full range 
of samples included in this study, a standard curve for the assay was constructed which 
covered the Cp range 22-37 cycles. The starting point for the standard curve was a DNA 
miniprep of the cloned PCR product generated with Primer Set 2. This was diluted as 
shown in Table 3.23 and resulted in a standard curve with efficiency of 1.581 and error of 
0.0669 (Figure 3.14). Each standard was assayed in duplicate. Melt peak analysis of the 
PCR products showed that all, except one replicate of the weakest standard, six, generated a 
single product with Tm of -86°C. The small peak at -81°C in standard 6, replicate 1 most 
likely represents primer-dimer (Figure 3.15). 
To determine the reproducibility of the assay, standard number 3 was assayed on six 
separate occasions. Analysis of the obtained Cps gave a coefficient of variation of 4% 
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(Table 3.24). It was also noted that intra-assay variation between replicates of a single 
sample was very low (data not shown), therefore it was determined that assaying each 
sample and standard in duplicate gave sufficient accuracy. 
3.5.4 Summary of HBD1 Assay 
The optimised assay for HBDI mRNA is a LUX assay and uses LC480 Probes Master mix 
on the Light Cycler 480. The final preparation and conditions required for the analysis of 
the HBDI mRNA expression in human tonsil and HaCaT cells are described in Table 3.25. 
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3.6 HBD2 assay development 
3.6.1 Oligonucleotide primer and probe design 
Two sets of primers were used in the development of the HBD2 assay. These are listed in 
Table 3.26. Primers were tested by amplifying human tonsil, or HaCaT cell cDNA. 
3.6.2 Assay optimisation 
Assay development for HBD2 followed the same path as described for LL-37 and HBDI 
assays. Two styles of assay, Sybr-green and LUX, were tested. In contrast to LL-37 and 
HBD 1, reactions using Sybr-green detection and the appropriate master mix gave better 
results for HBD2 quantification than did the LUX assay. Primer Set 1, the LUX assay, 
consistently generated a significant amount of primer-dimer despite attempts at 
optimisation (Figure 3.16) and so was abandoned. Primer Set 2 was originally designed for 
use in the semi-quantitative PCR assays described in Chapter 2. It was confirmed that the 
product of amplification with these primers from HaCaT cells and tonsil was -320bp long 
and identical to the HBDI mRNA sequence (Genbank accession no. NM_004942) (Figure 
3.17). Initially, these primers gave very poor amplification in real-time PCR and resulted 
in a low yield of a product with Tm of -87°C (Figure 3.18). This was significantly 
improved by purchasing primers which were HPLC purified; salts and other reaction 
components carried over from oligonucleotide synthesis can have severe adverse effects on 
real-time PCR, removing these improves reaction efficiency and product yield (Figure 
3.18). Further optimisation showed that required conditions in 1 x LC480 Sybr Green 
Master mix (Roche) were annealing temperature of 58°C and primer concentration of 111M. 
No adjustments to the MgCIz concentration were required. For the standard curve, a DNA 
miniprep of the cloned HBD2 fragment shown in Figure 3.17 was diluted as shown in 
Table 3.27 and the Cp of each standard determined. Each was measured in duplicate. Of 
the six standards, only 1-5 generated useable Cp values. Following melt curve analysis it 
was found that the product of amplification of standard six differed from that of all other 
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standards (Tm of 80°C compared to 87°C) and was most likely primer-dimer rather than the 
required HBDI product. Melt curve analysis of standards 1-5 were as of Standard 1 at 
8rC (Figure 3.18). Thus only standards 1-5 were included in the plotted standard curve 
(Figure 3.19), which has an efficiency of 1.963, error of 0.0408 and covers the Cp range 
24.68-34.09 cycles. Human tonsil samples ranged in Cp from -29-34 cycles, thus this was 
an appropriate standard range (Table 3.28). 
To determine the reproducibility of the assay, standards 1-4 were assayed on six separate 
occasions. Analysis of the obtained Cps showed that the coefficient of variation ranged 
from 3-6 (Table 3.29). These standards were included in each PCR carried out and a 
standard curve plotted for each run. It was also noted that intra-assay variation between 
replicates of a single sample was low (data not shown), therefore it was determined that 
assaying each sample and standard in duplicate gave sufficient accuracy. 
3.6.3 Summary of HBD2 Assay 
The optimised assay for HBD2 mRNA measurement is a Sybr-green assay and uses LC480 
Sybr-green Master Mix on the Light Cycler 480. The final preparation and conditions 
required for the analysis of the HBD2 mRNA expression in human tonsil and HaCaT cells 
are described in Table 3.30. It was essential for this assay that primers were HPLC-
purified. 
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3.7 HBD3 Assay Development 
3.7.1 Oligonucleotide primer and probe design 
Two sets of primers were used in attempts to develop a HBD3 assay. These are listed in 
Table 3.31. Primers were tested by amplifying human tonsil or HaCaT cell eDNA and 
confirmed to generate products of the correct size or sequence in end-point PCR (Figure 
3.20). 
3.7.2 Assay optimisation 
Despite confirming that the two primers sets used to amplify HBD3 generated the expected 
product from both tonsil and HaCaT cells (Figure 3.20) it was not possible to develop an 
accurate or reproducible real-time peR assay for this AMP using either. Melting 
temperature analysis of products generated during real-time PCR showed multiple melt 
peaks, indicative of the formation of primer-dimer and other non-specific products (Figure 
3.21). Repeat analysis of a series of samples of tonsil and HaCaT samples showed 
significant intra- and inter-assay variation that was not abolished by any optimisation 
procedure. It is possible that HBD3 is expressed at very low levels within the samples 
tested and thus was not reliably detected. A semi-quantitative assay for HBD3 using 
Primer Set I was developed as described in Chapter 2. Results from this are reported in 
Chapter 5. As real-time PCR is generally expected to be more sensitive and reliable than 
end-point PCR for the quantification of nucleic acid abundance it is possible that an 
alternative approach, such as using a specific oligonucleotide probe, may be successful. 
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3.8 Hepcidin Assay Development 
3.8.1 Oligonucleotide primer and probe design 
A single set of primers were used in the development of the hepcidin assay. These are 
shown in Table 3.32. These primers had previously been shown to specifically amplify 
hepcidin sequence fragment from human tonsil (Ball, Siou et al. 2007). Further 
investigations in this study, they also amplified a product of -190bp from HaCaT cell 
cDNA (Figure 3.22). This was cloned in p-GEM-T-Easy and sequenced; analysis showed 
it to have 91 % identity to human hepcidin (Genbank Accession No. NM_021175). 
Although this was a poor match, this was the best match identified by BLAST and the 
result of poor sequence data (Figure 3.22). 
3.8.2 Assay development 
As with HBD3, it was not possible to develop an assay suitable for the measurement of 
hepcidin mRNA abundance. Similar strategies to those used in the development of assays 
for LL-37 and HBD I and HBD2 were employed, including the testing of HPLC purified 
primers in a Sybr-green assay mix. However, the Cps recorded for a series of HaCaT cell 
samples were high, ranging from 36.11-39.93 cycles. When it was attempted to produce a 
standard series appropriate to this range, it was found that only the most concentrated 
standard produced a product with the predicted Tm, all others had a lower Tm indicative of 
primer-dimer formation (Figure 3.23). At the lower dilutions, the HBD3 clone was no 
longer sufficiently concentrated to form a product; thus the primers preferentially bind to 
each other and produce primer-dimer. The same results were seen in repeats of the assay 
and when PCR products were subjected to electrophoresis it was seen that only in standard 
1 were products of the predicted size, approximately 200bp, generated; in all other dilutions 
only primer-dimer, represented by bands at approximately 25bp, was visible (Figure 3.23). 
As this assay was problematic and because the fundamental role of hepcidin is in iron 
transport and metabolism rather than its antimicrobial activity (Yamaji, Sharp et al. 2004; 
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Verga Falzacappa and Muckenthaler 2005; Vyoral and Petrak 2005; Shinzato, Abe et al. 
2008), this assay was not developed further. The primers were, however, found to be 
suitable for semi-quantitative PCR and were used to generate the data in Chapter 5. 
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3.9 LEAP-2 Assay Development 
3.9.1 Oligonucleotide primer and probe design 
Primers used in the development of the LEAP-2 assay are listed in Table 3.33. Primers 
were tested by amplifying human tonsil and HaCaT cell cDNA. This primer set was 
designed to have short amplicons of 161 bp suitable for real-time PCR, however, they were 
also used in semi-quantitative RT-PCR assays described in Chapter 2. PCR products of 
this size were amplified from both human tonsil and HaCaT cell cDNA (Figure 3.24) and, 
when cloned into p-GEM-T-Easy, sequence analysis confirmed them to be derived from 
human LEAP-2 (Genbank Accession No. NM_052971) (Figure 3.24). 
3.9.2 Assay optimisation 
The LEAP-2 real-time PCR assay was developed using Sybr-green detection, LC480 Sybr-
green master mix and was run exclusively on the LightCycler 480. Initial observations 
showed that prior to optimisation, the Cp of HaCaT cell samples was ~32 cycles whereas 
that of tonsil samples was ~ 34-35 cycles. The first step in optimisation was to introduce 
HPLC purified primers. This reduced the CP of HaCaT samples to ~28-29 cycles and that 
of tonsil samples to ~30-31 cycles. Melt curve analysis of products from HaCaT cell 
cDNA amplification showed that the specific LEAP-2 product had a Tm of ~85°C (Figure 
3.25). A standard curve was developed, focused around the Cp range 23-34 cycles (Table 
3.34 and Figure 3.26). At lower concentrations the standards (4 and 5) showed poor 
reproducibility between replicates, however melt curve analysis showed the products to be 
LEAP-2 specific, therefore all points were used to plot the concentration curve (Figure 
3.26). This had an efficiency of 1.945 and error of 0.0806. 
To determine the reproducibility of the assay, standards 1-4 were assayed in six PCRs 
performed on different days and times. The coefficient of variation was calculated and was 
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in a range of 6-8% (Table 3.35). These standards were included in each PCR performed 
and a standard curve plotted on each occasion. It was also noted that intra-assay variation 
between sample replicates was low (data not shown) and therefore it was determined that 
assaying each sample in duplicate would produce reliable results. 
3.9.3 Summary of LEAP-2 assay 
The optimised assay for LEAP-2 mRNA measurement is a Sybr-green assay and uses 
LC480 Sybr-green Master Mix on the Light Cycler 480. The sample preparation and 
conditions required for the analysis of LEAP-2 mRNA expression in human tonsil and 
HaCaT cells are described in Table 3.36. 
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3.10 GAPDH Assay Development 
3.10.1 Oligonucleotide primer and probe design 
The set of primers used in the development of the GAPDH assay are listed in Table 3.37. 
The prImers used In the semi-quantitative RT-PCR assays (5', 
TGAAGGTCGGAGTCCACGGA TTTG; 3' ,CA TGT AAACCATGT AGGTTGAGGTC) had large 
amplicons of 983bp, therefore GAPDH Primer Set 1 were specifically designed to produce 
a short amplicon of 177bp suitable for real-time PCR and were HPLC purified. Primers 
were tested by amplifying human tonsil, or HaCaT cell cDNA. The specificity of this 
primer pair was confirmed by amplifying human tonsil and HaCaT cDNA and subsequent 
sequencing of the PCR products, which were shown to be 100% identical to human 
GAPDH cDNA (Genbank Accession No. NM_002046) (Figure 3.27). 
3.10.2 Assay optimisation 
The Cps of GAPDH PCR products from experimental samples was required to be 
measured. PCR reactions using three HaCaT cell cDNA samples (1:2 dilution of each) 
were performed using 1 x LC480 Sybr-green master mix and l/-lM of each primer on the 
LC 480. These samples gave Cps of 17.09, 15.97 and 17.99 cycles. Melt curve analysis of 
the products showed peaks representing GAPDH at 85°C (Figure 3.28). It was determined 
from this that sample cDNA being used as template in this assay should be diluted 1: 1 00 
with nuclease-free water; this would reduce the amount of the sample required for the assay 
and still give a Cp of ~ 22-25 cycles. 
To generate a standard curve a dilution series of a single HaCaT cDNA sample was made. 
This stock was diluted so that standards with Cps ranging from 20 - 30 cycles were 
produced (Table 3.38). It was possible to use this means of generating the standard series 
because GAPDH mRNA is of high abundance. Each standard in the series was assigned an 
arbitrary concentration value (Table 3.38) which was plotted against its Cp to produce the 
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standard curve for GAPDH shown in Figure 3.29. The efficiency of the curve is 1.552 and 
the error 0.0111. Melt peak analysis, shown in Figure 3.30, showed all standards had a 
peak at 84.5°C. 
To determine the reproducibility of the assay, a comparison of Cp values of standard four 
from six PCRs performed on different days was conducted. The coefficient of variation 
was 0.5% (Table 3.39). Due to the low levels of variation observed between reactions it 
was decided to import the standard curve shown in Figure 3.29 to each run and use an 
internal calibrator method to allow comparisons between PCRs. The data for the curve are 
stored in the LightCycler software and then in subsequent runs only a single standard is 
assayed, thus saving reagents and time. Standard number four was chosen as the calibrator 
sample. It was also determined that assaying each sample in duplicate was sufficient to 
produce an accurate reading. 
3.10.3 Summary of GAPDH assay 
The optimised assay for GAPDH uses the LightCycler 480, LC 480 Sybr-green Master 
Mix, and HPLC purified primers. The final sample preparation and conditions required for 
the analysis of GAPDH expression in human tonsil, and HaCaT cells are described in Table 
3.40. 
83 
Template Preparation 
1. Tissue collection 
2. RNA extraction 
3. Reverse Transcription 
I 
peR Development 
1. Selection of detection format 
2. Primer design and confirmation of 
specificity 
3. Optimisation of PCR conditions 
4. Standard Curve Formation 
l 
[ Analysis of samples J 
Figure 3.1: Steps in real-time peR assay development. 
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a b 
28S rRNA 
18S rRNA 
Figure 3.2: Denaturing gel electrophoresis of RNA extracted from human tonsil tissue preserved and stored 
in a) liquid nitrogen or b) RNA Later. All samples show strong bands indicating the presence of 28S and 18S 
rRNA (labelled). 
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a) 
2 3 4 
28S rRNA 
18S rRNA 
1 2 
b) 
28S rRNA 
18S rRNA 
Figure 3.3: Representative denaturing gel electrophoresis of human tonsil RNA extracted using a) the SV 
Total RNA Extraction kit rotor-stator homogenisation and b) the Micro-Midi Pure-Link RNA Purification 
System. In a) O.5~g RNA from four independent samples (lanes 1-4) was loaded. In b) I~g RNA from two 
independent samples was loaded (lanes 1-2). On each gel bands representing 28S and 18S rRNA are visible, 
however the samples on gel a) are clearly degraded. 
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Table 3.1: Representative spectroscopy results from RNA extracted from human tonsil samples with either 
a) SV Total RNA Isolation kit or b) Micro-Midi Pure-Link RNA Purification System. 
a) 
Sample AzJO Auo Azso AZ60/Az80 AZ60/A2JO Calculated 
(absorbance (absorbance (absorbance ratio ratio concentration 
units) units) units) (,..g/,..l) 
1 0.745 1.330 0.644 2.01 1.79 0.532 
2 1.029 2.011 0.988 2.04 1.96 0.804 
3 0.512 0.955 0.463 2.06 1.87 0.382 
4 1.585 3.065 1.567 1.96 1.93 1.226 
b) 
A230 A260 A280 A260/A280 AZ60/A230 Calculated 
Sample (absorbance (absorbance (absorbance ratio ratio concentration 
units) units) units) (/-lg//-ll) 
1 0.792 1.648 1.006 1.64 2.08 0.66 
2 1.464 2.981 1.706 1.75 2.04 1.19 
3 0.218 0.406 0.282 1.44 1.87 0.162 
4 0.776 1.484 0.830 1.79 1.91 0.59 
5 0.962 1.949 1.072 1.82 2.1 0.78 
6 0.338 0.563 0.432 1.3 1.66 0.23 
7 0.614 0.981 0.554 1.77 1.6 0.39 
8 1. t 6 t 0.731 0.411 1.78 0.63 0.29 
9 0.732 1.355 0.804 1.69 1.85 0.54 
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Table 3.2: Spectroscopy results from a representative set of eleven HEp-2 cell RNA samples. 
Sample A2JO A l60 A l80 Al6ofAl80 Al6ofA2JO Calculated 
(absorbance (absorbance (absorbance ratio ratio concentration 
units) units) units) (/-lg/~d) 
1 0.390 0.83 0.406 2.04 2.13 0.332 
2 0.389 0.840 0.406 2.07 2.16 0.336 
3 0.259 0.609 0.292 2.09 2.35 0.244 
4 0.209 0.511 0.246 2.07 2.44 0.204 
5 0.254 0.58 0.280 2.09 2.3 0.234 
6 0.369 0.755 0.363 2.08 2.05 0.302 
7 0.299 0.684 0.325 2.1 2.29 0.273 
8 0.212 0.445 0.212 2.1 2.1 0.178 
9 0.218 0.509 0.244 2.09 2.34 0.204 
10 0.107 0.288 0.135 2.14 2.7 0.115 
11 0.165 0.374 0.178 2.11 2.26 0.150 
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Table 3.3: Spectroscopy results from a representative set of eleven HaCaT cell RNA samples. 
Sample A230 (absorbance AZ60 AZ80 AZ601Az8o AZ60/Az30 Calculated 
units) (absorbance (absorbance ratio ratio concentration 
units) units) (Ilg/Ill) 
1 0.184 0.322 0.164 1.96 1.75 0.l30 
2 0.l58 0.297 0.150 1.99 1.88 0.l20 
3 0.345 0.439 0.218 2.01 1.27 0.180 
4 0.427 0.334 0.167 2.01 0.78 0.l30 
5 0.311 0.239 0.121 1.97 0.77 0.100 
6 0.803 0.467 0.232 2.02 0.58 0.190 
7 0.223 0.186 0.1 1.87 0.84 0.070 
8 0.934 0.461 0.259 1.78 0.49 0.180 
9 0.339 0.511 0.251 2.04 1.51 0.200 
10 0.146 0.068 0.038 1.79 0.47 0.030 
11 0.303 0.099 0.070 1.41 0.33 0.040 
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a) 
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288 rRNA 
188 rRNA 
285 rRNA 
185 rRNA 
Figure 3.4: a) Representative HEp-2 cell RNA from 10 individual samples separated by denaturing gel 
electrophoresis . O.5llg of RNA was loaded per lane. Samples 1-10 correspond to 1-10 shown in Table 3.2. 
b) HaCaT cell RNA from two samples (I and 2, corresponding to samples I and 2 in Table 3.3) separated by 
denaturing gel electrophoresis. Sample I = 364ng, sample 2 = 336ng. 
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Table 3.4: List of primer sets designed to amplify regions of the mRNA sequence encoding human LL-37. 
Primer Primer sequences (5'-3') Position in cDNA! Predicted product 
set base numbers in size (bp) 
NM_OO4345 
Forward: TCGGATGCTAACCTCTACCG 1 291-310 
1 65 
Reverse: GTCTGGGACCCCA TCCA T 356-339 
Forward: GTCCTCGGATGCTAACCTCTAC2 286-308 
2 70 
Reverse: GTCTGGGACCCCA TCCA T 356-339 
Forward: CATGAAGACCCAAAGGGATG 140-160 
3 518 
Reverse: CACACT AGGACTCTGTC 657-638 
Forward: ~GACGGGCTGGTGAAGcG3 444-460 
4 104 
Reverse: CCCAGCAGGGCAAATCTCTT 547-528 
I ThIs primer set reqUIred the FAM labeIled oligonucleotIde probe no. 85 from the Umversal Probe LIbrary to 
quantify LL-37 gene expression. 
2 This primer set required the F AM labeIled oligonucleotide probe no. 79 from the Universal Probe Library to 
quantify LL-37 gene expression. 
3 This primer was labelled with the fluorescent probe FAM, which excites at 488nM and emits at 518nM, at 
position 'c' and had a 4bp 5' extension (shown underlined) to enable hairpin formation for LUX assays. 
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a) 1 2 M 
" . 
" f +-- 500bp 
b) 
1 2 3 M 
500bp 
Figure 3.5: Agarose gel electrophoresis of PCR products amplified from a) HEp-2 and b) HaCaT cell cDNA 
with LL-37 Primer Set 3. In a) lane I is no template control, lane 2 shows products from HEp2 cell cDNA 
and M is the DNA size marker. In b) lane I shows products from HaCaT cells treated with 1,25 
dihydroxyvitamin D3, lanes 2 and 3 show products from untreated HaCaT cells and M is DNA size marker. 
LL-37 was not detectable in untreated HaCaT cells. On both gels the position of the 500bp DNA marker is 
shown. 
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Query: 1 catgaagacccaaagggatggccactccctggggcggtggtcactggtgctcctgctgct 60 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 140 catgaagacccaaagggatggccactccctggggcggtggtcactggtgctcctgctgct 199 
Query: 61 gggcctggtgatgcctctggccatcattgcccaggtcctcagctacaaggaagctgtgct 120 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 200 gggcctggtgatgcctctggccatcattgcccaggtcctcagctacaaggaagctgtgct 259 
Query: 121 tcgtgctatagatggcatcaaccagcggtcctcggatgctaacctctaccgcctcctgga 180 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 260 tcgtgctatagatggcatcaaccagcggtcctcggatgctaacctctaccgcctcctgga 319 
Query: 181 cctggaccccaggcccacgatggatggggacccagacacgccaaagcctgtgagcttcac 240 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 320 cctggaccccaggcccacgatggatggggacccagacacgccaaagcctgtgagcttcac 379 
Query: 241 agtgaaggagacagtgtgccccaggacgacacagcagtcaccagaggattgtgacttcaa 300 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 380 agtgaaggagacagtgtgccccaggacgacacagcagtcaccagaggattgtgacttcaa 439 
Query: 301 gaaggacgggctggtgaagcggtgtatggggacagtgaccctcaaccaggccaggggctc 360 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 440 gaaggacgggctggtgaagcggtgtatggggacagtgaccctcaaccaggccaggggctc 499 
Query: 361 ctttgacatcagttgtgataaggataacaagagatttgccctgctgggtgatttcttccg 420 
111111111111111111111111111111111111111111111111111111111111 
Sbjct: 500 ctttgacatcagttgtgataaggataacaagagatttgccctgctgggtgatttcttccg 559 
Query: 421 gaaatctaaagaaaagattggcaaagagtttaaaagaattgtccagagaatcaaagggat 480 
111111111111 11111111111111111111111111111111111111111 1111 
Sbjct: 560 gaaatctaaagagaagattggcaaagagtttaaaagaattgtccagagaatcaa--ggat 617 
Query: 481 tttttgcggaatctttgtacccaggacaga 510 
1111111111111 1111111111111111 
Sbjct: 618 tttttgcggaatc-ttgtacccaggacaga 646 
Figure 3.6: Sequence of the PCR product amplified from HEp-2 cell cDNA with LL-37 Primer Set 3 aligned 
to the LL-37 cDNA sequence. Sequence analysis performed by BLAST 
(http://www.ncbi.nlm.nih.gov/blastIBlast.cgi) matched the cloned PCR product ('Query') to the Genbank 
sequence ('Sbjct') for LL-37 (NM_004345) with 99.2% identity. 
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Table 3.5: Cp values from primer titration in an LL-37 specific PCR using Primer Set 3 and Sybr-green 
detection on the LightCycler 1.2. The same tonsil cDNA sample was used in all reactions. 
Primer concentration (11M) Cp (cycle number) 
0.5 33.52 
1.25 29.00 
2 27.61 
Table 3.6: Cp values from MgCl2 titration in an LL-37 specific PCR using Primer Set 3 and Sybr-green 
detection on the LightCycler 1.2. The same tonsil cDNA sample was used in all reactions. 
Concentration of MgCh (mM) Cp (cycle number) 
7.00 33.52 
8.25 33.52 
10.13 33.55 
12.00 >38* 
'" (an accurate Cp value was not registered as the product was not detected at significant strength) 
Table 3.7: Cp values from cDNA titration in an LL-37 specific PCR using Primer Set 3 and Sybr-green 
detection on the LightCycler 1.2. The same tonsil cDNA sample was used in all reactions. 
Amount of cDNA (Ill) Cp (cycle number) 
2 36.41 
4 33.52 
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500bp 
100bp 
Figure 3.7: Agarose gel electrophoresis of PCR products amplified from the cloned sequence of LL-37 with 
Primer Set 4. These PCR products correspond to melt peaks of 86°C (Figure 3.8), representing LL-37 PCR 
products melting temperature. 
3.4-
3.0-
2.5-
2.0-
1.5-
1.0-
0.5-
0.0-
Temperature rc) 
Figure 3.8: Melt peak analysis of products generated in real-time PCR using Primer Set 4 with cloned LL-37 
PCR product as template on the LightCycler 1.2. The major peak shows that the product of this amplification 
has a T m of 86°C. 
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Table 3.8: Cp values of six human tonsil cDNA samples from an LL-37 specific PCR using Primer Set 4 on 
the LightCycler 1.2. 
Sample number Cp 
1 31.76 
2 31.65 
3 36.92 
4 36.68 
5 31.83 
6 33.11 
Table 3.9: Cps from LL-37 specific real-time PCR using Primer Set 4 on the Lightcycler 1.2 showing the 
effect of primer concentration. Results from two human tonsil cDNA samples are shown 
Primer concentration (11M) 
Cp value 
Sample 1 Sample 2 
0.5 33.34 34.61 
1 32.62 34.3 
1.5 32.42 36.97 
2 32.56 35.27 
2.5 32.82 35.5 
3 32.67 36.35 
Table 3.10: Cp values from LL-37 specific real-time PCR using Primer Set 4 on the Lightcycler 1.2 showing 
the effect ofMgCI2 concentration. Results from a single human tonsil cDNA sample are shown. 
Total M2Ch concentration (mM} Cp value 
6 31.76 
7 31.81 
8 31.64 
9 31.75 
10 31.55 
11 31.70 
12 31.57 
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Table 3.11: Cp values from LL-37 specific PCRs using Primer Set 4, conducted at annealing temperatures of 
55, 56, 58 and 60°C on the LightCycler 1.2. Results from a single human tonsil cDNA sample are shown. 
Annealing temperature (OC) Cp value 
55 32.84 
56 32.87 
58 32.47 
60 32.93 
Table 3.12: Cp values from LL-37 specific PCRs using Primer Set 4 with varying amounts (2fll each of a 1:2 
dilution series) of human tonsil RT product added. Performed on the LightCycler 480. 
Dilution of cDNA in 
nuclease-free water 
Cp (cycle number) 
1:2 32.29 
1 :4 32.98 
1 :8 35.21 
1: 16 33.99 
1 :32 34.29 
1 :64 33.08 
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Table 3.13: Cp values from a dilution series of cloned LL-37 sequence fragment, amplified with Primer Set 4 
on the LightCycler 480. Dilution of mini prep and arbitrary concentration values are shown. 
Standard Mean Cp Dilution of Concentration 
(2 replicates) master stock (arbitrary values) 
1 29.70 1 in 1xlO' 3125 
2 32.47 1 in 5x107 625 
3 34.93 1 in2.5x108 125 
4 38.33 1 in 1.25x 109 25 
5 38.05* 1 in 6.25x 109 5 
6 >40* 1 in 3. 125xl0 lo 1 
"'the amplIfication product in the samples is probably primer-dimer as mdlcated by T m, therefore these values 
are not included in the final standard curve used for analysis. 
98 
Standard 1 
Standard 5 
Standard 6 
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Figure 3.9: Melt peak analysis of LL-37 peR products: 
Melt peak analysis for LL-37 standards. The peak for standard I, shown in red, at 88°C represents the LL-
37 product. For standard 5, yellow trace, peaks at 82 and 87°C represent the PCR product peak and primer-
dimer. Standard 6 (brown) does not display a peak, indicating no PCR products were formed. The no 
template control is shown in blue. 
Standard Curve 
{~ 
l36 
~34 
'I 
e32 
u 
2 3 
log concmration 
Figure 3.10: A representative LL-37 standard curve using standards 1-4 shown in Table 3.13. ST 1: 
Standard I, ST 2: Standard 2, ST 3: Standard 3, ST 4: Standard 4. Plot of log standard concentration vs. 
crossing point. 
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Table 3.14: Cp values of standards 1-4 from six independent PCRs from which the coefficient of variation of 
the assay was calculated. 
Experiment Coefficient 
1 2 3 4 5 6 of variation (%) 
Standard 1 31.90 34.50 23.39 31.42 31.11 35.06 15 
Standard 2 34.69 34.99 31.14 33.67 33.51 36.24 5 
Standard 3 36.63 38.33 33.36 35.83 35.10 39.32 6 
Standard 4 38.71 36.74 35.28 36.81 37.56 41.4 6 
Table 3.15: Summary ofLL-37 assay. 
Step Process 
Sample preparation Reverse transcribe I j.1g of RNA in a 50j.11 reaction using 
MMLV RNAseH+ RT. Dilute product 1:2 with nuclease-
free water. Use 5j.11 in a 20j.11 PCR reaction. 
Standard curve Using 'miniprep' of cloned LL-37 PCR product. 
Dilute clone 1: 1 xl 07 then make 4x 1 in 5 dilution series. 
Use 5j.11 per dilution per 20j.11 reaction. 
Assigned arbitrary concentration values of 3125, 625, 125 
and 5 to respective standard. 
Primers Primer Set 4: 
Forward: cgctGACGGGCTGGTGAAGcG 
Reverse: CCCAGCAGGGCAAA TCTCTT 
Concentration: 1 j.1M of each. 
PCR instrument LightCycler 480 
Reaction mix 1 x Probe Master (Roche). 
PCR conditions Pre-incubation: 2 min at 50°C, 2 min at 95°C. 
45 cycles of: 5s at 94°C, lOs at 55°C and lOs at noc. 
Melt curve: Performed over 60-95°C 
Cooling: 40°C 
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Table 3.16: List of primer sets designed to amplify regions of the mRNA sequence encoding HBDI. 
Primer Primer sequences (S'-3') Position in cONAl Predicted product 
set base numbers in size (bp) 
NM_OOS218 
I Forward: CCATGAGAACTTCCTACCTTC 149-169 221 
Reverse: GTCACTCCCAGCTCACTTG 369-351 
2 Forward: GTCAGCTCAGCCTCCAAAGGA 100-80 87 
Reverse: cgcCGGT AGGAAGTTCTCATGGcG1 147-166 
J .. , , , This primer was labelled with the fluorescent probe ALX 568 at pOSitIOn c and had a 4bp 5 extension 
(shown underlined) to enable hairpin formation for LUX assays. 
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a) 1 2 3 M b) 1 2 M 
200bp 
200bp 
Figure 3.11: Agarose gel electrophoresis of a) HEp-2 cell and b) HaCaT cell PCR products amplified using 
HBD 1 Primer Set 1. a) Lanes L, HBD 1 amplification product; lanes 2 and 3 HBD3 amplification products 
(see Section 3.7); lane M, DNA size ladder. b) Lanes I and 2, HBDI products; Lane M, DNA size ladder. 
The position of the 200bp size marker is given for each gel 
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Figure 3.12: Melt peak analysis from real-time PCR generated from human tonsil cDNA using HBD I Primer 
Set L and human tonsil cDNA. A single peak representing HBD 1 can be seen at approximately 85°C. No 
product was detected in the no template control. 
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Query 1 CAGCACTTGGCCTTCCCTCTGTAACAGGTGCCTTGAATTTTGGTAAAGATCGGGCAGGCA 60 
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ 
Sbjct 350 CAGCACTTGGCCTTCCCTCTGTAACAGGTGCCTTGAATTTTGGTAAAGATCGGGCAGGCA 291 
Query 61 GAATAGAGACATTGCCCTCCACTGCTGACGCAATTGTAATGATCAGATCTGTGGCCAAGG 120 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 290 GAATAGAGACATTGCCCTCCACTGCTGACGCAATTGTAATGATCAGATCTGTGGCCAAGG 231 
Query 121 CCTGTGAGAAAGTTACCACCTGAGGCCATCTCAGACAAAAGTAAGCAGAGAGTAAACAGC 180 
I I /I I I I I /I /I /I /I /I I I I I /I /I I I I /I /I /I /I I I I " I I I " I I I I I I I I I I I I I 
Sbjct 230 CCTGTGAGAAAGTTACCACCTGAGGCCATCTCAGACAAAAGTAAGCAGAGAGTAAACAGC 171 
Query 181 AGAAGGTAGGAAGTTCTCATGGCGACTGGCAGGCAACACCCAGGATTTCAGGAACTGGGG 240 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 170 AGAAGGTAGGAAGTTCTCATGGCGACTGGCAGGCAACACCCAGGATTTCAGGAACTGGGG 111 
Query 241 AGACGCTGGC 250 
1111111111 
Sbjct 110 AGACGCTGGC 101 
Figure 3.13: Sequence of PCR product from human tonsil amplified using HBDI Primer Set 2. Sequence 
analysis performed by BLAST (http://www.ncbi.nlm.nih.gov/blastiBlast.cgi) matched the cloned PCR 
product ('Query') to the Genbank sequence ('Sbjct') for HBDI (NM_005218.3) with 100% identity. 
Table 3.17: Cp values of six human tonsil samples from an HBDI specific PCR using Primer Set 2 on the 
LightCycler 1.2. 
Sample number Cp value 
1 31.11 
2 29.91 
3 33.68 
4 33.66 
5 30.05 
6 27.78 
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Table 3.18: Cp values from a single human tonsil sample amplified with HBDI Primer Set 2 on the 
LightCycler 1.2 in reactions with varying primer concentration. 
Primer concentration (11M) Cp value 
I 31.92 
1.5 33.36 
2 34.00 
2.5 34.14 
3 34.09 
Table 3.19: Cp values from a single human tonsil sample amplified with HBDI Primer Set 2 on the 
LightCycler 1.2 in reactions with varying MgCI2 concentration. 
Total M2CIz concentration (mM) Cp value 
6 29.82 
7 29.82 
8 29.76 
9 29.72 
10 29.38 
11 29.66 
12 29.77 
13 29.02 
Table 3.20: Cp values from a single human tonsil sample amplified with HBDI Primer Set 2 on the 
LightCycler 1.2 in reactions with varying annealing temperature. 
Annealin2 temperature eC) Cp value 
55 25.09 
56 25.14 
58 23.25 
60 23.08 
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Table 3.21: Cp values of four tonsil samples from an HBDI specific PCR using Primer Set 2 on the 
LightCycler 480. 
Sample number Cp value 
1 27.35 
2 28.00 
3 27.77 
4 28.17 
Table 3.22: Cp values of four HaCaT cell samples from an HBDI specific PCR using Primer Set 2 on the 
LightCycler 480. 
Sample number Cp value 
1 33.20 
2 35.05 
3 33.01 
4 33.46 
Table 3.23: Cp values from a dilution series of cloned HBDI PCR product, amplified with Primer Set 2 on 
the LightCycler 480. Dilution of miniprep and assigned arbitrary concentrations are shown. Used to plot the 
standard curve shown in Figure 3.14 
Standard Cp value Dilution Concentration 
(arbitrary value) 
1 22.18 1 in 1.25xl07 15625 
2 25.87 1 in 6.25x 107 3125 
3 27.37 1 in 3.125x 108 625 
4 32.85 1 in 1.5625xlO9 125 
5 34.84 1 in 7.8125x10
9 25 
6 37.09 1 in3.90625x10
1o 5 
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Standard Curve 
ST5 ST4 
Log Concentr.tion 
Figure 3.14: HBD I standard curve plotted from dilution series shown in Table 3.23. Plot of log standard 
concentration vs. Cp (Cycle No.). 
Standard 1 
Standard 2 
Standard 3 
SllIndord 5 
Standard 6 
No template control 
~ n 11 ~ li 00 ~ ~ ~ ~ E • ~ M " ~ ~ G ~ 
'-.-.... rc) 
Figure 3.15: Melt peak analysis of HBD I standards. A major peak representing HBD I is seen at 86°C for all 
standards. Peaks are not generated in negative control reactions (ntc). A smaller peak at 81°C in standard 6 
probably represents primer-dimer. 
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Table 3.24: Cp values from six independent PCR reactions from which the coefficient of variation of the 
assay was calculated. 
Experiment Cp 
1 25.51 
2 29.04 
3 28.06 
4 28.18 
5 28.39 
6 28.11 
Coefficient of Variation 4 (%) 
Table 3.25: Summary of HBDI assay. 
Step Process 
Sample preparation Reverse transcribe 1 flg of RNA in a 50fll reaction using 
MMLV RNAseH+ RT. Dilute product 1:2 with nuclease-
free water. Use 5fll in a 20fll PCR. 
Standard curve Using 'miniprep' of cloned HBDI PCR product: Dilute 
clone I: 1.25x 107 then make 6x 1 in 5 dilution series. Assign 
arbitrary concentration values of 15625,3125,625,125,25 
and 5 to respective standard. Use 5fll in a 20fll PCR 
Primers Primer Set 2: 
Reverse: cgccGGTAGGAAGTTCTCATGGcG1 
Forward: GTCAGCTCAGCCTCCAAAGGA 
Concentration: 1 flM of each. 
PCR instrument LightCycler 480 
Reaction mix 1 x Probe Master (Roche). 
PCR conditions Pre-incubation: 2 min at 50°C, 2 min at 95°C. 
45 cycles of: 5s at 94°C, lOs at 60°C and lOs at noc. 
Melt curve: Performed over 60-95°C. Tm of product = 85°C 
Cooling: 40°C 
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Table 3.26: List of primer sets designed to amplify regions of the mRNA sequence encoding HBD2. 
Primer Primer sequences (5'-3') Position in cDNA! Predicted product 
set base numbers in size (bp) 
NM_OO4942 
I Forward: CATCAGCCATGAGGGTCTTG 29-48 102 
Reverse: ~AAGGCAGGT AACAGGATcGI 132-113 
2 Forward: GTGAAGCTCCCAGCCATCAG 15-34 324 
Reverse: GA TTGCGT A TCTTTGGACACC 339-318 
I This pnmer was labelled with the fluorescent probe FAM, which excItes at 488nM and emIts at 518nM, at 
position 'c' and had a 5bp 5' extension (shown underlined) to enable hairpin formation for LUX assays. 
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Figure 3.16: Melt peak analysis of PCR products generated from human tonsil cDNA with HBD2 Primer Set 
1. A large peak representing HBD2 is seen at 81°C, a smaller peak representing primer-dimer is also seen at 
approximately 71°C. 
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a 
500bps--+ 
400bps--+ 
300bps--+ 
M 1 2 
b 
Query : 1 ccatgagggtc t tgtatc t cctcttc t cg t tcctcttcatattc c t gatgcc t cttccag 60 
1 11 11 11111111111 11 1111 11 1 11 111 11 1 11 11111111111 1111111 11 11111 
Sbjct : 35 ccatgagggtct t gtatctcctcttct cgttcctc t tcatat t cctgatgcctcttccag 94 
Query: 61 gtgtttttggtggtataggcgatcc t gttacctgccttaagagtggagccata t gtcatc 120 
11111111 1 1 1 1 11 1 111 1 1111 111 1 1 111 11 11 11 11 111 11111 11111111 1 1 1 11 
Sbjct: 95 gtgtttttggtggt ataggcgatcctgttacctgccttaagagtggagccatatg tcatc 1 54 
Query : 1 2 1 cagtcttttgccctagaaggtataaacaaattggcacctgtggtctccctggaaca aaa t 1 80 
111111 1111 11111 1 1111 11 11111 11 111 1 111111 1 111 11 1111111111 1 1111 
Sbjct : 1 55 cagtcttttgccctagaaggtataaacaaattggcacctgtggtctccct ggaacaaaat 2 14 
Query: 1 81 gctgcaaaaagccat gaggaggcc aagaagctgctgtggctgatgcggat tcagaaaggg 240 
111111 11111111111 1 1 111 1 1 1 1 1111 11 111 11 111 11 111111 1111111 111 11 
Sbjct : 215 gctgcaaaaagccatgaggaggccaagaagctgc tg tggctga t gcggattcagaaaggg 274 
Query: 24 1 ctccctcatcaga gacgtgc gacatgtaaaccaa attaaactatggtgtccaaagatacg 300 
11 1 1111 111 11 1 11111 1 11 1111111 1 111 1 1111 11 11 1 1111 11 1 1111111 1 1 1 1 
Sbjct: 275 ctccctcatcagagacgtgcgacatgtaaaccaaattaaactatggtgtccaaagatacg 334 
Qu ery : 301 ca 302 
II 
Sbjct: 335 ca 336 
Figure 3.17: a) Agarose gel electrophoresis of PCR products amplified using HBD2 Primer Set 2 from 
HaCaT cell (lane I) and tonsil (lane 2) cDNA. The position of 300, 400 and 500bp size markers are shown. 
b) Sequence of the PCR product shown in lane 2, aligned to the HBD2 cDNA sequence. Sequence analys is 
performed by BLAST (http://www.ncbi.nlm.nih.govlblastIBlast.cgi) matched the cloned PCR product 
('Query' ) to the Genbank sequence ('Sbjct' ) for HBD2 (NM_OO4942) with 100% identity. 
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Figure 3.18: Melt peak analysis of PCR products generated from human tonsil cDNA with HBD2 specific 
primers. In a) a human tonsil sample was amplified using reverse-phase cartridge purified primers, b) shows 
the same sample amplified using HPLC-purified primers and in c) the HBD2 standard sample representative 
of al l in standard curve (Figure 3.19) from the dilutions shown in Table 3.27. The standard was amplified 
using HPLC-purified primers. 
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Table 3.27: Cp values from a dilution series of cloned HBD2 PCR product, amplified with Primer Set 2 on 
the LightCycler 480. For each standard the dilution of starting DNA stock and assigned arbitrary 
concentrations are shown. 
Standard Cp value Dilution Concentration 
(arbitrary value) 
1 24.68 1 in lx107 3125 
2 27.07 1 in5x107 625 
3 29.29 1 in 25x108 125 
4 31.89 1 in 1.25xl09 25 
5 34.09 1 in 6.25x 1 0
9 5 
--
32 ~T4 
31 
J ~ ST3 
I,. 
,. 
ST2 
" 
,. 
Figure 3.19: A representative HBD2 standard curve from standards 1-5 of the dilution series shown in Table 
3.27. Plot of log standard concentration vs . Cp (Cycle No.). 
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Table 3.28: Cp values of three human tonsil samples from an HBD2 specific PCR using Primer Set 2. 
Sample number Cp (mean of 2 replicates) 
1 34.04 
2 29.53 
3 30.94 
Table 3.29: Cp values ofHBD2 standards 1-4 from six independent PCR reactions from which the 
coefficient of variation for each was calculated. 
Experiment Coefficient 
1 2 3 4 5 6 of variation (%) 
Standard 1 24.99 24.80 23.69 24.11 24.66 25.8 3 
Standard 2 27.26 27.75 25.45 26.82 27.59 28.31 4 
Standard 3 30.52 30.30 28.41 29.49 29.97 30.77 3 
Standard 4 28.78 32.75 31.33 32.27 33.91 33.06 6 
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Table 3.30: Summary ofHBD2 assay. 
Step Process 
Sample preparation Reverse transcribe I /1g of RNA in a 50/11 reaction using 
MML V RNAseH+ RT. Dilute product 1:2 with nuclease-
free water. Use 5/11 in a 20/11 PCR reaction. 
Standard curve Dilute cloned HBD2 PCR product I: I x I 0' then make 5x 1 
in 5 dilution series. Assign concentrations of 3125, 625, 
125, 25 and 5 to respective standards. 
Primers Primer Set 2 - HPLC purified 
Forward: GTGAAGCTCCCAGCCATCAG 
Reverse: GA TTGCGT A TCTTTGGACACC 
Concentration: I /1M of each 
PCR instrument LightCycler 480 
Reaction mix Sybr Green Master Mix (Roche). 
PCR conditions Pre-incubation: 2 min at 50°C, 2 min at 95°C. 
45 cycles of: 5s at 94°C, lOs at 58°C and lOs at noc. 
Melt curve: Performed over 60-95°C 
Cooling: 40°C 
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Table 3.31: List of primer sets designed to amplify regions of the mRNA sequence encoding HBD3. 
Primer Primer sequences (5'-3') Position in cDNA! Predicted product 
set base numbers in size (bp) 
NM_OOI081551 
I Forward: gttccaggtcatggaggaatc 270-290 180 
Reverse: ccacactctcgtcatgtttcag 450-428 
2 Forward: ~CCTTTTCATCCAGCTTCAGcG 178-196 203 
Reverse: CCTGCCGA TCTGTTCCTCCTTT 380-358 
I This pnmer was labelled with the fluorescent probe FAM, which excites at 488nM and emits at 518nM, at 
position 'c' and had a 5bp 5' extension (shown underlined) to enable hairpin formation for LUX assays. 
115 
a) 
300bps 
200bps 
100bps 
M 1 2 
b) 
Score = 390 bits (203), Expect = 1e-105 
Identities = 203/203 (100 %), Gaps = 0 /2 03 (0 %) 
Strand=Plus / Plus 
Query 10 CCTTTTCATCCAGTCTCAGCGTGGGGTGAAGCCTAGCAGCTATGAGGATCCATTATCTTC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 178 CCTTTTCATCCAGTCTCAGCGTGGGGTGAAGCCTAGCAGCTATGAGGATCCATTATCTTC 
Query 70 TGTTTGCTTTGCTCTTCCTGTTTTTGGTGCCTGTTCCAGGTCATGGAGGAATCATAAACA 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 238 TGTTTGCTTTGCTCTTCCTGTTTTTGGTGCCTGTTCCAGGTCATGGAGGAATCATAAACA 
Query 130 CATTACAGAAATATTATTGCAGAGTCAGAGGCGGCCGGTGTGCTGTGCTCAGCTGCCTTC 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 298 CATTACAGAAATATTATTGCAGAGTCAGAGGCGGCCGGTGTGCTGTGCTCAGCTGCCTTC 
Query 190 CAAAGGAGGAACAG 213 
11111111111111 
Sbjct 358 CAAAGGAGGAACAG 371 
69 
237 
129 
297 
189 
357 
Figure 3.20. Analysis of HBD3 PCR products. a) Agarose gel electrophoresis of products from two HaCaT 
cell samples amplified using HBD3 Primer Set I. Both samples generated a single band of approximately 
180bp. b) Sequence of PCR product amplified from human tonsil cDNA with HBD3 Primer Set 2. Sequence 
analysis performed by BLAST matched the cloned PCR product ('Query') to the HBD3 cDNA sequence 
('Sbjct'; Genbank Accession no. NM_OO 1081551) with 100% identity 
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Figure 3.21: Melt peak analysis of PCR products generated from human tonsil cDNA with HBD3 Primer Set 
2. A large peak representing HBD3 is seen at 85°C. Other smaller peaks, including one representing primer-
dimer at 81°C, are representative of non-specific reaction products. 
117 
Table 3.32: Sequence of oligonucleotide primers used to amplify a region of the mRNA sequence encoding 
human hepcidin. 
Primer Primer sequences (5'·3') Position in cDNA Predicted product 
set (base numbers in size (bps) 
NM_021175) 
I Forward: CAGTGGCTCTGTITIC 104-119 186 
Reverse: GTCTTGCAGCACATCCCACAC 289-268 
a) 300bps 
200bps 
100bps 
M 2 
b) 
Query : 12 
Sbjct: 117 
agtggctctgttttcccacaactagacanggacaacttgcntaagctgcaaccccagnac 71 
""""""""""" "" """"'" '''''''''''''''' agtggctctgttttcccacaac-agac-gggacaacttgcaga-gctgcaaccccaggac 173 
Query: 72 
Sbjct: 174 
agagctggagccagggccaactggatgcccatgttncagangcgaangaggcgangacac 131 
"""""""'"" 11111111111111' 1111 ""' 111111' 1111' agagctggagccagggccagc tggatgcccatgttccagaggcgaaggaggcga-gacac 232 
Query: 132 
Sbjct: 233 
ccacttccccatctgcattttcttgcctgcaggctgcttgtcatcgatcaaagtgtggg 190 
"""'''"""""'''' II "" "'" '"""""""'''"' ccacttccccatctgcattttct-gc- tgc - ggctgc-tgtcatcgatcaaagtgtggg 287 
Figure 3.22. Analysis of hepcidin PCR products. a) Agarose gel electrophoresis of PCR products from two 
HaCaT cell samples amplified using hepcidin primers. Both samples generated a single band of 
approximately 190bp. b) Sequence of PCR product amplified from human tonsil cDNA with hepcidin Primer 
Set I . Sequence analysis performed by BLAST matched the cloned PCR product (,Query') to the hepcidin 
cDNA sequence ('Sbjct'; Genbank Accession no. NM_021175) with 91 % identity. 
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Figure 3.23: Analysis of real-time PCR products generated form the cloned hepcidin target sequence 
amplified with hepcidin specific primers. a) Melt curve analysis. For standard I a peak representing hepcidin 
was seen at 89°C. For all other standards peaks representing primer-dimer were seen at approximately 82°C. 
PCR products were not formed in the no template control; b) Agarose gel electrophoresis of products from 
standards 1,2 and 6 shown in a). Only for standard I is a band of the predicted size (-190bp) visible. Lane 
M, DNA size ladder; lanes I and 2, standard 1 products; lane 3, standard 2 product; lanes 4 and 5, standard 6 
product. The position of the 200bp and 25 bp markers are indicated. 
Table 3.33: Sequence of oligonucleotide primers designed to amplify regions of the mRNA sequence 
encoding human LEAP-2. 
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Primer Primer sequences (5'-3') Position in cDNA! Predicted product 
set base numbers in size (bp) 
NM_052971 
1 Forward:TGTTGGGCCAGATAGATGGCTC 76-97 161 
Reverse: GTTCCGAT ACGTCTTTTTCTGCG 236-215 
120 
2 M 
a) b) 
."--200bp 
.. 100bp 
(c) 
Query 1 CCCAATACCAGAAGTGAGTTCGGCAAAGAGAAGGCCAC 60 
11 11111 1 11 1111111111111111111111111111111 1 1111111111 1 1111 11 1 
Sbjct 76 TGTTGGGCCAGATAGATGGCTCCCCAATACCAGAAGTGAGTTCGGCAAAGAGAAGGCCAC 135 
Query 61 GGAGAATGACCCCATTTTGGAGAGGGGTTTCCCTCAGGCCTATTGGAGCCTCCTGCCGGG 12 0 
111111111111111111111111111111111111111111111111111111111111 
Sbjct 136 GGAGAATGACCCCATTTTGGAGAGGGGTTTCCCTCAGGCCTATTGGAGCCTCCTGCCGGG 195 
Query 121 ATGATTCTGAGTGTATCACAAGGCTATGCAGAAAAAGACGC 161 
11111111111111111111111111111111111111111 
Sbjct 19 6 ATGATTCTGAGTGTATCACAAGGCTATGCAGAAAAAGACGC 2 36 
2 M 
... -- 200b~ 
Figure 3.24: Analysis of PCR products amplified with LEAP-2 specific primers. a) Agarose gel 
electrophoresis of human tonsil PCR. Lanes I and 2, human tonsil samples; lane M, DNA size marker. 
LEAP-2 PCR products can be seen at approximately 160bp. b) Agarose gel electrophoresis of HaCaT cell 
PCR products. Lanes I and 2, HaCaT samples; lane M, DNA size marker. LEAP-2 PCR products can be seen 
at approximately 160bp. c) Sequence of PCR product. Sequence analysis performed by BLAST 
(http://www.ncbi.nlm .nih .gov/blastiBlast.cgi) matched the cloned PCR product ('Query') to the Genbank 
sequence ('Sbjct') for LEAP-2 (NM_052971) with 100% identity. 
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Figure 3.25: Melt peak analysis of PCR products generated from HaCaT cDNA with LEAP-2 Primer Set 1. 
Peaks representing LEAP-2 amplification products were seen at 85°C. 
Table 3.34: Cp values from a dilution series of cloned LEAP-2 PCR product, amplified with Primer Set 1 on 
the LightCycler 480. For each standard the dilution of starting DNA stock and assigned arbitrary 
concentrations are shown. 
Standard Cp value Dilution Concentration 
(arbitrary value) 
1 23.53 1 in lxl06 3125 
2 26.42 1 in 5x106 625 
3 27.75 1 in 25x107 125 
4 33.98 1 in 1.25x108 25 
5 32.08 1 in 6.25x108 5 
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Standard Curve 
2 3 
Log Concentration 
Figure 3.26: A representative LEAP-2 standard curve from standards 1-5 of the dilution series shown in 
Table 3.34. Plot of log standard concentration vs. Cp (Cycle No.). 
Table 3.35: Cp values of LEAP-2 standards 1-4 from six independent PCR reactions from which the 
coefficient of variation for each was calculated. 
Standard Experiment Coefficient 
1 2 3 4 5 6 of variation 
(%) 
1 33.39 27.69 27.68 30.93 27.79 27.75 8 
2 34.50 30.05 30.05 35.04 29.88 29.89 8 
3 35.18 32.26 32.26 39.05 32.88 32.05 8 
4 37.00 33.88 33.88 38.41 34.10 33.90 6 
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Table 3.36: Summary of LEAP-2 assay. 
Step Process 
Sample preparation Reverse transcribe Illg of RNA in a 50111 reaction using 
MMLV RNAseI-t RT. Dilute product 1:2 with nuclease-
free water. Use 5111 in a 20111 PCR reaction. 
Standard curve Dilute cloned LEAP-2 PCR product 1: 1 x 106 then make 6x 1 
in 5 dilution series. Assign concentrations of 3125, 625, 
125,5 and 1 to respective standards. Include standards in 
each assay; measure in duplicate. 
Primers Primer Set 1 - HPLC purified: 
Forward: TGTTGGGCCAGAT AGA TGGCTC 
Reverse: GTTCCGA T ACGTCTTTTTCTGCG 
Concentration: 111M of each. 
PCR instrument LightCycler 480 
Reaction mix Ix Sybr Green Master Mix (Roche). 
PCR conditions Pre-incubation: 2 min at 50°C, 2 min at 95°C. 
45 cycles of: 5s at 94°C, lOs at 58°C and lOs at 72°C. 
Melt curve: Performed over 60-95°C 
Cooling: 40°C 
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Table 3.37: Sequence of oligonucleotide primers designed to amplify a fragment of the mRNA sequence 
encoding human GAPDH. 
Primer Primer sequences (5'-3') Position in cDNA Predicted product 
set (base numbers in size (bp) 
NM_OO2046) 
Forward: CGGAGTCAACGGA TTTGGTC 120-139 
1 177 
Reverse: CCGTTCTCAGCCTTGA 279-296 
Query 15 GGGCTGCTTTTAACTCTGGTAAAGTGGATATTGTTGCCATCAATGACCCCTTCATTGACC 74 
11111111111111111111 11 11 11 11 1 11 111 1 11 11111111111111111111111 
Sbjct 161 GGGCTGCTTTTAACTCTGGTAAAGTGGATATTGTTGCCATCAATGACCCCTTCATTGACC 22 0 
Query 7 5 TCAACTACATGGTTTACATGTTCCAATATGATTCCACCCATGGCAAATTCCATGGCAC 132 
11 11 1111 11 11 11 1 11 11 11 11 11 11 1111 111111111111 11 1 1 11 11 1 11 1 1 11 
Sbjct 221 TCAACTACATGGTTTACATGTTCCAATATGATTCCACCCATGGCAAATTCCATGGCAC 27 8 
Figure 3.27: GAPDH sequence. Sequence analysis performed by BLAST 
(http://www.ncbi.n1m.nih.govlblastIBlast.cgi) matched the PCR product ('Query') to the Genbank sequence 
('Sbjct') for GAPDH (NM_002046) with 100% identity. 
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Figure 3.28: Melt peak analysis of PCR products generated from three HaCaT cDNA samples 1-3 with 
GAPDH Primer Set I . Peaks representing GAPDH were seen at 85°C for all three samples . The negative 
control (ntc) did not have a melt peak. 
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Table 3.38: Cp values from a dilution of GAPDH cDNA, amplified with Primer Set 1 on the LightCycler 
480). Dilution of cDNA and arbitrary values are shown. 
Standard Mean Cp value Dilution Concentration 
(2 replicates) (arbitrary value) 
1 22.58 1 x lxlO:l 16 
2 23.63 0.5 x lx102 8 
3 24.75 0.25 x lx102 4 
4 25.73 0.125 x lx102 2 
5 26.90 0.0625 x lx102 1 
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Figure 3.29: GAPDH standard curve from dilution series shown in Table 3.38. Plot of log standard 
concentration vs. Cp value (Cycle No.). 
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Figure 3.30: Melt peak analysis of PCR products with GAPDH Primer Set 1. Peaks representing GAPDH 
were seen at 84.5°C 
Table 3.39: Cp values from six independent PCR reactions from which the coefficient of variation was 
calculated. 
Experiment Cp 
1 25.25 
2 25.21 
3 25.14 
4 25.21 
5 25.52 
6 28.30 
Coefficient of Variation 0.5 (%) 
92 
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Table 3.40: Summary ofGAPDH assay. 
Step Process 
Sample preparation Reverse transcribe 11lg of RNA in a 50111 reaction using 
MMLV RNAseH+ RT. Dilute product 1: 100 with nuclease-
free water. Use 5111 in a 20111 PCR reaction. 
Standard curve Using neat HaCaT cell cDNA prepared as above. Dilute 1 
in 100 then make 5x 1 in 5 dilution series. Assign arbitrary 
concentration values of 16, 8, 4, 2 and 1 to respective 
standards. N.B. A standard curve made in this way is stored 
in the LightCycler 480 software, it should be imported into 
each PCR run by including standard 4 in the assay as a 
calibrator sample and following instructions in the Light 
Cycler software. 
Primers Primer Set 1 -HPLC purified: 
Forward:cGGAGTCAACGGATTTGGTC 
Reverse: CCGTTCTCAGCCTTGA 
Concentration: 111M of each. 
PCR instrument LightCycler 480 
Reaction mix Ix Sybr Green Master Mix (Roche). 
PCR conditions Pre-incubation: 2 min at 50°C, 2 min at 95°C. 
45 cycles of: 5s at 94°C, 10s at 58°C and 10s at noc. 
Melt curve: Performed over 60-95°C 
Cooling: 40°C 
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Chapter 4 
In Vivo Expression of Antimicrobial Peptides in 
Human Tonsils from Control and Tonsillitis 
Patients 
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4.1 Introduction 
Human palatine tonsils play important roles in host immunity at both local and systemic 
levels. Their localisation at the openings of both the gastrointestinal and respiratory 
tracts make them ideal antigen sampling organs that function to alert the primary and 
secondary immune responses of the host. As described previously each palatine tonsil 
has a lymphoid core, encapsulated by a stratified, non-keratinising epithelium. This 
protective epithelial layer provides not only a physical barrier but also through the 
synthesis of antimicrobial peptides (AMP) an effective innate defence mechanism (Bals 
2000). Although tonsils provide a shield against invading pathogens, the Gram-positive 
bacterium, S. pyogenes often breaches these defences and causes tonsillitis. This 
infection is often recurrent and sufferers present with swollen and painful palatine 
tonsils. Treatment is, in the first instance, with antibiotics such as erythromycin or 
penicillin which are prescribed to stop the infection and to reduce swelling in the 
tonsils. Often, when the infection is severe or recurrent, a tonsillectomy may be 
undertaken and in fact approximately 65 out of every 10,000 British children undergo 
this procedure each year (Van Den Akker, Hoes et al. 2004). However despite 
tonsillitis being relatively common, the physiological and immunological factors that 
allow this infection to perpetuate remain elusive. 
Expressed at epithelial and mucosal surfaces, AMPs provide a first-line of defence 
against potential pathogens (Bals 2000). Moreover these molecules have also been 
reported to be up-regulated in response to infection (Schaller-Bals, Schulze et al. 2002). 
Globally, many studies have investigated the roles of AMPs in different disease states 
(Bajaj-Elliott, Fedeli et al. 2002; Chen, Schaller-Bals et al. 2004; Fahlgren, 
Hammarstrom et al. 2004; Heilborn, Nilsson et al. 2005; Voss, Wehkamp et al. 2006; 
Warnke, Springer et al. 2006), yet one area that is not well researched is the role of 
AMPs in the defence of the human palatine tonsils. 
Prior to this study, Ball, working in Newcastle examined the expression and synthesis of 
LL-37, HBDI, HBD2, HBD3, hepcidin and LEAP-2 in tonsil samples using end-point 
PCR and immunohistochemical analyses (Ball, Siou et al. 2007). The molecular results 
suggested that the LL-37, HBDI, HBD2, HBD3 and hepcidin and LEAP-2 genes were 
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expressed in whole tonsils removed from control subjects for sleep apnoea and snoring 
(n=2), and in tonsils excised from patients suffering RAT (n=13). However the sample 
size of the study was small and the levels of expression of each AMP were not 
determined. 
The hypothesis was therefore proposed that a defect in the innate immune response 
involving host AMPs, such as a deficiency in AMP expression at the epithelial surface 
and/or a failure of the AMPs to up-regulate in response to infection, is a cause or 
contributory factor to recurrent acute tonsillitis. To investigate this further a total of 93 
tonsil samples excised from control and RAT patients respectively were analysed to 
determine and compare AMP mRNA expression profiles using the more accurate 
quantitative real-time PCR assays described in Chapter 3. 
4.2 Subjects and Methods 
Tonsils were collected with informed consent from patients undergoing tonsillectomy 
for recurrent acute tonsillitis (RAT) or for reasons other than bacterial tonsillitis, such as 
obstructive sleep apnoea, snoring or enlarged tonsillar crypts (control non-RAT). 
4.2i Sample size 
Prior to the study, power calculations were completed to ascertain the patient sample 
size required to show statistically significant trends or differences within the data. 
These were performed in conjunction with Dr Tom Chadwick (School of Population 
and Health Sciences). The number of patient samples required for the study was based 
on power calculations performed on preliminary data in Mini-Tab 14. 
The sample size calculation was based on the use of the 2-sample T -test to compare the 
mean value of epithelial LL-37 mRNA expression between the control (non-RAT) and 
RA T groups. The standard deviation (SO) of this measure was estimated as 1000 from 
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preliminary data and the detectable (clinically significant) difference was chosen to be 
1000. We use a significance level of 0.05 and 80% power. For these choices a sample 
size of 17 per group would be required. 
A similar calculation was made for lymphoid samples. Here, the SD of this measure 
was estimated as 1100 from preliminary data and the detectable (clinically significant) 
difference was chosen to be 1000. We use a significance level of 0.05 and 80% power. 
For these choices a sample size of21 per group would be required. 
Additionally, the differences observed between different tonsils from one individual, 
determined that each excised tonsil could be analysed as one sample. 
4.3 Quantitative Real-Time PCR Analysis of Control Subjects 
and Tonsillitis Patients, Measuring LL-37, HBD1, HBD2 and 
LEAP-2 mRNA 
Quantitative real-time peR data measuring LL-37, LEAP-2, HBD1 and HBD2 mRNA 
expression in a total of 93 tonsil samples was analysed. A total of 37 samples were 
collected from control subjects and 56 samples were collected from patients undergoing 
tonsillectomy for RAT (the majority of which were not suffering from infection at the 
time of surgery). This sample size exceeded the number of samples predicted by power 
calculations to show significant differences. Tonsils are usually removed from 
tonsillitis sufferers when the patient is not experiencing an episode of tonsillitis, 
therefore it can be presumed that the majority of tonsils used in this study were excised 
when the patient was not suffering an active infection. The decision as to when the 
patient is in a suitable condition for tonsillectomy was taken by the clinician. Upon 
removal tonsils from chronic tonsillitis sufferers often showed signs of necrosis or 
scarring. Heavily scarred areas of epithelium were difficult to dissect from the 
lymphoid core but were still used in experiments when possible. Tonsils excised from 
control patients tended to be large and relatively unscarred. All data were ·adjusted to 
GAPDH mRNA and data analyses were performed. 
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As variation between samples was seen to be large, any samples which were outside of 
± two standard deviations of the mean were not included in analyses. If the inclusion of 
these samples made a statistically significant difference to the data sets and therefore the 
final graphs and conclusions they were included in the data set. The inclusion or 
exclusion of the samples lying outside the normal range is stated in the Figure legend of 
each graph. 
For data analysis involving two groups of data an unpaired T-test was performed. This 
test was chosen following guidelines in the Prism statistical guide which is included 
with the software, (Motulsky 2003) as the two groups of data for analysis were not 
matched i.e. the data were not before/after data, or samples from twins or parent child 
pairs etc. For data analysis involving more than three groups of data a one way 
ANOVA was used followed by a Bonferroni post-test as appropriate as each data set 
was required to be compared to each other set. Prism guidelines were once again 
followed to determine choice of test. 
4.3.1 All patient samples 
The quantitative real-time peR data collected from all the subjects were analysed 
initially to investigate AMP gene expression in the whole sample population in terms of 
tissue type (epithelial or lymphoid). 
4.3.1 i Epithelial and lymphoid tissues 
Patient samples were classified based on tissue type. Data from epithelial samples, 
dissected from the undulating outer surface of the tonsils were compared to data from 
samples from the lymphoid tissue core which was encapsulated by the epithelium. 
The results for LL-37 mRNA expression are shown in Figure 4.1a. A total of 83 
samples were analysed (49 epithelial and 34 lymphoid). The means ± the standard error 
of the mean (± SEM) of epithelial and lymphoid groups were similar, 16±7 and 10±1 
arbitrary units (AU) respectively and no statistically significant differences were 
identified. The majority of samples from both groups were observed to express 
between and 63AU of LL-37 mRNA. Two samples were recorded outside of this 
range. 
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A total of 88 tonsil samples were analysed for LEAP-2 mRNA expression, of which 55 
were epithelial and 37 were lymphoid samples (Figure 4.1b). No statistically significant 
differences were recorded between the groups. As observed with LL-37 mRNA 
expression in Figure 4.1a, a number of out-lying points were observed within the 
epithelial group. These values related to samples from both control and RAT patients. 
Immunohistochemical analysis of RAT tonsil using an antibody to LEAP-2 (anti-
human-LEAP-2 purified IgO (Phoenix Pharmaceuticals, 0-075-40», identified LEAP-2 
immunoreactivity in both epithelial and lymphoid tissues (Figure 4.2). 
HBDI mRNA expression of 53 epithelial and 35 lymphoid samples is shown in Figure 
4.1 c. No statistically significant differences were observed between the groups. The 
values relating to HBDI mRNA expression were however widespread (5-572AU). The 
samples with elevated HBD I mRNA levels were identified and investigated further, but 
there was no correlation between the two groups i.e. no single subject or groups of 
subjects were high expressers in both epithelial and lymphoid groups respectively. 
Figure 4.1 d shows data relating to HBD2 gene expression from 92 tonsil samples (52 
epithelial and 40 lymphoid). The epithelial samples expressed HBD2 mRNA at a 
statistically significantly higher level than the lymphoid samples (P<0.05). The mean 
(± SEM) values of the groups were 42±10 and 2±OAU for epithelial and lymphoid 
groups respectively. 
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4.3.2 Tissue type and disease state 
To investigate the effects of recurrent acute tonsillitis (RAT) on AMP gene expression 
patterns the data from the control and diseased tonsils was compared (Figure 4.3). 
The data from 84 tonsil samples analysed for LL-37 expression were considered in 
terms of disease state and tissue type (Figure 4.3a). The values recorded in the majority 
of the samples were between 0.1 - 43AU of LL-37 mRNA, although the measured 
values of two control epithelial samples, 63 and 127AU respectively, were elevated in 
comparison (Figure 4.3ai). The mean (± SEM) expression of LL-37 mRNA was not 
statistically different between groups. 
The LEAP-2 mRNA expreSSIon data (Figure 4.3b) no statistically significant 
differences were seen between the mean values of the epithelial groups (means (± SEM) 
13±5 and 10±3AU) respectively and the lymphoid groups (means (± SEM) 2±0 and 
3±OAU respectively). However, it was observed that LEAP-2 mRNA expression was 
more variable in the epithelial compared to the lymphoid groups; LEAP-2 values in the 
epithelial groups ranged from 0.4 - 40AU whereas the values in the lymphoid tissues 
were focussed between O.l-lOAU. Two out-lying values shown in Figure 4.3bi, and 
recorded as 96 and IIIAU respectively, were both epithelial derived; one was from the 
tonsil of a control (non-RAT) subject and the other from a RAT patient. A further 
sample, also of epithelial origin, with value of201AU (Figure 4.1b) was not included in 
these analyses as all data was standardised to within ± two standard deviations of the 
mean of the group and any samples that fell outside of this limit, including this one was 
removed from the data set. 
Analyses of the HBD 1 mRNA expression results according to tonsil disease state are 
shown in Figure 4.3c. No statistically significant differences were observed. However, 
interestingly, a large range of HBDI mRNA expression was observed in the epithelial 
tissues of the control and RAT tonsils (ranging between 5-516AU) and in the RAT 
lymphoid tissues not the control lymphoid tissues. 
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The HBD2 mRNA expreSSIOn data of the control and RAT subject groups were 
similarly analysed (Figure 4.3d), once again no statistically significant differences were 
observed. As noted with HBDI, considerable variations in the epithelial HBD2 mRNA 
values were observed (O.1-955AU). 
4.3.3 Gender 
The HBD 1 analyses indicated that gender may influence AMP expression profiles. To 
investigate this further all the AMP expression data was re-analysed according to the 
gender of the subjects. 
4.3.3i Intra-gender differences 
Analyses of the LL-37 and LEAP-2 mRNA expression data relating to the male subjects 
only (Figure 4.4a & b) revealed no statistically significant differences between the 
groups. No statistically significant differences were also seen in HBD 1 and HBD2 
mRNA expression levels between disease state and tissue type groups in males (Figure 
4.4c & d). 
Analyses of the data relating to tonsils excised from females was compromised by the 
reduced sample numbers (n=5 maximum in the control epithelial group). Analyses of 
the LL-37, LEAP-2, HBDI and HBD2 mRNA expression data relating to the female 
subjects only (Figure 4.5a, d, c & d) revealed no statistically significant differences 
between the control or RAT groups from either tissue type. 
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4.3.3ii Gender and disease state 
Presentation of all the tonsil AMP expression data in terms of gender is provided in 
Figures 4.6a-d. Despite the low sample numbers in some of the groups the patterns of 
LL-37 and LEAP-2 expression detected in males and females were comparable and no 
statistically significant differences between groups were recorded. After HBD 1 and 
HBD2 mRNA expression analysis no statistically significant differences were seen. 
Interestingly, a large range of HBDI mRNA expression was recorded, as seen 
previously in Figure 4.1 & 4.3. 
4.3.4 Age of subject and disease state 
Children between the ages of six and ten years present most frequently with tonsillitis 
(Batra, Safaya et al. 2004). Thus the tonsil AMP expression profiles of a group of 
children suffering recurrent acute tonsillitis were investigated and compared to those of 
similarly aged control children. 
4.3.4i Expression of AMP mRNA in children <10 years old 
Epithelial AMP expression data from patients who were <10 years old at the time of 
tonsillectomy is presented in Figure 4.7. The age range was three to nine years, and the 
median ages of the control and RAT groups were four years six months and five years 
respectively. 
Comparison of the LL-37 mRNA expressIOn data from 12 control and 15 RAT 
epithelial samples (22±11 compared to 8±2AU respectively) indicated no statistically 
significant difference in the mean values (Figure 4.7a). It was noted that two of the 
values determined in the control group (127 and 63AU respectively) were at least six to 
twelve times higher than the other values. However re-calculation of the data with these 
sample values excluded resulted in mean values of 7±2 and 8±2AU respectively and 
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only re-affirmed that tonsil LL-37 expression did not appear to be significantly altered 
in the young tonsillitis sufferers. 
Similarly no statistical difference was observed between the mean LEAP-2 mRNA 
expression values of the two groups (Figure 4. 7b). Indeed the values detected in each of 
the groups were comparable and in the range 0-40AU, with a sample indicative of very 
high expression detected in the control group (96AU respectively) and one in the RAT 
group (I I IAU). 
Comparison of the mean values relating to the HBDI mRNA expression (Figure 4.7c) 
determined that no statistically significant differences were present in the data. The 
values were however very variable, with expression values ranging from 0.1 to >500AU 
in both groups. 
A similar pattern was observed in relation to HBD2 expression with no statistically 
significant difference recorded between the means of the control 75±28 AU and RAT 
56±20 AU groups (Figure 4.7d). As observed with HBDI mRNA, the expression 
values varied greatly, ranging from 0.1 to >200AU in both the control and RAT groups. 
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4.3.4ii Expression of AMP mRNA in under 45s compared to the over 
45s. 
It has also been reported in the literature that the proportion of asymptomatic carriers of 
S. pyogenes, known to be a causal factor in RAT, differs between those under and over 
45 years of age (Hoffmann 1985). Thus the tonsil data was analysed to investigate 
whether AMP expression profiles of the control and RAT groups, further divided 
according to age i.e. >45 years or < 45 years respectively, differed. Unfortunately no 
data from samples excised from RAT patients >45 years were collected. These analyses 
included the AMP expression data relating to the children <10 years age. 
The tonsil epithelial samples were analysed for LL-37 mRNA expression in relation to 
age and the results are presented Figure 4.8a. No statistically significant differences 
were seen between age groups in the control patients. 
Analyses of the tonsil LEAP-2 gene expression data in relation to age are presented in 
Figure 4.8b. Again, as with the LL-37 data, no statistically significant differences were 
detected between the mean values of the three other groups. 
The mean expression values of the HBD 1 and HBD2 genes followed similar profiles 
(Figure 4.8c & d) and no statistical significant differences were detected between the 
groups. 
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4.3.5 Previous or current infections 
As part of the study information was collected from the subjects regarding the time of 
their last sore throat or bout of tonsillitis. Although not confirmed clinically these data 
were used to investigate potential links between the levels of AMP mRNA expression 
and the time since each subject's last sore throat. For these analyses the AMP 
expression data was plotted according to the period oftime since each subject's last sore 
throat i.e. currently, 1-4 weeks, 1-6 months, 6-12 months, 2-5 years or 'never' . 
The complete data are presented in Figure 4.9. The LL-37 expression data is shown in 
Figure 4.9a. Each group, apart from the 6-12 month group, is characterised by the 
diverse spread of the LL-37 expression values and statistical analyses of the data 
revealed no significant differences between the groups. 
Similar AMP expression profiles were observed in relation to LEAP-2, HBD 1 and 
HBD2 expression (Figure 4.9b-d). In all cases statistical analyses of the data revealed 
no significant differences between the groups although again it should be noted that the 
6 -12 months, 2-5 years or 'never' groups had small numbers of subjects. 
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4.4 Discussion 
A pilot study by our group in Newcastle using end-point peR investigated the 
expression of the genes encoding AMPs in tonsils excised from 13 RAT patients and 
two control (non-RAT) subjects. The molecular analyses suggested that the LL-37, 
HBD I, HBD2, HBD3 hepcidin and LEAP-2 genes were expressed in both sets of 
tonsils and, using semi-quantitative analyses, the results indicated that the tonsil 
epithelium expressed AMP mRNAs at increased levels compared to the lymphoid 
tissues (Ball, Siou et al. 2007). However the sample size of the study was small and the 
actual levels of expression of each AMP were not determined. Thus to address the 
hypothesis that a defect in the host innate immune response involving AMPs, such as a 
deficiency in AMP expression at the tonsil epithelial surface and/or a failure of the 
tonsil AMPs to up-regulate in response to infection, is a cause or contributory factor to 
recurrent acute tonsillitis a much larger study was conducted. In this study, the largest 
recorded to date, the levels ofLL-37, HBD1, HBD2 and LEAP-2 AMP gene expression 
were quantified and compared in over ninety tonsils removed from control subjects and 
RAT patients. 
Power calculations indicated that the data from groups of 21 control and RAT tonsils 
respectively was required to have an 80% chance of detecting differences at the 5% 
significance level, in the AMP expression levels of the epithelial and lymphoid tissues. 
A total of 93 tonsil samples (37 from control subjects and 56 from RAT patients) were 
analysed. Moreover the tonsils removed from the control subjects were considered as 
healthy organs as the controls comprised those individuals referred to surgery to address 
problems such as sleep apnoea and snoring caused, in the main, by enlarged but 
functionally 'normal' tonsils. As such the reduced numbers of control tonsils reflected 
the smaller numbers of patients referred to surgery to address such problems. 
Initial analyses of the AMP data compared the levels of AMP expression In the 
epithelial and lymphoid layers of all tonsils. The mean data indicated that the levels of 
HBD2 mRNA expression were significantly higher, by approximately twenty-fold, in 
the epithelium compared to the lymphoid tissues. In contrast no significant differences 
were observed in relation to the LL-37, HBDI and HBD2 expression patterns. These 
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results conflicted with those observed previously (Ball, Siou et al. 2007), but can 
probably be explained by the more sensitive real-time analyses used in this study and 
the increased sample size. However in some respects the LL-37, HBDI and HBD2 
results were unexpected. The tonsil epithelium functions in part as a physical barrier 
against potential pathogens and the AMPs can be considered as an 'antiseptic layer' on 
its surface. Thus from an initial defence point of view it would be more efficient if the 
AMP levels were higher in the outer epithelial layers than the inner lymphoid tissues. 
However this study investigated only AMP gene expression and it is feasible that the 
encoded peptide concentrations were higher in the epithelial layers. Indeed previous 
work reported by our group using frozen sections of tonsil and antibodies to the AMPs 
showed HBDI, HBD2, HBD3 and LL-37 peptides to be localised specifically to the 
surface epithelium rather than the lymphoid tissues, and to be reduced in the surface 
epithelia of tonsils from RAT patients (Ball, Siou et al. 2007). 
Furthermore comparison of the mean epithelial LL-37, HBDl, HBD2, LEAP-2 data in 
relation to the control and RAT tonsils did not support any differences in the levels of 
AMP gene expression. A similar picture was evident for the lymphoid tissues. These 
data therefore countered our original hypothesis that a deficiency in AMP expression at 
the tonsil epithelial surface contributes to recurrent acute tonsillitis (RAT). It was also 
proposed that RAT is caused by a failure of the AMPs to up-regulate in response to 
infection. AMPs are induced in host cells in response to microbes (Dorschner, 
Pestonjamasp et al. 2001; Chromek, Slamova et al. 2006; Rivas-Santiago, Hernandez-
Pando et al. 2008) and as the RAT patients recruited to the study were about to undergo 
a tonsillectomy and thus presumably infection free it was perhaps not surprising that 
elevated levels were not observed. 
Reports have been published which show that the cathelicidin LL-37 is particularly 
active against S. pyogenes (Nizet, Ohtake et al. 2001; Lee, Ohtake et al. 2005) the major 
bacterial cause of tonsillitis. Some patients recruited to the study indicated recent bouts 
of sore throat or tonsillitis prior to their surgery and it was perhaps unexpected therefore 
that there were no significant clusters of elevated LL-37 values in either the epithelial or 
lymphoid RAT samples. However the data may have reflected the reliability of patient 
self-diagnosis. Conversely, the commensal Streptococcus salivarius Kl2 has been 
shown to promote down-regulation of innate immune responses in epithelial cells 
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through the inhibition of activation of the NFKB pathway (Cosseau, Devine et al. 2008). 
It is therefore feasible that the pathogenic streptococci involved in RAT, if present, were 
able to prevent the up-regulation of AMP gene expression in the tonsil epithelium. 
However a report, in which the up-regulation of cathelicidin mRNA transcripts in 
tonsils excised from patients with RAT is described (Song, Hwang et al. 2006), does not 
support this. The semi-quantitative RT-PCR data provided in their study indicated that 
LL-37 was expressed at very low levels in tonsils removed from control subjects, and in 
fact cDNA bands indicative of expression were not visible on their ethidium bromide 
stained gels. LL-37 transcripts were in contrast identified in all control tonsils analysed 
in the Newcastle study and moreover peptide was detected in the tonsillar epithelia of 
control subjects (Ball, Siou et al. 2007). Thus my observations and those of Song, 
Hwang et al (2006) are difficult to reconcile, but the data reported in this study do not 
support the up-regulation of AMP gene expression in tonsils excised from RAT 
patients. 
HBD 1 is acknowledged classically as being constitutively expressed at epithelial 
surfaces and, as expected, statistical analyses of the RAT and control tonsil HBD 1 
expression data did not provide any significant differences between the groups. Indeed 
previous studies admittedly involving very small subject cohorts, have also reported 
HBD I to be constitutively expressed in both control and RAT tonsils (Chae, Lee et al. 
2001; Weise, Meyer et aI. 2002; Wang, Dong et aI. 2004). However the data obtained 
in my study was interesting with HBDI expression values indicative, potentially, of 
high and low expresser subjects within the population (Figure 4.3c). When these data 
were further analysed according to the gender of the subjects from which the tonsils 
were taken it became obvious that high and low expressers existed in both male and 
female groups. 
Recently, it has been reported that the expression of HBDI can be regulated by 
circadian clock proteins (Sherman and Froy 2008). Thus it is feasible that the higher 
HBD 1 levels observed in the study reflected the time of day a tonsil was excised. 
However as the majority of tonsils were excised between 8 and lOam this is probably 
unlikely, but not impossible as some tonsil samples were collected in the late afternoon. 
It has also been documented that female menstrual status affects the levels of the 
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antibacterial agent Secretory Leukocyte Protease Inhibitor, (SLPI). This molecule 
functioning in the innate defences of the body, has been identified in uterine cell 
secretions, and is increased in premenopausal compared postmenopausal females 
(Fahey and Wira 2002). Whether HBDI is similarly affected by hormonal changes has 
not been reported although in this study elevated HBD 1 values were observed in female 
subjects <10 years old, which dilutes, but does not eliminate the argument for hormones 
playing significant roles in HBD 1 expression. 
As described previously comparison of the RAT and control tonsil mean HBD2 levels 
did not indicate a significant difference in their levels and these data supported the 
results published in 2003 by (Claeys, de Belder et al. 2003). Again however the 
Newcastle study identified distinct populations of expressers within the epithelial group 
(Figure 4.1 d), and like HBD 1 these populations were found in both the control and RAT 
tonsil groups, and equally divided between male and female subjects. Reasons for the 
differences in individual HBD 1 and HBD2 gene expression levels remain unknown 
although it is feasible that single nucleotide polymorphisms, for example in the 5' 
untranslated regions of the respective genes and affecting gene expression may be 
responsible. 
Children between the ages of six and ten years present most frequently with tonsillitis 
(Batra, Safaya et al. 2004). Thus the tonsil AMP expression profiles of children <10 
years of age and suffering recurrent acute tonsillitis were investigated, and compared to 
those of similarly aged control children. Statistical analysis of the data indicated that 
the AMP gene expression profiles of the two groups were similar although it was noted 
that the sample sizes, between 12 and 17 per group, were below those recommended by 
the power calculations to show a significant difference between groups. The data also 
highlighted that within the groups for each AMP were 'high' and 'low' expressers. 
Further investigation of the origins of these samples provided no obvious patterns e.g. 
the high HBD 1 expressers were not high HBD2 expressers. Thus the tonsil AMP data 
did not provide an explanation as to why some children are susceptible to RAT 
compared to others. 
It has also been reported in the literature that the proportion of asymptomatic carriers of 
S. pyogenes, known to be a causal factor in RAT, differs between those under and over 
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45 years of age (Hoffmann 1985). An aim therefore was to investigate whether the 
AMP expression profiles of the control and RAT groups, further divided according to 
age i.e. >45 years or < 45 years respectively, differed. However no tonsils from 
subjects aged >45 years were collected, which prohibited such analyses. Lack of RAT 
samples from those aged >45 years probably reflected the fact that those with the 
disease had their tonsils removed at a much earlier age. It would however be of interest 
to investigate if age itself has an affect on AMP expression and thus host innate 
defences. 
The LEAP-2 gene was chosen for analyses in this study as it encodes a novel AMP 
about which little is known. In fact LEAP-2 gene expression has been shown in tonsil 
to produce four transcripts, presumably encoding four different peptides (Ball, Siou et 
al. 2007). In this study the expression of the 161 bp transcript encoding the secreted 
peptide with antimicrobial activity was studied. LEAP-2 mRNA expression was not 
found statistically to be significantly different in the epithelial compared to the 
lymphoid samples. This disagreed with the results of the pilot study which showed 
differences between mRNA expression in these tissue types (Ball, Siou et al. 2007). 
However results from immunohistochemical studies, using an antibody specific to 
LEAP-2 yielded results which agreed with the LEAP-2 mRNA expression study in 
Figure 4.1 as LEAP-2 immunoreactivity was observed at both the epithelial surface of 
the tonsil and within the lymphoid tissues (Figure 4.2). However the discrepancy in the 
results here and in the pilot study may be explained by the immunohistochemical 
studies not being quantitatively analysed. Another explanation may be that assuming 
that the other three LEAP-2 transcripts observed in the tonsil tissues following end-
point peR (Ball, Siou et al. 2007) encode intracellular peptides with primary sequences 
showing identity to that of the secreted LEAP-2 molecule, and that the LEAP-2 
antibody detects these peptide forms. Although not proven these data suggest that 
LEAP-2, as an innate defence molecule, is more atypical than previously thought. 
No difference in LEAP-2 expression levels were observed in the RAT compared to the 
control tonsils (Figure 4.3b). Although it is has been shown, using a zone inhibition 
assay, that mature LEAP-2 peptide will kill Gram-positive bacteria (Krause, Sillard et 
al. 2003), it is not known whether LEAP-2 expression can be regulated by such 
organisms. Indeed to date LEAP-2 gene expression has only been shown to be up-
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regulated in avian (Townes, Michailidis et al. 2004), and porcine gut tissues (Sang, 
Ramanathan et al. 2006) in response to Salmonella enterica serovar Typhimurium 
infection. 
Patients were asked to state the length of time prior to their tonsillectomy since their last 
sore throat and these data were plotted in relation to AMP expression levels (Figure 
4.9). No statistically significant differences were seen between the groups, possibly due 
to small sample numbers, and no trends were evident. However as patients are usually 
infection free at the time of their tonsillectomy and the patients were self-assessing the 
reliability of this data must be questioned. In hindsight it would have been more useful 
if the last clinical diagnosis of tonsillitis had been documented and used. 
In summary, this study investigated and compared the levels of LL-37, HBDI, HBD2 
and LEAP-2 AMP mRNA expression in over ninety tonsils excised from RAT patients 
and control subjects. The data indicated that all AMP genes examined were expressed, 
that considerable variability was detected between the AMP expression levels of 
individual subjects but that the mean AMP expression levels between the RAT and 
control groups was not significantly different. These data did not therefore support a 
defect in the innate immune response involving host AMPs, such as a deficiency in 
AMP expression at the epithelial surface, as being a cause or contributory factor in an 
individual's susceptibility to recurrent acute tonsillitis. However this study was 
conducted using tonsils excised from RAT patients at the time of their surgery when, 
despite their self diagnosis, they were probably not suffering a streptococcal infection. 
Thus it could be argued that in order to answer the question of whether RAT is due to 
failure of the AMPs to up-regulate in response to infection, we need to look at AMP 
responses in tonsils when actively infected with streptococci. 
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Figure 4.1: Expression of LL-37, LEAP-2, HBDI and HBD2: mRNA adjusted to GAPDH (AU) in all subjects, classified in terms of epithelial and lymphoid 
samples. In graphs a), c) and d) all samples outside ± two standard deviations of the mean were omitted. In graph b) all samples have been included as they have an 
impact on statistical significance (see 4.3). n: numbers of samples analysed. One sample per tonsil collected was assayed in duplicate except for LL-37 which was 
assayed in quadruplicate. Error bars represent mean values ± SEM. * = P<O.05. Statistical analysis was performed with an unpaired T-test. 
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Figure 4.2: Localisation of LEAP-2 in tonsil: a) Shows a frozen human tonsil section. Fixed in 
2% Paraformaldehyde (PFA, Sigma) in PBS for 30min on ice. With PFA fixation tonsil section was 
permeablised with 0.1 % Triton X-lOO for 30min at room temperature. All tissue sections were 
blocked in 10% goat serum in PBS (Sigma) for Ih on ice before incubation with anti-human LEAP-2 
purified IgG (I: 1 00 in PBS) over night at 4°C. The sections were then incubated with goat anti-
rabbit antibody-FITC (Chemicon), 1 : 50 in PBS for 3h before being mounted on slides with 
Vectashield. LEAP-2 expression is shown in bright green and can be seen to be localised to 
epithelial surfaces and lymphoid follicles of the tonsil. The tonsil was excised from a RAT patient. 
The epithelial lined crypt can be observed. b) Control without primary antibody. 
148 
~ 
-.0 
a) 
5'50 
~ 
<40 
Z 
a:: 
E 30 
'0 
c 20 
.2 
"' ~ 10 
Co 
>< 
W 
• 
ai) 
LL-37 L 
• 
• ,. 
"" ~ ,.., 
Control,Epltl'lelium 
• 
n = 19 
• 
••• 
-* i· .. • 
Control Epthellum RAT EpttIelium Control L)1IT1)h RAT L)'tI'1:Ih 
Tonsil tissue s3fTllie 
n= 17 29 15 21 
c) HBD1 
5 700, • ~600 
~1 • • • •• E 400 •• • 
- • o 300 
c: 
0 
'iii 200 
1/1 
~ 100 
a. 
X 
w 0 
Control Epithelium RAT EpIthelium ControlLynph RATL""ph 
Tonsil tissue sample 
n= 19 33 16 21 
b) 
5' 5' 
~ 
< 40~ • z 
a:: 
E 30~ • 
'0 
• :s 20 
• u; 
lfl 10 
a 
>< 
w 0 
bi) 
lEAP-2 ~ .. ;;, ..• ;, .. 
• 
.l.l 
t!.l 
Control Epithelium RAT EplthelUlm 
n = 20 32 
• 
~ 
COI'ItnII EPithelium RAT Epthela.n Control L)fIl)h RAT L~ 
n= 19 
d) 
510001 
::s. 800 
« 600 ~ 3001 
'0 200 
c: 
o 
.~ 100 
~ 
a. 
• 
• 
• 
Tonsil tissue sample 
31 16 
HBD2 
• 
•• 
• 
•• 
21 
Jj 0' ".7 . 'ft. ., m ••• 
Control Epithelium RAT EpitheUum Control L)mph RAT l)1JlPh 
Tonsil tissue sample 
n= 21 33 18 25 
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Chapter 5 
Antimicrobial Peptide Gene Expression in an In 
Vitro HaCaT Cell Model 
161 
5.1 Introduction 
The results of the previous chapter indicated that human tonsils excised from control 
(non-RA T) subjects, removed for either apnoea or snoring, and those suffering RAT 
expressed a broad spectrum of AMPs. While patterns of AMP expression were 
identified, overall the levels of expression did not appear to be significantly different 
between the two groups. It is well known that AMPs are induced in host cells in 
response to microbes (Dorschner, Pestonjamasp et al. 2001; Nizet, Ohtake et al. 2001; 
Chromek, Slamova et al. 2006; Johansson, Thulin et al. 2008), and thus it could be 
argued that the RAT patients recruited to the clinical study were, in the main, in the 
quiescent phase of their disease and thus probably not actively infected with S. 
pyogenes, a major causal factor in the pathology of recurrent acute tonsillitis. To 
explore this further the direct effects of S. pyogenes on the expression of AMP genes in 
the tonsil epithelium required investigation. 
It is neither ethical nor moral to investigate the direct effects of S. pyogenes on tonsil 
epithelium in vivo i.e. using human volunteers, thus in this chapter the aim was to 
identify a suitable in vitro system to model the tonsil epithelium and investigate the 
effects of streptococcal binding on the host AMP response. 
The use of an immortalised cell line to model the tonsil epithelium has many 
advantages; these include performing each independent study in a controlled 
environment and the simultaneous generation of large numbers of samples, both of 
which help reduce sample variability. Moreover, the homogeneity of an in vitro cell 
line also ensures that the resulting data relates to one cell type only rather than to a mix 
of cells as can occur in vivo. 
In this chapter statistical analysis was performed using either an unpaired T-test or one 
way ANOV A followed by a Bonferroni post-test, as described in 4.2ii. Here, a one way 
ANOVA followed by a Dunnett's post-test was also used. This was suggested by the 
Prism statistics guidelines for tests where each data set is required to be compared to a 
control (Motulsky 2003). 
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5.1.1 Aims of Investigation 
The aims of the studies described in this chapter were (i) to select an immortalised in 
vitro cell line model that modelled the tonsil epithelium and to describe its AMP 
expression profile and (ii) to challenge the cells in vitro with S. pyogenes and to 
determine the effects of binding and infection on AMP gene expression. 
5.2 Consideration of HEp-2 cells as a tonsil model 
The HEp-2 cell line (Figure 5.1) was initially considered for this study as these cells 
exhibit epithelial characteristics and were derived originally from laryngeal cells. It can 
be argued that the close proximity of the laryngeal cells, in the environment of the 
pharynx, to the tonsils supports their use as a suitable in vitro system to model the tonsil 
epithelium, and therefore to investigate AMP expression in tonsil in response to a 
bacterial challenge. Moreover, additional support for the use of this cell line was 
provided in a preliminary study by Ball (2004), who identified HBD1 and HBD3 
mRNA expression in the HEp-2 cells and localised the peptides to the epithelial surface 
of the cells. It was of concern however that neither the expression of LL-37, HBD2, 
hepcidin nor LEAP-2 mRNA was detected. 
Reanalysis of HEp-2 cell RNA using primers specifically designed to amplify the LL-
37, HBD2, hepcidin and LEAP-2 genes using end-point PCR, agarose gel 
electrophoresis and DNA sequencing confirmed expression of HBDI and HBD3 
(Figure 5.2). LL-37 expression was also detected (Figure 5.3), but only after 40 cycles 
of PCR (compared to 30 cycles employed by Ball (2004)). A faint cDNA band was 
detected following amplification of the HEp-2 cell RNA using HBD2 primers (results 
not shown) but this product was not confirmed by sequencing as the cDNA product 
could not be cloned successfully. None the less these expression data supported the 
use of the HEp-2 cell line as a suitable in vitro model to investigate AMP gene 
expression in response to a streptococcal challenge. 
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However, there were major concerns regarding the actual use of this cell line as a model 
for tonsil. First information from the cell supplier ATCC (www.atcc.org), described 
,'r· 
this laryngeal model cell line as being contaminated with HeLa (cervical cancer) cells. 
Second, significant information suggesting the unsuitability of these cells as a tonsil 
model was published by our group comparing the binding of S. pyogenes to tonsils and 
HEp-2 cells (Abbot, Smith et al. 2007). This study found that HEp-2 cells were unable 
to model the tonsillar-streptococcal interactions, and thus were not an appropriate model 
to investigate host AMP profiles in response to pathogen challenge. However the 
results of the study by Abbot, Smith et al (2007), suggested that HaCaT cells were an 
appropriate model as the interactions observed between the cells and S. pyogenes 
mimicked those of the tonsil and the bacterium. 
5.3 Consideration of HaCaT cells as a model for tonsil 
The HaCaT cell line, an immortalized skin cell-line, was therefore considered as an in 
vitro model for the AMP expression studies. As the AMP expression profile of this cell 
line was not known, initial experiments focussed on determining the AMP (LL-37, 
HBDl, HBD2, HBD3, hepcidin and LEAP-2) gene expression profiles and whether 
such expression could be regulated. For the regulatory studies the HaCaT cells were 
challenged with bacterial and environmental agents including lipoteichoic acid (L T A), 
lipopolysaccharide (LPS), phorbol 12-myristate 13-acetate (PMA) and 1,25 
dihydroxyvitamin-D3 (D3). 
L T A is a Gram-positive cell wall component of particular interest to this study as S. 
pyogenes is a Gram-positive bacterium. In addition LTA has been reported to induce 
HBD2 expression in human endometrial epithelial cells (King, Fleming et al. 2002). 
LPS is a Gram-negative cell wall component used to up-regulate antimicrobial peptides 
directly (Mac Redmond, Greene et al. 2005), or indirectly through another immune 
effecter molecule such as IL-l P (Pioli, Weaver et al. 2006). The environmental 
component PMA has previously been reported to induce HBD3 and HBD4 expression 
in human primary keratinocytes, and HBD4 expression in HaCaT cells (Harder, Meyer-
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Hoffert et al. 2004). D3 was chosen as it has been shown to up-regulate LL-37 mRNA 
expression in skin cells (Weber, Heilborn et al. 2005). 
5.4 AMP Gene Expression in HaCaT cells Treated with Bacterial 
and Environmental Agents 
5.4.1 End-point PCR studies of AMP mRNA expression in HaCaT 
cells treated with bacterial and environmental components 
End-point PCR analyses of HaCaT cell RNA resulted in the detection of cDNAs 
supportive ofHBD1, HBD2, HBD3, hepcidin and LEAP-2 gene expression (Figures 5.4 
& 5.5). However LL-37 expression was found to be very low and often, following the 
RT-PCR analyses, cDNA bands were not observed (Figure 5.4b lanes 2 & 3). 
In view of the latter observations the effects of bacterial and environmental agents on 
the AMP gene expression patterns were investigated. For these studies the HaCaT cells 
were cultured to confluency and challenged for up to 22 hours with the appropriate 
agent. AMP gene expression was determined by semi-quantitative RT-PCR. 
Essentially, HaCaT cells (l x 106) were seeded and grown in 12mm diameter wells for 
4-5 days at 37°C and 5% C02. Once confluent the cells were incubated for three hours 
in cell growth medium without either FCS or antibiotics, and the appropriate treatment 
(D3 (Fluka, final concentration 200nM), LT A (from S. pyogenes, Sigma final 
concentration 2I-lg/ml), LPS (Sigma, final concentration 0.2I-lg/ml), and PMA (Sigma, 
final concentration 20I-lM» in a total volume of 1ml added before incubation at 37°C in 
5% CO2 for the pre-determined time period. The cells were then washed in PBS and the 
RNA extracted (Section 2.5.2). The RNA was reverse transcribed and the cDNA 
analysed using the appropriate primers (described in Chapter 3) and end-point PCR for 
LEAP-2, LL-37 and GAPDH expression. The samples were analysed for LEAP-2 
expression as this gene encodes a novel four cysteine AMP (Krause, Sillard et al. 2003), 
and for LL-37 expression, as the encoded host peptide is known to interact with 
streptococci (Dorschner, Pestonjamasp et al. 2001; Nizet, Ohtake et al. 2001; Nyberg, 
Rasmussen et al. 2004; Johansson, Thulin et al. 2008). 
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Results of these analyses are shown in Figure 5.4a-c. The data indicated that L T A, 
LPS, PMA and D3 treatment did not affect LEAP-2 mRNA expression. Similarly 
LTA, LPS and PMA treatment did not affect LL-37 mRNA expression but the presence 
of a 500bp cDNA band in response to D3 treatment suggested that the vitamin D 
metabolite was able to up-regulate LL-37 gene expression. 
5.4.2 Treatment of HaCaT cells with 1,25 dihydroxyvitamin-D3 
These results indicated that LL-37 gene expression was up-regulated in HaCaT cells in 
response to D3 (200nM) treatment. To confirm this, the 03 challenge experiments 
were repeated and in addition the affects ofD3 treatment on HBOI, HB02, HB03 and 
hepcidin gene expression were also investigated. For such experiments the HaCaT 
cells were cultured as previously and incubated with 200nM D3 for up to 22 hours. 
Post-treatment, the cells were washed, lysed, RNA extracted and, using the appropriate 
primers, analysed by semi-quantitative end-point PCR. Representative gel data are 
shown in Figure 5.5. The densitometry data derived from the gels was normalised to 
GAPDH and plotted as a percentage of control (Figure 5.6). 
The semi-quantitative data showed that treatment of HaCaT cells with 03 resulted in a 
one to two fold increase in LL-37 mRNA expression. In contrast the expression of the 
HB01, HBD2, HBD3, hepcidin and LEAP-2 genes did not change in response to the 
D3 treatment. It is however acknowledged that the data relating to LEAP-2 mRNA 
expression was from one gel only. It is also acknowledged that the lack of sensitivity of 
the densitometry and the small sample sizes created large errors, which may have 
masked small, but potentially important, changes in gene expression. This was 
particularly evident in relation to the expression of HBD3 where it could be argued that 
D3 treatment was in fact inhibitory. 
None the less these results, detailing the expression of AMP genes and the up-regulation 
of LL-37 mRNA, in conjunction with those reported by Abbot, Smith et al (2007) 
supported the use of the HaCaT cell line as an in vitro system to model the tonsil 
epithelium. 
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5.5 Expression of Antimicrobial Peptides Genes in HaCaT Cells 
Infected with S. pyogenes M1 Serotype 
Streptococcus pyogenes is a major bacterial cause of tonsillitis in humans (Brook and 
Gober 2005), and the focus was now to investigate whether infection of the HaCaT cells 
with streptococci caused any effects on the expression of the AMP genes. As 
preliminary experiments using the Gram-positive bacterial cell wall component L T A 
did not affect either LL-37 or LEAP-2 gene expression (Figure 5.4), the decision was 
taken to use whole bacteria in all subsequent experiments. 
F or such experiments 1 x 106 HaCa T cells were seeded per 12mm dish and cultured at 
37°C and 5% C02 for 3-4 days in growth medium until confluent. Infection 
experiments were performed as described in Section 2.3.3. Essentially, the HaCaT cells 
were washed and incubated for three hours in medium lacking FCS and antibiotics, and 
infected with 1 x 108 cfu S. pyogenes expressing GFP, cultured as described previously 
(Section 2.3.4) to an OD6oo of 0.5. The bacterial cells were washed, pelleted and 
resuspended in normal cell growth media lacking antibiotics and FCS. The HaCaT cells 
were incubated with the bacteria for an appropriate pre-determined period of time 
(either 2, 4 or 6 hours) before being washed with PBS, lysed and the RNA extracted. 
The RNA samples were analysed for LL-37, HBD1, HBD2, HBD3, hepcidin and 
LEAP-2 gene expression via both semi-quantitative end-point PCR and quantitative 
real-time PCR. No later time points were investigated as infection periods of greater 
than six hours were associated with cell death (E. Abbot, personal communication). 
A binding control was included in these experiments. This control, described in Section 
2.3.5, was used to ensure that the S. pyogenes had bound to the HaCaT cells. 
Essentially, HaCaT cells were grown to confluence on 10mm coverslips and incubated 
as above with S. pyogenes. Following a two hour infection period the cells were fixed 
and stained, as described in Section 2.3.5, to allow visualisation of both the HaCaT cell 
morphology and numbers of bound S. pyogenes (Figure 5.7). 
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5.5.1 HaCaT infection at 2, 4 and 6 hours: Semi-quantitative studies 
Following infection of the HaCaT cells for 2, 4 and 6 hours respectively, RNA from 
both control and infected cells was extracted, reverse transcribed and analysed for LL-
37, HBD1, HBD2, HBD3, hepcidin and LEAP-2 mRNA expression by end-point PCR. 
PCR products were separated on 2% agarose gels, the cDNA bands analysed by 
densitometry and the data normalised via the housekeeping gene GAPDH. Statistical 
analysis was by one way ANOVA followed, where appropriate, by a Dunnett's post-
test. 
Results of the LL-37 expression analyses are shown in Figure 5.8a, b & c. As observed 
previously LL-37 expression in the control (unchallenged) cells was low (Figure 5.8a 
lanes 2 & 3). Although an increase in HaCaT LL-37 expression was detected in 
response to D3 treatment (Figure 5.8a, lane 10), no such response was observed when 
the cells were challenged with S. pyogenes. Densitometry analysis confirmed this result 
as no statistically significant differences in LL-37 expression mRNA were recorded 
compared to the expression levels in uninfected control cells after 2, 4 or 6 hours of 
infection with S. pyogenes (Figure 5.8c). 
The results ofHBD1 and HBD2 gene expression analyses are shown in Figures 5.9 and 
5.10 respectively. The graphs illustrate a similar pattern of AMP gene expression with 
reduced levels observed at four to six hours post challenge. In both cases the observed 
reduction at six hours post infection was statistically significant (P<O.O 1). In contrast 
no change in HBD3 expression was observed in response to S. pyogenes (Figure 5.11). 
Figure 5.12 a, b & c shows the results of the hepcidin analyses. No statistically 
significant differences in gene expression were observed post infection. 
The LEAP-2 mRNA expression patterns following S. pyogenes infection are shown in 
Figure 5.13 a & b. No significant differences were observed between the mean LEAP-
2 gene expression values recorded at either two, four or six hours of infection 
respectively. 
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Figure 5.14 shows the AMP gene expression results following treatment of the HaCaT 
cells with D3 for two hours. This was included as a positive control for cell 
responsiveness, and when compared to earlier experiments (Section 5.4.2). The data 
showed that 03 treatment did not cause an increase in LL-37 expression after two 
hours, this disagreed with the data shown in 5.4 indicating that D3 caused LL-37 
mRNA up-regulation but it must be acknowledged that the two hour incubation here is 
significantly less than the 22 hour incubation time in the experiment with results in 
Figure 5.4. D3 also did not affect the expression of the HBD 1-3, hepcidin or LEAP-2 
genes after two hours of treatment. 
Table 5.1: Summary of semi-quantitative peR data after two, four and six hours of infection with S. 
pyogenes M I serotype. 
AMPmRNA Semi-quantitative peR result 
LL-37 +-+ 
HBOI ~6h 
HB02 ~6h 
HB03 +-+ 
Hepcidin +-+ 
LEAP-2 +-+ 
.. 
...... No statistically significant differences In gene expression compared to control 
! Statistically significant decrease in gene expression compared to control 
The results of the semi-quantitative analyses are summarised in Table 5.1. These results 
indicated that challenging HaCaT cells with S. pyogenes Ml serotype for up to six hours 
caused a significant reduction in HBDI and HBD2 gene expression but did not affect 
LL-37, BBD3, hepcidin or LEAP-2 gene expression. However these data were 
dependent on the densitometry of a large number of gels which often resulted in large 
error bars that ultimately reduced the sensitivity of the analyses. 
5.5.2 HaCaT infection at 2, 4 and 6 hours: Quantitative studies (Real-
time PCR) 
The semi-quantitative studies were plagued by large error bars. To try and address this 
and provide more accurate quantification of the data a more sensitive analysis was 
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required. Thus real-time PCR, using the assays established in Chapter 3, was employed. 
For such analyses all target gene values were normalised to the housekeeping gene 
GAPDH and statistical analyses was performed using a one way ANOV A followed, 
where appropriate, by a Dunnett's post-test. 
The results of the gene expression analyses for LL-37 expression using the real-time 
methodology are presented in Figure 5.15. These data measures the LL-37 mRNA 
expression in the HaCaT cells in response to the S. pyogenes MI serotype and 03 
treatment. However none of these data were found to be statistically significant. At this 
point it is worth noting that the level of LL-37 expression in the control cells was found 
to be low and consequently a high number of cycles (55) were required in the real-time 
PCR to amplify enough LL-37 PCR product to allow quantification. Although 
frustrating technically, this result was concomitant with that observed following 
electrophoresis of the cDNA samples following end-point PCR. However the low 
levels of LL-37 mRNA expression, as with the semi-quantitative analyses, resulted in 
large error bars, which again reduced the sensitivity of the statistical analyses. 
The results of the real-time PCR analyses for HBD1 expression are shown in Figure 
5.l6a. These data supported previous observations (Figure 5.9) and indicated a 
reduction in HBDI mRNA at four to six hours post streptococcal infection. Statistical 
analysis confirmed this decrease in mRNA expression to be significant at both four and 
six hours of infection respectively (P<0.05). 
Figure 5.16b shows the results of the real-time analyses of HBD2 expression. No 
statistically significant changes were identified after 6 hours of infection. 
The LEAP-2 mRNA real-time expression data are shown in Figure 5.16c, and provided 
evidence for a statistically significant increase (P<O.OI), in LEAP-2 mRNA expression 
after six hours of S. pyogenes infection. In fact at six hours of infection the mean (± 
SEM) LEAP-2 expression value was 195±39% of control indicating an almost two-fold 
increase in gene expression. In comparison the semi-quantitative PCR data identified 
no changes between the mRNA levels following infection (Figure 5.13), although as 
stated previously these latter data were beset by large error bars. 
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Real-time PCR analyses of the samples were not performed for HBD3 and hepcidin due 
to technical difficulties, described in Chapter 3, during the development of the real-time 
PCR assays. 
Table 5.2: Summary of quantitative peR data after two, four and six hours of infection with S. pyogenes. 
AMPmRNA Quantitative peR result 
LL-37 ~ 
HBDI !4-6 h 
HBD2 ~ 
LEAP-2 j6 h 
~ No statistically significant differences in gene expression compared to control 
1 Statistically significantly increase in gene expression compared to control 
~ Statistically significantly decrease in gene expression compared to control 
Table 5.2 summarises the results of the quantitative analyses. These results indicated 
that challenging HaCaT cells with the S. pyogenes Ml serotype for up to six hours 
caused a statistically significant reduction in HBD 1 gene expression, a statistically 
significant increase in LEAP-2 gene expression and no statistically significant changes 
in LL-37 or HBD2 gene expression compared to the control. These data, with respect to 
LL-37 and HBDI gene expression were consistent with that obtained by the semi-
quantitative analyses. The HBD2 and the LEAP-2 results were however inconsistent; in 
the case of the later the real-time data strongly supported a significant increase in 
LEAP-2 expression (two-fold) six hours following streptococcal infection. 
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5.5.3 HaCaT infection at 5, 15, 30, 60 minutes of infection with S. 
pyogenes 
While these experiments were on-going data was published that showed challenging 
urinary tract cells with E. coli resulted in the up-regulation of LL-37 mRNA after only 
five minutes of infection (Chromek, Slamova et al. 2006). As the earliest time point 
investigated in my studies was two hours, shorter time periods (5, 15, 30 and 60 min) in 
relation to S. pyogenes infection were investigated. These experiments were performed 
as described previously and binding controls were performed at each time point to 
confirm the S. pyogenes had bound to the HaCaT cells. These data are presented in 
Figure 5.17. While at five minutes very few bacteria had bound to the HaCaT cells the 
numbers binding did increase with time. 
5.5.4 Quantitative studies at 5, 15, 30 and 60 minutes of infection 
RNA was collected from the HaCaT cells infected with S. pyogenes for 5, 15, 30 and 60 
minutes and analysed by quantitative real-time PCR for HBDl, HBD2 and LEAP-2 
gene expression. LL-37 analysis of the samples was not undertaken due to the low 
levels of mRNA expression resulting in sensitivity problems. As previously HBD3 and 
hepcidin analyses were not undertaken as real-time PCR assays were not available. 
The real-time results relating to HBDl, HBD2 and LEAP-2 expression are shown in 
Figure 5.18a, b & c. These data indicated that infection of the HaCaT cells with S. 
pyogenes did not significantly affect HBD 1, HBD2 or LEAP-2 expression at times up to 
one hour of infection. It was also observed that the standard errors associated with the 
short infection data were very large. 
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Table 5.3: Summary of quantitative peR data after 5, 15, 30 and 60 minutes of infection with S. 
pyogenes M I serotype. 
AMPmRNA Quantitative peR result 
HBDI ~ 
HBD2 ~ 
LEAP-2 ~ 
.. 
+-+ No statIstIcally slgmficant dIfference In gene expressIOn compared to control. 
The results of the quantitative analyses relating to the 'short' infection experiments are 
summarised in Table 5.3. In summary, when the HaCaT cells were challenged with the 
S. pyogenes M I serotype for times up to one hour, HBD 1, HBD2 and LEAP-2 mRNA 
expression were not significantly altered compared to control. 
5.6 Gene Expression in HaCaT Cells Infected with S. pyogenes 
(Wild-type), M2 Serotype 
The S. pyogenes Ml serotype binds to cells (HaCaT and tonsil) via pili (Abbot, Smith et 
al. 2007). Compared to the M I serotype, the M2 serotype is known to have a large 
number of pili on its surface (Personal communication W.D. Smith, Newcastle). Thus 
to determine whether the serotype of S. pyogenes affected the AMP mRNA responses in 
HaCaT cells, the bacterial challenge experiments were repeated using the S. pyogenes 
M2 serotype. 
Binding data relating to the S. pyogenes M2 serotype experiments are shown in Figure 
5.19. Although not quantified very few bacteria were found to bind to the HaCaT cells 
after 5min, however this number increased with time and was comparable at two hours 
to that seen previously with the M 1 serotype (Figure 5.7). The levels of HBD 1, HBD2 
and LEAP-2 gene expression in response to binding were analysed by real-time PCR. 
All the data was normalised to GAPDH and the results were expressed as a percentage 
of the control. Statistical analysis was performed with a one way ANOVA followed, 
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where appropriate, by a Dunnett's post-test. LL-37, HBD3 and hepcidin expression 
were not quantified for reasons described in Section 5.5.2. 
5.6.2 Quantitative studies 
The results of the S. pyogenes M2 serotype challenge experiments are presented in 
Figure 5.20a-c. Figure 5.20a shows the data relating to the expression of HBD 1 mRNA 
over a range of time points between five minutes and six hours respectively. The 
standard errors relating to each of the data points were large and statistical analysis of 
the data revealed no significant changes in HBD1 mRNA expression, indicating that the 
expression of HBD 1 mRNA by the HaCaT cells was not affected by the S. pyogenes 
M2 serotype challenge. 
The data relating to HBD2 expression is shown in Figure 5.20b. These data were also 
affected by large error bars and statistical analysis showed no significant differences 
between the time points. 
Figure 5.20c shows that LEAP-2 mRNA expression levels were significantly reduced at 
30 and 60 minutes compared to the control (P<0.05), and the mean levels remained low 
(~ 50% of control) up to six hours post infection. 
Table 5.4: Expression patterns of AMP mRNA with M2 serotype S yogenes . P. 
AMPmRNA M2 serotype 
HBDI ...... 
HBD2 ...... 
LEAP-2 t 
30 and 60 minutes 
.. 
...... No statIstIcally slgmficant dIfferences In gene expressIOn compared to control 
! Statistically significant decrease in gene expression compared to control 
The results of the quantitative analyses relating to the M2 infection experiments are 
summarised in Table 5.4. In summary, when the HaCaT cells were challenged with the 
S. pyogenes M2 serotype the data suggested no statistically significant changes in 
HBD 1 and HBD2 gene expression. However LEAP-2 gene expression was 
significantly reduced compared to control after 30 and 60 minutes of infection. 
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These data suggested that the affects of the M2 serotype on AMP expression in HaCaT 
cells were not identical to that of the Ml serotype especially with relation to LEAP-2 
expression. 
5.7 Gene Expression of HBD1 and LEAP-2 in HaCaT Cells 
Infected with Pili-defective S. pyogenes M1 Serotype 
Pili are expressed on the surface of S. pyogenes and have been reported by this research 
group to affect the in vitro infectivity of this Gram-positive bacterium (Abbot, Smith et 
al. 2007). Essentially it was found that deletion of the genes encoding pilus-like 
structures prevents the adhesion of S. pyogenes to HaCaT cells and tonsils. To 
determine the absence of pili on the AMP response of the HaCaT cells to a 
streptococcal infection, the M 1 mutant strains ~spy 129 and ~spy 1154 were used in the 
bacterial challenge experiments. The mutant strain ~spy129 lacks the pilus-associated 
sortase (SrtC 1) and fails to synthesise pili, while the ~spy 1154 mutant lacks pili and 
various surface binding molecules such as adhesins (Personal communication, W.D. 
Smith). The wild-type S. pyogenes Ml serotype was included in the challenge 
experiments and acted as the control. Analysis of AMP gene expression was performed 
at six hours only, as previous data (Figure 5.16) indicated significant changes in AMP 
gene expression at this time point. 
The bacterial binding data relating to these experiments are shown in Figure 5.21. 
These data confirmed that the S. pyogenes (wild-type) Ml serotype bound to the HaCaT 
cells while, in comparison, the pili-defective mutants did not. 
5.7.1 Expression patterns 
Following the challenge experiments the RNA collected from the HaCaT cells was 
analysed by real-time PCR for HBDI and LEAP-2 expression. As previously, the data 
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was nonnalised to GAPDH and expressed as a percentage of control. No HBD2 
analysis was perfonned due to problems with the assay at the time of the investigation. 
The results relating to the challenge experiments with the wild-type and mutant M 1 
strains are presented in Figure 5.22. After six hours of infection with wild type S. 
pyogenes, HBDI expression (Figure 5.22a) was significantly decreased (P<O.Ol), which 
agreed with previous results (Figure 5.l6a). In addition HBD 1 expression was 
significantly reduced (P<O.Ol), following challenge with both pili-defective mutants i.e. 
/1spy129 and /1spy1l54. This indicated that the effects on HBDI expression were not 
dependent on the binding of the streptococci to the HaCaT cells. 
The data shown in Figure 5.22b showed no statistically significant differences between 
HaCaT cell expression of LEAP-2 mRNA after six hours of infection with S. pyogenes 
(wild-type) when compared to the control. It was observed that the data relating to the 
Figure 5.22b control and wild-type results were characterised by large standard errors. 
When the HaCaT cells were incubated with the pili-defective mutant /1spy129 no 
statistically significant differences were observed. LEAP-2 expression in response to 
/1spy 1154 was comparable to the wild-type results. 
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5.8 Discussion 
The results of the clinical study presented in Chapter 4 did not support any statistically 
significant differences between the AMP expression profiles of tonsils excised and 
analysed from control subjects and RAT patients. These data therefore favoured the 
premise that susceptibility to recurrent acute tonsillitis was not due to a defect in the 
innate immune response involving host AMPs. However the fact that the RAT tonsils 
analysed in the patient study were excised and analysed during a quiescent phase of the 
disease, rather than during active infection, may have accounted for the lack of AMP 
responses observed between the control (non-RAT) and RAT tissues. To explore this 
further an investigation of tonsil AMP responses during an active streptococcal 
infection was necessary and this was attempted, initially, using an in vitro cell line that 
modelled the tonsil epithelium. 
There is to our knowledge no tonsil-derived cell-line, thus to begin with HEp-2 cells, a 
laryngeal cell line, was considered for use, as these cells had previously been used by 
other groups to model the tonsil epithelium (Greco, De Martino et al. 1995; Cheng, 
Stafslien et al. 2002; Wang, Li et al. 2006). Moreover in a pilot study in Newcastle the 
AMP profile of the HEp-2 cells revealed HBDI and HBD3 expression and peptide 
synthesis, which was comparable to that of the tonsil epithelium, although it was of 
concern that neither LL-37 nor HBD2 expression was detected (Ball 2004). Further 
analyses of the HEp-2 cell AMP expression profile using RT-PCR identified LL-37 
transcripts, but only by increasing the number of PCR cycles from 30 to 40. Moreover 
a cDNA band indicative of HBD2 gene expression was observed, but not confirmed due 
to cloning problems arising from the low amounts of product. Why LL-37 and HBD2 
expression specifically should be reduced in this cell line is not known. However the 
explanation may include the fact that the HEp-2 cells are not homogeneous, but 
contaminated with cervical cancer derived HeLa cells. The use of the HEp-2 cell line as 
a model for tonsil was finally vetoed in light of the results of a study in Newcastle 
(Abbot, Smith et al. 2007), which investigated and compared the interactions of S. 
pyogenes, a bacterium able to infect the oropharynx and skin, with tonsils and epithelial 
cell lines. In this study the authors reported that the infection of tonsil with S. pyogenes 
was pili-dependant while that of HEp-2 cells was not. These data thus identified an 
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important difference between the HEp-2 cells, seen classically as modelling the tonsil, 
and the tonsil per se. Interestingly, the study by Abbot, Smith et al (2007), also 
discounted A549 cells, an alveoli-derived cell line often used as a model for 
streptococcal interactions (Cue and Cleary 1998), as again S. pyogenes binding to the 
cells was not found to be pili-dependent. 
As the nature of the investigations planned in my studies probably depended on the 
interaction between the eukaryote cells and the streptococci the HEp-2 cell line was 
deemed unsuitable for subsequent experiments. Abbot, Smith et al (2007), did show 
however that streptococci bound to human primary keratinocytes and HaCaT cells in a 
pili-dependent manner. This indicated that the HaCaT cell line could be used as an 
appropriate in vitro model of the tonsil to examine AMP profiles in response to 
streptococci. The immortalised HaCaT cell line was chosen in preference to primary 
keratinocytes as it provided a reliable homogenous in vitro system that was easy to 
passage and maintain in culture. 
Before the HaCaT cells could be adopted as a model of the tonsil their AMP expression 
profile required investigation. End-point PCR analyses confirmed HBD 1-3, hepcidin, 
LEAP-2 and LL-37 gene expression, which matched that of the tonsil; however the 
expression of LL-37 mRNA was found to be low and required 40 cycles of PCR in 
order to detect a cDNA band indicative of LL-37 transcription. Interestingly in the 
studies reported by Kim, Kim et al (2005), also using HaCaT cell RNA, the 
investigators were unable to detect LL-37 expression, although this might be explained 
by the fact that they used only 35 PCR cycles, rather than 40, in their PCR reaction. 
Streptococci form part of the normal commensal flora of the mouth, skin, and upper 
respiratory tract of humans, and considering that the LL-37 peptide is known to interact 
with streptococci (Dorschner, Pestonjamasp et al. 2001; Nyberg, Rasmussen et al. 
2004; Fernie-King, Seilly et al. 2006; Johansson, Thulin et al. 2008), and kill through 
disruption of the bacterial membrane (Oren, Lerman et al. 1999; Henzler-Wildman, 
Martinez et al. 2004), it was surprising that LL-37 expression was not easily detectable. 
However in support it has been reported that LL-37 mRNA expression is very low in 
healthy skin keratinocytes and increased only following skin injury (Lande, Gregorio et 
al. 2007). Moreover the AMP LL-37 has been shown to be associated with skin 
disorders such as psoriasis (Lande, Gregorio et al. 2007) and rosacea (Yamasaki, Di 
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Nardo et al. 2007) suggesting that elevated LL-37 skin levels can in fact be potentially 
harmful. 
Before using the HaCaT cells as a model in the bacterial challenge experiments it was 
necessary to confirm that AMP gene expression could be regulated in this system. The 
active metabolite of vitamin D, D3, has been shown to induce keratinocyte 
differentiation (Bikle 2004), and previous studies had reported that LL-37 mRNA 
expression could be up-regulated in keratinocytes and HaCaT cells in response to 
treatment with D3 (Wang, Nestel et al. 2004; Weber, Heilborn et al. 2005; Schauber, 
Dorschner et al. 2006). Treatment of the HaCaT cells in this study with 200nM D3 also 
caused up-regulation of LL-37 expression after 22 hours (Figure 5.4), indicating the 
sensitivity of our detection system and the suitability of the model. It was probable that 
this up-regulation was due to the direct effects of D3 on the vitamin D response element 
(VDRE) situated in the promoter region of the human cathelicidin gene (Wang, Nestel 
et al. 2004). No comparable effects on LL-37 expression were recorded in response to 
treatment with LPS, L T A or PMA, with the LPS results supporting previous 
observations reported by Kim, Kim et al (2005). 
Lipoteichoic acid (LT A) is a surface-associated molecule associated with Gram-positive 
bacteria and the negative results observed following LT A treatment of the HaCaT cells 
hinted that challenging the cells with streptococci would not affect the AMP expression. 
However it was known from the studies of Abbot, Smith et al (2007), that infection was 
associated with the actual binding of the bacteria to the cells thus while the negative 
result was acknowledged it was decided to continue with the challenge experiments 
involving whole live bacteria. It was noted that LL-37 expression was shown to be up-
regulated in human sinus epithelial cells following treatment with LTA (Nell, Tjabringa 
et al. 2004). However the concentration of agent and the incubation periods used were 
not comparative between studies. For example in the studies reported in this thesis the 
amount of L T A at 2/lg/ml was five times less than that in the study of Nell, Tjabringa et 
al (2004), and the incubation time was 22 hours compared to two weeks. 
The initial challenge studies using chemical agents also targeted the LEAP-2 gene. 
None of the agents appeared to affect LEAP-2 gene expression. This was surprising 
especially in relation to LPS, as LEAP-2 gene expression in epithelial cells has been 
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shown to be up-regulated in response to a live Salmonella challenge (Townes, 
Michailidis et al. 2004; Sang, Ramanathan et al. 2006). None-the-Iess, these interesting 
in vitro results and the lack of literature describing LEAP-2 expression patterns in 
response to Gram-positive bacteria, supported the continuation of the in vitro 
streptococcal challenge experiments. 
All the challenge experiments using the S. pyogenes Ml serotype, were performed in 
media lacking FCS. This media supplement was omitted as it had been suggested that 
serum can reduce peptide bactericidal activity (Bartlett, McCray et al. 2004). Using a 
FCS free system thus allowed us the opportunity to measure potential peptide 
antimicrobial activities, although in fact time constraints meant that such measurements 
were not made. In all bacterial challenge experiments the binding of the streptococci to 
the eukaryote cells was checked using GFP labelled bacteria and microscopy. 
Moreover the initial AMP expression analyses were performed at two hours of infection 
as previous data (Abbot, Smith et aI, 2007) had shown that by this time approximately 
10 to 20% of the bacteria added initially were adhering strongly to the cells (l00% 
adherence). Experiments investigating AMP expression at earlier time points (5 to 
60min) concomitant with only 10-40% adherence (Abbott, Smith et aI, 2007), did not 
provide any additional insights into the host response, except perhaps for LEAP-2 
where an immediate reduction in gene expression was observed (Figure 5.20). 
The effects of the streptococcal challenges on AMP gene expression were initially 
performed using a less reliable semi-quantitative system. These analyses used 
densitometry to quantify the levels of gene expression, but the variability in the quality 
of the gels, often resulted in large error bars that ultimately reduced the sensitivity of the 
analyses. The gene expression ofLL-37 was observed to be very low when analysed by 
this method. Data from the reanalysis of the RNA samples with the more sensitive 
technique of real-time PCR was also unfortunately plagued by large error bars (again 
probably due to low gene expression requiring large numbers of cycles) and the 
expression of LL-37 mRNA was not different to the uninfected control cells to a 
statistically significant level. The low levels of LL-37 gene expression in fact provided 
questions over the suitability of the HaCaT cells as a good tonsil model, as LL-37 
expression was detected easily in the tonsil RNA samples. 
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The semi-quantitative analyses did however show statistically significant decreases in 
HBD 1 and HBD2 mRNA expression after six hours of infection with the S. pyogenes 
Ml serotype. HBDI results were mirrored by the real-time data and were interesting as 
classically HBD 1 is recognised as being constitutively expressed in tissues, including 
skin and those of the oral cavity (Mathews, Jia et al. 1999; Ali, Falconer et al. 2001; 
Wang, Dong et al. 2004; Kimball, Nittayananta et al. 2006; Schroder and Harder 2006). 
Regulated expression has however been reported, for example increased HBD 1 
expression was shown in HCT -116 cells, in response to albumin and amino acids 
(Sherman, Chapnik et al. 2006), and in cultured human mesangial cells maintained in 
high glucose (Malik and AI-Kafaji 2007). Interestingly a loss of HBDI has been 
documented, but in renal cell carcinomas and prostate cancers and explained by either 
promoter polymorphisms and/or deletion of the gene residing on the short arm of 
chromosome 8 (Donald, Sun et al. 2003; Sun, Arnold et al. 2006). Inhibition of HBD2 
gene expression in response to the streptococcal challenge was also atypical as the 
literature generally favours the induction of HBD2 gene expression in response to 
potential pathogens (Pivarcsi, Nagy et al. 2005; Mendez-Samperio, Alba et al. 2007). 
However down-regulation of HBD2 has been reported in cultured keratinocytes in 
response to stress, namely heat shock (Bick, Poindexter et al. 2004). Similarly a 
decrease in cathelin-related AMP (CRAMP) and mouse beta-defensin 3, the closest 
murine homologue of HBD2, was reported in the skin of female hairless mice in 
response to psychological stress (Aberg, Radek et al. 2007). Moreover this down-
regulation of AMP gene expression was associated with the increased susceptibility of 
the mice to Streptococcus infection and proposed to function through the increased 
production of endogenous glucocorticoids. 
HBD3 is an inducible peptide (Harder, Bartels et al. 2001) shown to have antimicrobial 
activity (MIC/LC9o of 12f.!g/ml) against S. pyogenes (Dhople, Krukemeyer et al. 2006) 
as well as other potentially pathogenic oral strains (Song 2008). It was therefore 
interesting that the expression data from the semi-quantitative studies indicated that the 
streptococcal infection of the HaCaT cells did not affect HBD3 gene transcription 
(Figure 5.11), although it was recognised that the results were beset by large error bars 
and thus lacked sensitivity. It was therefore disappointing that the results could not be 
verified by real-time PCR due to problems with the assay. However no induction of 
HBD3 gene expression was observed in response to the mouth commensal 
181 
Streptococcus gordonii (Ji, Kim et al. 2007) although in contrast a substantial eight-fold 
increase in expression was reported in oral epithelial cells in response to Candida 
albicans (Feng, Jiang et al. 2005). 
The hepcidin peptide is known to be strongly induced during infections and 
inflammation, causing intracellular iron sequestration, reduced plasma iron levels which 
in tum limits the amounts of iron available to invading micro-organisms (Vyoral and 
Petrak 2005). In addition the peptide has intrinsic antimicrobial activity. Thus the 
statistical result indicating that hepcidin (HAMP) gene expression was not significantly 
different to that of the control after four and six hours of S. pyogenes M1 infection was 
surprising. However interpretation of the semi-quantitative hepcidin expression data 
was complicated by the large error bars, which in conjunction with the lack of a real-
time assay system meant that these data were not authenticated. While the liver is the 
major site of hepcidin production other tissues and cells are known to express the gene 
and recently a TLR4 dependent increase in HAMP gene expression was reported in 
macrophages and neutrophils in response to an infection with S. pyogenes 
(Peyssonnaux, Zinkemagel et al. 2006), again presumably to limit the availability of 
iron to the invading micro-organisms. To date the roles of the hepcidin peptide in the 
skin are not known and thus the mechanisms and consequent effects of gene down-
regulation are conjecture, but the loss of hepcidin can only result in a more successful 
pathogen. 
The LEAP-2 gene encodes a peptide with antimicrobial activity against Gram-positive 
bacter.ia (Krause, Sillard et al. 2003) Semi-quantitative analyses of LEAP-2 gene 
expression following challenge of the HaCaT cells with the streptococci suggested that 
the LEAP-2 gene was not regulated in response to the bacterial challenge and these data 
concurred with the results of the L T A challenge. However this result was contradicted 
by the more sensitive real-time assay data that indicated the gene to be up-regulated. 
There is little information published in relation to LEAP-2 expression in cells in 
response to a bacterial challenge, although two mammalian studies involving the Gram-
negative organism S. enterica serovar Typhimurium rather than a Gram-positive 
bacterium, support the up-regulation of the LEAP-2 gene in response to a microbial 
assault (Townes, Michailidis et al. 2004; Sang, Ramanathan et al. 2006). 
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Overall the HaCaT data showed that HBDI gene expression were down-regulated, 
whereas LEAP-2 was up-regulated, in response to the S. pyogenes challenge. It also 
showed that LL-37 and HBD2 gene expression was not changed to a statistically 
significant level under the conditions in these tests. These data indicated that the S. 
pyogenes M 1 serotype was able to modulate defensin gene expression but the 
mechanisms by which the organism achieved this are not known. It is acknowledged 
that the p-defensin genes are activated through TLR signalling pathways; in 
keratinocytes these include the NF -KB and mitogen activated protein kinase pathways 
although different organisms appear to trigger distinct signalling cascades (Chung and 
Dale 2004; Joly, Organ et ai. 2005; Schauber, Dorschner et ai. 2006; Mendez-Samperio, 
Alba et ai. 2007; Wehkamp, Schauber et ai. 2007). Also studies in HaCaT cells have 
described the expression of TLRI, TLR2, TLR3, TLR4, TLR5 and TLRIO in this 
immortalized cell line (Pivarcsi, Koreck et ai. 2004; KoIIisch, Kalali et al. 2005). These 
studies have considered the effects the expression of these receptors may have on the 
immune responses of this cell line. The study by Pivarcsi, Koreck et aI, 2004 described 
how the expression of TLRs 2 and 4 mRNA increase with the differentiation state of 
HaCaT cells. The work by KoIIisch, Kalali et aI, 2005 used LPS to induce TLR4 
expression in HaCaT cells, suggesting that bacterial components such as LPS may 
trigger a TLR related response in this cell line. It thus appears that S. pyogenes 
interferes with these signalling systems and disrupts the host AMP response. The 
molecular mechanisms regulating LL-37 expression are poorly described but 
computational analysis of the hCAP 18 promoter has identified a number of potential 
transcription factor binding sites, including Spl, PU-l and C/EBP amongst others, 
indicative of complex regulatory systems (Elloumi and Holland 2008). To date nothing 
is known of the signalling systems regulating LEAP-2 expression although the 5' 
flanking sequence of the chicken gene is characterised by a potential NF-KB binding site 
(Lynn, Lloyd et al. 2003; Townes, Michailidis et al. 2004). The data from the challenge 
experiments suggested that LEAP-2 expression was up-regulated in the streptococcal 
challenged HaCaT cells indicative of increased transcription, peptide synthesis and a 
host innate response. However as no peptide levels were measured it cannot be 
discounted that the S. pyogenes blocked mRNA translation and thus peptide synthesis. 
Both the MI and M2 serotypes of S. pyogenes have been identified in the throat 
(Tyrrell, Lovgren et ai. 2002). The initial bacterial challenge experiments in this study 
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were performed using the M 1 serotype as it had been well characterised and was known 
to bind HaCaT cells in a pili-dependant manner (Abbot, Smith et al. 2007). To 
investigate whether the host AMP response was affected by the S. pyogenes serotype 
the challenge experiments were repeated but using the M2 serotype, which has 
increased numbers of pili. Binding of the M2 serotype to the HaCaT cells, although 
SUbjective, appeared comparable to that of MI. HBD 1 and HBD2 gene expression 
profiles were different to what was observed in M 1 infections as no difference was seen 
in expression compared to the uninfected control cells after a total of 6 hours of 
infection. The LEAP-2 expression profile was also different in that no significant up-
regulation of gene expression was detected. Because nothing is known of the signalling 
systems regulating LEAP-2 expression it is difficult to explain or indeed comment on 
this novel result, but the two serotypes will probably provide useful tools for future 
studies investigating the pathways controlling LEAP-2 expression. 
The choice of the HaCaT cells for use in the in vitro experiments investigating AMP 
gene expression was directed by the fact that the cells bound S. pyogenes and modelled 
the tonsil. Once the AMP expression patterns in relation to streptococcal binding were 
determined the experiments were repeated but using the pili-defective mutants I'1.spyl29 
and I'1.spy1l54, that were unable to bind to the HaCaT cells (Figure 5.21). These 
experiments, performed to determine whether streptococcal binding was necessary to 
elicit an AMP response, indicated that the reduction in HBD 1 mRNA expression 
following the streptococcal challenge· was in fact pili-independent. Moreover as 
I'1.spyl154 also lacked surface proteins such as adhesins, it was also deduced that such 
proteins were not involved in regulating HBD 1 gene expression. The LEAP-2 
expression data was complicated by the large error bars associated with the control and 
wild-type columns and no statistically significant differences were observed between 
uninfected control cells and both wild-type and mutant streptococci. The identity of the 
streptococcal factor or factors responsible for initiating the changes in HBD 1 mRNA 
expression is not known, but it is possible that secreted molecules, for example SIC or 
streptococcal specific proteases playa role. 
In summary, HaCaT cells were adopted as an in vitro model of the tonsil to investigate 
the effects of S. pyogenes MI and M2 serotypes on host AMP gene responses. This cell 
line was selected specifically as previous investigations had shown it to model tonsil-
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streptococcal interactions. The quantitative real-time expression data suggested that in 
response to the S. pyogenes M 1 serotype HBD 1 gene expression were decreased, 
HBD2 and LL-37 gene expression was unchanged and that of LEAP-2 was induced. 
The results of challenge experiments performed using pili-defective mutants also 
suggested that such changes in the host response occurred in the absence of 
streptococcal binding. The mechanisms by which S. pyogenes causes such effects are 
not known but the HaCaT cells provide a good model for such studies. HaCaT cells are 
not however derived from tonsil. Thus to further investigate streptococcal-tonsil AMP 
responses it was decided to utilise the ex vivo tonsil model developed by Abbot, Smith 
et al (2007). 
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Figure 5.1: HEp-2 cells: xlOO Magnification. Cell membrane is stained with Phalloidin-Rhodamine, an 
actin stain (shown in red). The cells show the typical appearance of a monolayer of epithelial cells. 
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a) 2 3 4 
500bp 
200bp 
b) 
Query: 5 caacactctcgtcatgtttcanggtttttatttctttcttcggcagcattttcggccacg 64 
111111111111111111111 11111111111111111111111111111111111111 
Sbjct : 449 caacactctcgtcatgtttcagggtttttatttctttcttcggcagcattttcggccacg 390 
Query: 65 cgtcgagcacttgccgatctgttcctcctttggaaggcagctgagcacagcacaccggcc 124 
1111111 111 1111111111111111111111111111 11111 11111111111111111 
Sbjct: 389 cgtcgagcacttgccgatctgttcctcctttggaaggcagctgagcacagcacaccggcc 330 
Query: 125 gcctctgactctgcaataatatttctgtaatgtgtttatgattcctccatgaccaggaac 1 84 
1111 1111 11111111111111 111 11111111 11111 1111 111111111111 11111 
Sbjct: 329 gcctctgactctgcaataatatttctgtaatgtgtttatgattcctccatgacctggaac 270 
Query : 185 a 185 
Sbjct: 269 a 269 
Figure 5.2: a) Agarose ge l results showing peR products amplified from cDNA reverse transcribed from 
HEp-2 cell RNA with HBD3 (lane I) and HBDl (lane 2-3) specific primers. (Product size is 
approximately 200bp for HBDl and 180bp for HBD3). M: Size marker (lane 4) . b) Sequence analysis 
performed by BLAST (http://www.ncbi.nlm.nih.gov/blastiBlast.cgi) matched the cloned HBD3 product 
(query) to the Genbank sequence (sbjct) for HBD3 with 98% identity. 
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a) 
t 
b) 
Query : 1 
Sbjct : 20 
Quer y : 61 
Sbjct: 80 
Query : 121 
Sbjct : 140 
Query : 181 
Sbjct : 200 
Query : 241 
Sbjct: 260 
Query : 301 
Sbjct: 320 
Query: 361 
Sbjct ! 379 
t t 
HEp-2 peR products M 
gccactccctggggcgg t ggtcactggtgctcctgc t gctgggcctggtgatgcc t ctgg 60 
11 11 111111 11 11111111111111 11 1 11 1 1 11111111111111111111111111 1 
gccactccctggggcggtggtcactggtgctcctgctgc t gggcc tggt gatgcctctgg 79 
ccatcattgcccaggtcc tcagc t acaaggaagc t gtgc t tcgtgctataga t ggca t ca 120 
11111 11 1111 1 1 1 1 11111 11111 1 11 1111111 1 1111 1 1 1111111111 111 11 1 11 
ccatcattgcccaggtcctcagctaca aggaagctgtgcttcgtgctatagatggcatca 1 39 
accag c ggtcctcggatgctaacctctaccgcctcctggacctggaccccaggcccacga 180 
1 11 11111111111111111 1 1 1 111111111 11 1 11 11 1 11 1 111111111 1 1 1111 11 
accagcggtcctcggatgctaacctctaccgcctcctggacctggaccccaggcccacga 199 
tggatggggacccagacacg ccaaagcctgtgagc t tcacagtgaaggagacagtgtgcc 240 
1 111 1111 11 1 1 11111 111111 111111 1111 1 1 1 11 11111111 1 111111 1111 111 
tggatggggacccagacacgccaaagcctgtgagcttcacagtgaaggagacagtgtgcc 259 
ccaggacgaca cagcagtcaccagaggattgtgacttcaagaaggacgggctggtgaagc 300 
1 111 11 11 111111 111111 1111111111 11 1 1 111111 1 1 1 1111111 1 1 11 111111 
ccaggacgacacagcagtcaccagaggattgtgacttcaagaaggacgggctggtgaagc 319 
ggtgtatggggacagtgaccctcaaccaggccaggggctcctttg acatcag t tgtgata 360 
11 11 111 11 1 1 11111 1111111 11111111 1 11 1 1111 1 1 11 1 11 11 1 1111 1 11111 
ggtgtatggggacagtgaccctcaaccaggccaggggctcctttgaca t cagttgtgat- 378 
aaggataacaagaagatttgccctgctgggtgat t tctttcccggaaatctaaagagaag 420 
1111 1 111 11 11 1111 1111111 111 1 11111111111 1 1 1 1 11111 111 111 111 1 
aaggataacaag-agatttg ccctgctgggtgatt t ctt--ccggaaatctaaagagaag 4 35 
Query : 421 attggcaaa 429 
111111 11 1 
Sbjct : 436 attggcaaa 444 
Figure 5.3: a) Agarose ge l results showing peR products amplified from cDNA reverse transcribed from 10 
HEp-2 cell samples with LL-37 specific primers (product size is approximate ly 500bp). M: size marker. b) 
Sequence ana lysis performed by BLAST (http: //www.ncbi .nlm.nih .govlb lastiBlast.cgi) matched the c loned 
sequence (query) to the Genbank sequence (sbjct: subject) for LL-37. 
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a) GAPDH 1 2 3 4 5 6 7 8 9 10 11 12 
1Kb 983bp 
b) LL-37 1 2 3 4 5 6 7 8 9 10 11 12 
500bp ~518bp 
c) LEAP-2 1234 5 678 91011121314 
200bp 
161bp 
Figure 5.4 GAPDH, LL-37, LEAP-2 expression in HaCaT cells: Agarose gel results showing RT-PCR 
products amplified with GAPDH, LL-37 and LEAP-2 specific primers. 
a) GAPDH PCR products: 1: Size marker; 2 & 3: untreated control cells; 4: cells treated with 1,25 
dihydroxyvitamin-D3; 5: cells treated with LTA; 6 & 7: cells treated with LPS; 8 & 9: cells treated with 
PMA; 10 & 11: cells treated with a combination of all treatment agents; 12: no template control. 
b)LL-37 PCR products: 1: Size marker; 2 & 3: untreated control cells; 4: cells treated with 1,25 
dihydroxyvitamin-D3 (a PCR product at approximately 500bp can be observed); 5 & 6: cells treated with 
PMA; 7 & 8: cells treated with LPS; 9 & 10: cells treated with a combination of all treatment agents; 11: 
cells treated with LTA; 12: no template control. 
c) LEAP-2 PCR products: I: Size marker, 2 & 3: untreated control cells; 4: cells treated with 1,25 
dihydroxyvitamin-D3; 5 & 6: cells treated with LPS; 7 & 8: cells treated with PMA; 9: cells treated with 
LTA; 10 & 11: cells treated with a combination of all treatment agents, 12 & 13: negative control no reverse 
transcriptase); 14: negative control (no template). 
Gels were performed once. Each test treatment was performed 1-2 times. 
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i) 2-6 hours 
LL-37 12 3 4 56 7891011 1213141516 
500bp 
518bp 
i) 2-6 hours Ii) 22 hours 
HBD1 1 2 3 4 56 7891011 121314151617 2 3 4 5 6 7 8 9 10 
200bp .... 
. _--- - " - - ' ...... -- +- 221bp ..... .. - ... .. 200bp 
HBD2 
i) 2-6 hours Ii) 22 hours 
1 2 3 4 5 6 7 8 9 1011121314 15 2 3 4 5 6 7 8 
300bp .- ... ,.. . . ... ,. ... +-324bp 300bp .... . . - . . - '"'-." - 324bp 
. -
I) 2-6 hours 
HBD3 123456 7 8 9 10 II 12 1314 151617 
Ii) 22 hours 
2 3 4 5 6 7 8 
200bp 200bp 
180bp 
... - ..... +-180bp 
Hepcidin I) 2-6 hours 
200bp 
LEAP-2 
200bp 
GAPDH 
1Kb 
123456 
.- .... .. .. 
. 
i) 2-6 hours 
i) 2-6 hours 
7891011 1213 1415 16 17 
186bp 
+-161bp 
Ii) 22 hours 
1 Kb 
983bp 
Figure 5.5: Representative RT-PCR results following challenge of HaCaT cells with 03. For all gels lane I is a size marker. 
LL-37 (518bp): i) 2-3 : 2 hour, control cells; 4-6: 2 hour, treated cells: 7-8 : 4 hour, control cells: 9- 11 : 4 hour, treated cells; 12- 13: 6 hour. 
control cells; 14-15: 6 hour, treated cells; 16: no template control. 
HBDI (22 Ibp): i) 2-3: 2 hour. control cells; 4-6: 2 hour, treated cells; 7-8: 4 hour, control cells; 9- 1 I : 4 hour, treated cells; 12-13: 6 hour. 
control cells; 14-16: 6 hour. treated cells; 17: no template control. ii) 2-4: 22 hour, control cells; 5-7: 22 hour, treated cells. 
HBD2 (324bp): i) 2-4: 22 hour. control cells; 5-7: 22 hour. treated cells; 8-9: HaCaT cells treated with 1, 25 dihydroxyvitamin-03 from a 
previous experiment; 10: no template control. ii) 2-4: 22 hour, control cells: 5-7: 22 hour, treated cells; 8: no template control. 
HBD3 (180bp): i) 2-3 : 2 hour, control cells; 4-6: 2 hour, treated cells; 7-8 : 4 hour, control cells; 9-11 : 4 hour, treated cells; 12-13 : 6 hour. 
control cells: 14-16 : 6 hour, treated cell s; 17: no template control. ii) 2-4 : 22 hour, control cells; 5-7: 22 hour. treated cells; 8: no template 
control . 
Hepcidin (l86bp): i) 2-3 : 2 hour. control cells: 4-6: 2 hour. treated cells; 7-8: 4 hour. control cells; 9-10: 4 hour. treated cells; 11-12: 6 
hour. control cells; 13-15 : 6 hour, treated cells; 16: no template control. 
LEAP-2 (16Ibp) i) 2: 2 hour, control cells; 3: 2 hour. treated cells; 4: 4 hour, control cells; 5: 4 hour. treated cells; 6: 6 hours, control 
cells; 7: 6 hours, treated cells. 
GAPDH (983bp): i) 2-3 : 2 hour, control cells; 4-6: 2 hour, treated cells ; 7-8: 4 hour. control cells; 9- 11 : 4 hour, treatr4..c);lls ; 12-13 : 6 
hour, control cells; 14-16: 6 hour, treated cells; 17 : no template control. ii) 2-4: 22 hour. control cells; 5-7: 22 hour, tltM~-Id cells. 
Gels were performed once. Each test was performed 2-3 times except for LEAP-2 samples for which treatment was performed only on 
one sample. 
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Figure 5.6: Densitometry analysis of AMP gene expression after treatment with 1,25 dihydroxyvitamin-D3. All 
data normalised to GAPDH and expressed as a percentage of control. All values represent mean ± SEM. Statistical 
analysis was performed with one way ANDV A followed by a Bonferroni post-test. * * = P<O.O I. n: number of 
samples analysed. Analysis of each gel was performed once. 
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2000l-'m 2 hours 
Figure 5.7: S. pyogenes binding control showing HaCaT cells after 2 hours of infection with 
S. pyo~enes, MI serotype (wild-type) expressing recombinant GFP plasmid (shown in green). 
HaCaT cells are visualised under transmitted light. (x20 magnification). 
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Figure 5.8: LL-37 expression in S. pyogenes infected HaCaT cells: 
a) & b) Representative 2% agarose gel showing separation of LL-37 (5 I 8bp) and GAPDH (983bp) PCR 
products generated from DNA template which was reverse transcribed from RNA extracted from control HaCaT 
cells, HaCaT cells infected with S. pyogenes, MI serotype and HaCaT cells treated with D3. I: Size marker; 2-
3: uninfected control cells; 4-5: HaCaT cells infected with S. pyogenes for 2H; 6-7: HaCaT cells infected for 4H-
8-9: cells infected for 6H; 10: cells treated with D3 for 2H; II: no template contro l. ' 
c) Graph shows data from densitometry analysis from the gels, normalised to GAPDH and expressed as a 
percentage of control. All values represent mean ± SEM. 
Statistical analysis was performed by one way ANOV A followed by a Dunnett's Post-test. 
Gels were performed once, 5 biological repeats were performed per infection time point. 191 
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Figure 5.9: HBDI expression in S. pyogenes infected HaCaT cells: 
9 10 11 
6H 
4 
+- 983bp 
a) and b) Representative 2% agarose gel showing separation of HBDI (22Ibp) and GAPDH 
(983bp) PCR products generated from DNA template which was reverse transcribed from RNA 
extracted from control HaCaT cells, HaCaT cells infected with S. pyogenes, MI serotype and 
HaCaT cells treated with D3 . I: Size marker; 2-3: un infected control cells; 4-5: HaCaT cells 
infected with S. pyogenes for 2H; 6-7: HaCaT cells infected for 4H; 8: cells infected for 6H; 9: 
cells treated with D3 for 2H; 10: no template control. 
b) I: Size marker; 2-3: uninfected control cells; 4-5: HaCaT cells infected with S. pyogenes for 2H; 
6-7: HaCaT cells infected for 4H; 8-9: cells infected for 6H, 10: cells treated with D3 for 2H. 
c) Graph shows data from densitometry analysis from the gels, normalised to GAPDH and 
expressed as a percentage of control. All values represent mean ± SEM. ** = P<O.O I 
Statistical analysis was performed by one way ANOVA followed by a Dunnett's Post-test. 
Gels were performed once, 4-5 biological repeats were performed per infection time pcMM· 
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Figure 5.10: HBD2 expression in S. pyogenes infected HaCaT cells: 
6H 
5 
+.--- 983bp 
a) & b) Representative 2% agarose gel showing separation ofHBD2 (324bp) and GAPDH (983bp) 
PCR products generated from DNA template which was reverse transcribed from RNA extracted 
from control HaCaT cells, HaCaT cells infected with S. pyogenes, MI serotype and HaCaT cells 
treated with D3. I : Size marker; 2-4: un infected control cells; 5-7: HaCaT cells infected with S. 
pyogenes for 2H; 8-10: HaCaT cells infected for 4H; 11-13: HaCaT cells infected for 6 H; 14-16: 
HaCaT cells infected and treated with D3 for 2H; 17-19: HaCaT cells treated with D3 for 2H; 20: 
no template control. 
c) Graph shows data from densitometry analysis from the gels, normalised to GAPDH and 
expressed as a percentage of control. All values represent mean ± SEM. ** = P<O.O I 
Statistical analysis was performed by one way ANOVA followed by a Dunnett's Post-test. 
Gel a) was performed once, gel b) was performed 3 times. 5 biological repeats were performed 
per infection time point. 
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Figure 5.11: HBD3 expression in S. pyogenes infected HaCaT cells: 
6H 
5 
a) & b) Representative 2% agarose gel showing separation of HBD3 (180bp) and GAPDH (983bp) 
PCR products generated from DNA template which was reverse transcribed from RNA extracted 
from control HaCaT cells, HaCaT cells infected with S. pyogenes, MI serotype and HaCaT cells 
treated with D3 . I : Size marker; 2-4: uninfected control cells; 5-7: HaCaT cells infected with S. 
pyogenes for 2H; 8-10: HaCaT cells infected for 4H; 11-13: HaCaT cells infected for 6 H· 14-16: 
HaCaT cells infected and treated with D3 for 2H; 17-19: HaCaT cells treated with D3 fdPfu; 20: 
no template control. 
c) Graph shows data from densitometry analysis from the gels, normalised to GAPDH and 
expressed as a percentage of control. All values represent mean ± SEM. 
Statistical analysis was performed by one way ANOV A followed by a Dunnett's Post-test. 
Gel a) was performed once, gel b) was performed 3times. 5 biological repeats were performed per 
infection time point. 
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Figure 5.12: Hepcidin expression in S. pyogenes infected HaCaT cells: 
a) & b) Representative 2% agarose gel showing separation of Hepcidin (I 86bp) and GAPDH 
(983bp) PCR products generated from DNA template which was reverse transcribed from RNA 
extracted from control HaCaT cells, HaCaT cells infected with S. pyogenes, MI serotype and 
HaCaT cells treated with D3. I: Size marker; 2-4: uninfected control cells; 5-7: HaCaT cells 
infected with S. pyogenes for 2H; 8-10: HaCaT cells infected for 4H; 11-13: HaCaT cells infected 
for 6 H; 14-16: HaCaT cells infected and treated with D3 for 2H; 17-19: HaCaT cells treated with 
D3 for 2H; 20: no template control. 
c) Graph shows data from densitometry analysis from the gels, normalised to GAPDH and 
expressed as a percentage of control. All values represent mean ± SEM. 
Statistical analysis was performed by one way ANOV A followed by a Dunnett's Post-test. 
Gel a) was performed once, gel b) was performed 3 times. 4-5 biological repeats were performed 
per infection time point. 197 
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Figure 5.13: LEAP-2 expression in S. pyogenes infected HaCaT cells: 
a) & b) Representative 2% agarose gel showing separation of LEAP-2 (161 bp) and GAPDH 
(983bp) PCR products generated from DNA template which was reverse transcribed from RNA 
extracted from control HaCaT cells, HaCaT cells infected with S. pyogenes, MI serotype and 
HaCaT cells treated with D3 . I: Size marker; 2-3: uninfected control cells; 4-5: HaCaT cells 
infected with S. pyogenes for 2H; 6-7: HaCaT cells infected for 4H; 8-9: cells infected for 6H; 10: 
cells treated with D3 for 2H. 
b) I: Size marker; 2-3: uninfected control cells; 4-5: HaCaT cells infected with S. pyogenes for 2H; 
6-7: HaCaT cells infected for 4H; 8-9: cells infected for 6H; 10: cells treated with D3 for 2H; 11: 
no template control 
c) Graph shows data from densitometry analysis from the gels, normalised to GAPDH and 
expressed as a percentage of control. All values represent mean ± SEM. 
Statistical analysis was performed by one way ANOV A followed by a Dunnett's Post-test. 
Gels were performed once, 4-5 biological repeats were performed per infection time po\ft~ 
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Figure 5.14: AMP gene expression patterns of control cells and cells treated with 1,25 dihydroxyvitamin-D3 for 2 hours . Densitometry results. Values are 
expressed as % of control. Statistical analysis was performed using an unpaired T -test. n = 3 samples analysed for control and treated cells, i.e. three 
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Figure 5.15: Expression ofLL-37 mRNA in HaCaT cells infected with S. pyogenes for 2,4 and 6 hours and 
treated with 1,25 dihydroxyvitamin-D3. All values represent mean ± SEM. Statistical analysis was 
performed using a one way ANDY A followed by a Dunnett's post-test. n=3 for all groups, i.e. three 
biological repeats were performed per test. Real-time PCR analysis was performed once in quadruplicate. 
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Figure 5.16: Expression of HBD1, HBD2 and LEAP-2 mRNA in HaCaT cells infected for 2, 4 and 6 hours with S. pyogenes, M l serotype (wild-type). 
Real-time PCR resul ts are normalised to GAPDH and expressed as a percentage of control. All values represent mean ± SEM. Statistical analysis was 
performed by one way ANOV A fo llowed by a Dunnett's post-test. * = P<O.05 compared to control, ** = P<O.O 1 compared to control. n: number of samples 
analysed, i.e. 5-8 biological repeats were used per test. Real-time PCR analysis was performed once in duplicate. 
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Figure 5.17: Binding control results 
showing HaCaT cells after 5, 15,30 and 
60 minutes of infection with S. pyogenes, 
Ml serotype (wild-type) expressing 
recombinant GFP plasmid (shown in 
green). HaCaT cells have been incubated 
with Phalloidin-TRITC (shown in red). 
Images are representative of images 
obtained each time an experiment was 
performed. Images are xl 00 
magnification. 
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Figure 5.18: Real-time PCR results showing expression ofHBDI, HBD2 and LEAP-2 mRNA in HaCaT cells infected 
with S. pyogenes, MI serotype (wild-type) for 5, 15,30 and 60 minutes. Results were normalised to GAPDH and 
expressed as a percentage of control. All values represent mean ± SEM. Statistical analysis was performed by one way 
ANOVA followed by Dunnett's post-tests. n: number of samples analysed, i.e. between 4-7 biological repeats were 
performed per test. Real-time PCR analysis was performed once in duplicate. 
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Figure 5.19: Binding control 
results showing HaCaT cells 
after 5, 30 and 60 minutes, 2, 4 
and 6 hours of infection with S. 
pyogenes M2 serotype (wild-
type) expressing recombinant 
GFP plasmid (shown in green). 
HaCaT cells have been stained 
with Phalloidin-TRITC (shown 
in red). Images are 
representative of those obtained 
-..J 2 Hours 4 Hours 6 Hours each time an infection was ;:, performed. Images are xl 00 ~ 
magnification. 
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Figure S.20: Real-time PCR data showing expression of HBDl, HBD2 and LEAP-2 in HaCaT cells infected with S. pyogenes 
M2 serotype (wild-type). Data was normalised to GAPDH and expressed as a percentage of control. All values represent mean 
± SEM. * = P<O.05 compared to control. Statistical analysis was performed using a one way ANOV A followed by a Dunnetts 
:5 post-test. n: number of samples analysed as shown on graphs, i.e. between 3-6 biological repeats were performed in each test. 
Jl Replicates are from two challenge experiments. Real-time PCR analysis was performed once, in duplicate. 
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Figure 5.21: Binding control results showing HaCaT cells after 6 hours of infection with S. pyogenes MI serotype wild-type and pili-defective 
mutants ~spyl29 and ~spy1154 expressing recombinant GFP plasmid (shown in green). HaCaT cells have been stained with Phalloidin-TRITC 
(shown in red). Images are representative of those obtained each time an infection was performed. Images are xlOO magnification. 
N 
o 
01 
..-
0 
~ 
..... 
c 
0 
u 
-0 
~ 0 
--« 
z 
a: 
E 
-0 
c 
0 
·w 
en 
Q) 
~ 
a. 
x 
UJ 
IV 
o 
-....I 
1 
1 
a HBD1 b LEAP-2 
60-1 .-rn ** --~ 
** 
C WT 129 1154 C WT 129 1154 
Type of S. pyogenes Type of S. pyogenes 
n= 4 3 3 4 n= 3 3 3 4 
Figure 5.22: Real-time peR results for a six hour incubation of HaeaT cell with control cells (e), and the S. pyogenes M1 strain, 
wild-type (wt) and pili-defective mutants L1spy129 (129) and L1spyl154 (1154). Data was normalised to GAPDH and expressed as a 
percentage of control. All values represent mean ± SEM. ** = P<O.Ol compared to control. Statistical analysis was performed using 
one way ANOVA followed by a Dunnett's post-test. n: number of samples analysed, i.e. between 3-4 biological repeats were 
performed for each test. Real-time peR analysis was performed once in duplicate. 
Chapter 6 
Antimicrobial Peptide Gene Expression in Human 
Palatine Tonsils 
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6.1 Introduction 
In the previous chapter the immortalised HaCaT cell line, used as an in vitro model of 
the tonsil epithelium, was challenged with streptococci and the effects of such 
challenges on AMP gene expression examined by real-time PCR. The resultant data 
suggested that in vitro, streptococci were able to affect HaCaT AMP gene expression 
patterns, with LL-37, HBDI and HBD2 gene expression reduced and LEAP-2 gene 
expression increased in response to as. pyogenes Ml serotype challenge. These data 
therefore suggested that the S. pyogenes Ml serotype, a causal agent in tonsillitis, can 
modulate and consequently evade the host innate AMP response. 
It is acknowledged that HaCaT cells are not tonsil derived but if similar effects were to 
occur in the tonsil per se then it may in part help explain the pathogenicity of the S. 
pyogenes Ml serotype in recurrent acute tonsillitis. Thus it was proposed to investigate 
the effects of streptococci on AMP gene expression in human palatine tonsils, and 
specifically to compare the patterns of AMP gene expression in tonsils excised from 
control (non-RAT) subjects and RAT patients challenged with the S. pyogenes MI and 
M2 serotypes. 
To facilitate such investigations the tonsil ex vivo model, developed and optimised by 
the group in Newcastle to study streptococcal binding and infection, was adopted 
(Abbot, Smith et al. 2007). In this model system freshly isolated samples of human 
palatine tonsil were cultured on filter supports with the apical surface partly exposed to 
the atmosphere. This technique allowed the conditions within the airways, where the 
tonsils are situated, to be mimicked. 
Thus the aims of this part of the study were to use this ex vivo tonsil model, reproducing 
the environment of the pharynx, to investigate and compare the effects of S. pyogenes 
MI and M2 challenges on the AMP gene expression patterns in human tonsils excised 
from control (non-RAT) subjects and RAT patients. 
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6.2 AMP Gene Expression in Human Tonsils Treated With 
Environmental Agents 
The quantitative antimicrobial peptide gene expression data relating to tonsils removed 
from control (non-RAT) subjects and RAT patients was presented in Chapter 4. In the 
Chapter 4 study the RNA used in the analyses was extracted from large segments of 
either epithelial or lymphoid tissue, however in this study the tonsil sections used in the 
ex vivo model were only 3 x 3mm in size and predominantly epithelial tissue. Thus the 
initial experiments were performed to demonstrate that the AMP gene expression 
profiles of such small amounts of tonsil material could be determined, and to investigate 
if potential changes in gene expression could be detected. For the latter experiments the 
same reagents as described previously i.e. D3, L T A, LPS and PMA were used. 
The challenge experiments were performed as described in Section 2.2.4. Briefly fresh 
human tonsils were dissected into 3 x 3mm sections and incubated apical side up for 
three hours in a tissue culture dish containing tonsil media with gentamicin (200llg mr 
I), to kill any bacteria on the tonsil surface. The tonsil samples were washed in PBS to 
remove any residual antibiotics before being placed apical side up in the upper chamber 
of a Transwell culture insert (O.4llm pore size). Medium without antibiotics was added 
to the lower chamber of the Transwell, thus immersing basolateral surfaces of the tonsil, 
but leaving the apical surface exposed to the atmosphere. Challenge reagents (D3 
(200nM), LTA (from S. pyogenes, 21lg/ml), LPS (0.2Ilg/ml) and PMA (20IlM)) were 
added directly to the exposed apical surface of the tonsil. Following incubation for a 
pre-determined time period, total RNA was isolated from each of the tonsil sections, 
DNase treated, reverse transcribed into cDNA and analysed as appropriate by real-time 
PCR. 
The challenge experiments were performed using seven different tonsils, two from 
control (non-RAT) subjects and five from RAT patients. As observed previously 
(Chapter 4), the levels of AMP gene expression between tonsils could be very variable 
and thus to improve accuracy two to four replicates of each sample were analysed by 
real-time peR. As previously all target gene expression values were normalised to the 
house-keeping gene GAPDH. Statistical analyses were performed using one way 
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ANOVA followed by Bonferroni post-tests used as described in 4.2ii or paired T-tests, a 
statistical test which is suitable for samples before and after treatment, as advised in the 
Prism statistics guide (Motulsky 2003). 
The results of the D3 , L T A, LPS and PMA challenge experiments are shown in Figures 
6.1- 6.4, and these data confirmed that AMP gene expression could be detected and 
quantified in the small tonsil tissue sections used in the ex vivo model system. 
The data relating to LL-37 gene expression is presented in Figure 6.1. Within the 
control (non-RAT) tonsil group none of the treatments had a statistically significant 
effect on gene expression. Moreover in relation to the PMA data, which was associated 
with a large SEM, it was noted that one LL-37 expression value in particular was at 
variance being 5-6 times greater than the four other values in the group. Statistical 
analyses of the data relating to the tonsils from RAT patients indicated none of the 
treatments had a significant effect on LL-37 gene expression although again the data 
was variable and characterised particularly by four values indicative of very high LL-37 
mRNA expression. 
Analyses of the HBDI data within the control (non-RAT) and RAT groups (Figure 6.2) 
identified no statistically significant differences between gene expression in the 
unchallenged and challenged tonsil samples. Moreover the expression patterns 
identified in relation to the control (non-RAT) and RAT samples analysed for HBD2 
(Figure 6.3) and LEAP-2 (Figure 6.4) expression were similar and not statistically 
significant. 
Overall these data indicated that AMP gene expression in the tonsil sections could be 
quantified, but that treatment of tonsils from either control (non-RAT) subjects or RAT 
patients with D3, LTA, LPS or PMA did not affect AMP gene expression significantly. 
As noted previously the levels of AMP gene expression within a particular challenge 
experiment were often quite variable. As the challenge studies used tonsils from a 
number of individuals it was feasible that such variability was linked to the responses of 
individual tonsils. 
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To consider this further the data was re-plotted in bar charts, focussing on the 
expression data relating to individual tonsil samples and their responses to treatment 
with the agents i.e. D3, LTA, LPS or PMA. These data are presented in Figures 6.5-8. 
It can be determined from statistical analysis of the data represented in this way that 
once again no statistically significant differences were seen between control (untreated) 
tonsil samples and those samples which had been incubated with any of the treatment 
agents. Although it is acknowledged that the data was constrained by the numbers of 
tonsils analysed e.g. only two control tonsils were used and by the low numbers of 
samples of each tonsil analysed, i.e. in many cases there was only one gene expression 
value per individual tonsil. 
None the less these data did support the use of the ex vivo model to investigate and 
compare the effects of a streptococcal challenge on the expression of the AMP genes in 
tonsils excised from control (non-RAT) subjects and RAT patients. However it was 
recognized that for the results to have significance, the numbers of tonsils could not be 
limiting and that for each tonsil more than one section per challenge was required. 
Moreover the use of the ex vivo model allowed the effects S. pyogenes on tonsil AMP 
expression patterns to be investigated directly. 
6.3 Expression of Antimicrobial Peptide Genes in Human 
Tonsils Infected with S. pyogenes M1 Serotype (Wild-type) 
In the HaCaT - S. pyogenes challenge experiments, the down-regulation of HBD I 
mRNA, and the up-regulation of LEAP-2 mRNA were observed after four to six hours 
of streptococcal infection. Thus in the following experiments the tonsil samples were 
incubated with S. pyogenes Ml for two, four and six hours respectively. The S. 
pyogenes (2 x 107 cfu), were added directly to the exposed apical surface of the tonsil. 
Importantly at each time point the experiments included both control (non-infected) and 
infected tonsil samples. In addition samples from each tonsil were used as binding 
controls. These controls were always sampled following two hours of incubation with 
S. pyogenes and provided confirmation that the bacteria had bound successfully to the 
tonsil. 
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For the bacterial challenge experiments tonsil sections from a total of 13 tonsils, three 
control (non-RAT) (TA-C) and ten RAT (TA-J), were used. In all experiments bacteria 
bound to the tonsil sections indicative of a streptococcal infection (Figure 6.9). 
6.3.1 Real-time peR data: all samples 
The tonsil samples were analysed for LL-37, HBD1, HBD2 and LEAP-2 gene 
expression by real-time PCR. All data was normalised to GAPDH and expressed as a 
percentage of control. Statistical analysis was performed using a paired T -test as 
described in 6.2 or a one way ANOVA followed, where appropriate, by Bonferroni 
post-tests as described in 4.2ii. It should be noted that the sample size for some time 
points was small, because only three control (non-RAT) tonsils were used in these 
experiments. 
The LL-37 expression data following streptococcal infection of the tonsils from control 
(non-RA T) subjects and RAT patients is presented in Figure 6.10. The mean data 
relating to both the control (non-RAT) and RAT tonsils was indicative of no statistically 
significant changes in LL-37 mRNA expression levels following two, four or six hours 
of incubation with S. pyogenes. 
Figure 6.11 shows the HBD 1 expression data. In the control (non-RAT) tonsils a 
statistically significant (P<O.OI) difference was identified between the mean HBDI 
expression in the non-challenged and the two hour S. pyogenes infected tonsil samples. 
In fact the mean data suggested a three-fold increase in HBDI expression. A 
comparable increase was not observed in the RAT tonsils. No differences in HBD 1 
gene expression were detected at either four or six hours of infection respectively in 
either the control (non-RAT) or RAT tonsil tissue sections. 
The HBD2 mRNA expression data is presented in Figure 6.12. After four hours of 
infection respectively, the mean data relating to the control (non-RAT) tonsils suggested 
a reduction in HBD2 expression to 58±14 and 23±7% of control values which was 
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statistically significant (P<O.05). Differences between control tissues and infected 
tissues were however not statistically significant at either two or six hours. 
HBD2 expression levels of the RAT tonsil sections exhibited no statistically significant 
differences after either two or four hours of infection respectively, although the latter 
time-point was skewed by two data points indicative of very high HBD2 mRNA 
expression, which related to one particular tonsil (sample TA; Figure 6.16). 
Figure 6.13 illustrates the data relating to the effects of a S. pyogenes M 1 serotype 
infection on LEAP-2 expression in tissue sections from control (non-RAT) and RAT 
tonsils. In both control (non-RAT) and RAT tonsils no differences were suggested 
between control and infected samples at each time point and this was confirmed 
statistically. 
These data were re-plotted in a bar chart format to show the response of individual 
tonsils (Figures 6.14-6.17). Once again no statistically significant differences can be 
observed between the control tonsil samples and the infected tonsil samples in both the 
control (non-RAT) and RAT tonsils. It can be observed that the data again, as with the 
experiment involving the treatments (Figures 6.5-6.8) illustrates the problems associated 
with using limited numbers of tonsil samples, and the variable responses of the 
individual tonsils. For example the HBD2 response of RAT tonsil TA to the 
streptococcal challenge (Figure 6.16 HBD2 RAT 4h), was very high compared to the 
values of the six other tonsil samples. Similarly the LEAP-2 expression pattern of RAT 
tonsil sample TD was contradictory when compared to those of other RAT tonsils 
(Figure 6.17). 
Overall AMP expression patterns of control (non-RAT) and RAT tonsils in response to 
as. pyogenes Ml challenge were identified and these are summarised in Table 6.1. 
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Table 6.1: Expression of AMPs in control (non-RAT) and RAT tonsils after 2, 4 and 6 hours of infection 
with S. pyogenes. 
Control 
2h 4h 6h 
LL-37 +-+ +-+ +-+ 
HBDI i +-+ +-+ 
HBD2 +-+ ! +-+ 
LEAP-2 +-+ +-+ +-+ 
..... No statJsllcally slgmficant difference In gene expressIOn compared to control 
! Statistically significant decrease in gene expression compared to control 
t Statistically significant increase in gene expression compared to control 
RAT 
2h 4h 
+-+ +-+ 
+-+ +-+ 
+-+ +-+ 
+-+ +-+ 
6.4 Expression of Antimicrobial Peptide Genes in Human 
Tonsils Infected with S. pyogenes M2 Serotype (Wild-type) 
As described previously the S. pyogenes M2 serotype, also known to be involved in the 
pathology of recurrent acute tonsillitis, is characterised by increased numbers of surface 
pili. In Chapter 5, it was shown that challenging the HaCaT cell line with the two 
different serotypes did not appear to affect the AMP expression profiles of the cells, 
except for LEAP-2, where the mean expression data showed a significant increase in 
LEAP-2 expression in response to the MI serotype but not in response to the M2 
serotype (Figure 5.20). Challenging the control (non-RAT) tonsils with the MI 
serotype also supported an increase in LEAP-2 expression at two hours post infection. 
Thus to determine and compare the effects of the S. pyogenes M2 serotype on tonsil 
AMP expression patterns, and specifically LEAP-2 expression, the bacterial challenge 
experiments were repeated using the ex vivo model and the S. pyogenes M2 serotype. 
This investigation used four control (non-RAT) tonsils. Each tonsil tissue sample was 
incubated with the S. pyogenes M2 serotype (2 x 107 cfu), for either two or four hours 
respectively and, as previously, unchallenged control samples were included at each 
time-point. Quantification of expression was performed using the real-time PCR 
assays, target gene expression normalised to GAPDH and expressed as a percentage of 
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control. Statistical analysis was performed by one way ANOV A and followed by a 
Bonferroni post-test where appropriate. 
Tissue sections from each tonsil were also used as binding controls. These controls 
were sampled following two hours of incubation with the S. pyogenes M2 serotype and 
provided confirmation that the bacteria had bound successfully to the tonsil. The data 
confirming binding of the S. pyogenes M2 serotype to each of the four tonsils (M2TC 1-
4) is presented in Figure 6.18. In all cases GFP-tagged bacteria (green) adhered to the 
tonsil section (red) indicative of infection. 
6.4.1 Real-time PCR- all samples 
The results of the quantitative AMP mRNA expression analyses are shown in Figures 
6.19 and 6.20 respectively. 
The LL-37 expression data following S. pyogenes M2 infection of the tonsils excised 
from control (non-RAT) subjects is presented in Figure 6.19a, and the mean data was 
indicative of no changes in LL-37 mRNA levels following either two or four hours of 
incubation with the bacteria. The data was however compromised by the small number 
of values at each time point, especially in relation to the four hour control (non-RAT) 
samples challenged with streptococci, and the variability of the data. 
Figure 6.19b shows the LEAP-2 expression data. Again no significant changes were 
identified in LEAP-2 expression following the S. pyogenes M2 serotype challenge and 
no obvious trends were observed. 
The HBD 1 and HBD2 mRNA expression data are presented in Figures 6.20a and b 
respectively. No significant changes were identified in the expression of either gene 
following the S. pyogenes M2 serotype challenge. However the mean AMP gene 
expression values in response to the S. pyogenes M2 serotype challenge were often 
associated with large SEM bars. This variability was evident when the expression data 
from the individual tonsils was presented in a bar chart format (Figures 6.21-6.24). For 
216 
example at two hours the LL-37 gene expression value relating to tonsil M2TCI in 
response to the streptococcal challenge «20% control) was at odds with those observed 
for tonsils M2TC2 and M2TC3 (-100%) respectively (Figure 2.21). Similarly at two 
hours the HBD2 mRNA expression data (Figure 6.23) relating to tonsils M2TCI and 
MCTC2 «5% control) were reduced compared to that recorded for tonsil M2TC3 
(>150%). 
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6.5 Discussion 
In Chapter 5 HaCaT cells were adopted as an in vitro model of the tonsil to investigate 
the effects of S. pyogenes Ml and M2 serotypes on host AMP gene responses. The 
quantitative real-time expression data suggested that in response to the S. pyogenes Ml 
serotype HBDI gene expression were decreased. As described previously HaCaT cells 
are not derived from tonsil. However if, for example, such patterns were observed in 
the tonsils of RAT patients but not control (non-RAT) subjects then it could explain the 
susceptibility of the former to infection and recurrent acute tonsillitis. Thus to further 
investigate streptococcal-tonsil AMP responses it was decided to utilise the ex vivo 
tonsil model developed by Abbot, Smith et al (2007). This model was developed 
originally by the group in Newcastle to explore S. pyogenes Ml-tonsil binding 
interactions and it has the distinct advantage of utilising tonsil material directly. 
Moreover the model involves sectioning each tonsil which provides, potentially, large 
numbers of samples although in practise the number of sections was actually 
constrained by the size of the tonsil and the amount of intact surface epithelia. A major 
disadvantage was that the tissue sections were not homogeneous. 
Experiments in which the HaCaT cells were challenged with D3, resulted in the up-
regulation ofLL-37 gene expression. When the D3 challenge was repeated using the ex 
vivo model no statistically significant changes in LL-37 gene expression were observed 
in tonsil sections from either control (non-RAT) subjects or RAT patients. Similarly 
treatment with L T A, LPS and PMA did not significantly affect the AMP gene 
expression profiles of the tonsils. It is known that vitamin D, synthesised in skin, is able 
to regulate immune defences (Liu, Stenger et al. 2006; Zasloff 2006). Indeed the active 
vitamin D metabolite, D3, has been shown to up-regulate cathelicidin gene expression 
in macrophages exposed to Mycobacterium tuberculosis, but interestingly to down-
regulate the transcription of the pro-inflammatory mediators IFNy and TNFa 
(Martineau, Wilkinson et al. 2007). Moreover Vitamin D deficiency in humans has 
been associated with reduced innate immune function and it has been proposed that 
antibiotic treatments of infections should be accompanied by Vitamin D 
supplementation (Zasloff 2007). 
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The mechanisms by which D3 could potentially down-regulate LL-37 gene expression 
are not known. Moreover the regulation of the cathelicidin gene is still poorly 
characterised, but it is of interest that regions mediating gene repression have been 
identified within the hCAP 18 gene promoter (Elloumi and Holland 2008). Interestingly 
the commensal S. salivarius K12, known to protect the host against pathogens causing 
throat infections, ensures its survival in the mouth, by down-regulating inflammatory 
responses and thus the innate immune response, by inhibition of the NF-KB pathway 
(Cosseau, Devine et al. 2008). 
The incidence of tonsillitis within the population indicates that S. pyogenes is a 
successful pathogen. It is known to overcome host innate defences, including cationic 
AMPs, through the synthesis of proteins including SIC (Frick, Akesson et al. 2003); 
SpeB (Schmidtchen, Frick et al. 2002) and GRAB (Nyberg, Rasmussen et al. 2004), 
which can inactivate the host defence peptides. Indeed of these SIC, is known to bind 
to and inhibit LL-37 as well as HBDI-3 activities (Fernie-King, Seilly et al. 2006). In 
addition there is evidence that SIC is taken up by human epithelial cells causing cell 
flattening and loss of the microvilli (Hoe, Ireland et al. 2002), which presumably 
damages the epithelial barrier and further weakens the host antimicrobial defences. 
The results of the S. pyogenes Ml challenge study showed a statistically significant 
difference in the HBDI AMP gene expression profiles of tonsils excised from control 
(non-RAT) subjects, with the levels of HBD 1 expression increased in the control tonsils 
in response to the streptococcal infection after two hours. There was also a statistically 
significant reduction in HBD2 expression in the control (non-RAT) tonsils (Figure 6.12) 
following four hours of infection, which supports the ability of S. pyogenes to weaken 
the tonsil AMP epithelial defences. Moreover as HBD2 is also known to bind to CCR6 
and induce the chemotaxis of either memory T-cells or immature dendritic cells (Yang, 
Chertov et al. 1999), its reduced synthesis in the tonsil would presumably cause a delay 
in the signalling to, and recruitment of, antigen presenting cells (APC). Again in vivo 
this would favour the survival of the streptococci. 
It was of note that the fall in HBD2 gene expression in the tonsils in response to the S. 
pyogenes Ml challenge was also observed in the HaCaT cells. Taken together these 
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data support, potentially, S. pyogenes targeting the mechanisms regulating tonsil HBD2 
gene expression. The tonsil is known to express an array of TLR genes (1-10) 
(Lesmeister, Bothwell et al. 2006), and it is presumed that HBD2 gene expression in the 
tonsil is activated through a TLR2 mediated mechanism, which in keratinocytes has 
been shown to involve P38, JUNK, ERK and NF-KB signalling pathways (Chung and 
Dale 2004). The mechanism by which S. pyogenes switches offHBD2 gene expression 
is not known but potentially involves disruption of one of the signalling pathways. To 
investigate whether the effects of streptococci on HBD2 gene expression were actually 
mediated through a TLR2 signalling pathway it would be interesting to repeat the tonsil 
challenge experiments in the presence ofTLR2 antibody. 
The skin and tonsils are two major sites of streptococcal infection and both have been 
shown to express the HBD3 gene (Harder, Bartels et al. 2001; Ball, Siou et al. 2007). 
This suggests that HBD3 may be particularly effective in the defence of the host against 
streptococci, and thus it was disappointing that no HBD3 mRNA expression data was 
available in this study. Recently it has been reported that the capacity of keratinocytes 
to kill Staphylococcus aureus is dependent on the constitutive synthesis of HBD3 
(Kisich, Howell et al. 2007). With this in mind, and the fact that, the RNA samples 
arising from the tonsil challenge studies are still available, it would be of interest to 
analyse these samples for patterns of HBD3 gene expression. 
The S. pyogenes M2 challenge results were disappointing and did not reveal any 
statistically significant differences in AMP gene expression patterns between the two 
sets of tonsils. Moreover the numbers of tonsils, and thus tonsil sections, used were 
small and it was difficult to detect potential patterns. In addition the small numbers 
further emphasised the variability of the data. 
Indeed the results of the studies described in this Chapter were characterised by large 
standard errors caused by the variability in AMP expression values measured between 
individual tonsils, and between sections derived from individual tonsils. This variability 
was caused by very elevated or low expression values, and combined with the low 
sample numbers probably masked potential changes in the AMP expression patterns. 
The reasons for the variable data are not known, but the tonsils used in the studies were 
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all from different individuals and as such the data is comparable to that observed in the 
clinical study reported in Chapter 4. 
Quantification of AMP expression was performed using the real-time PCR assays 
developed in Chapter 3. Although these assays were a common factor between the 
studies described in Chapter 4 and here in Chapter 6 respectively, the observed 
variability was not due to either intra- or inter-assay errors as each sample was assayed 
in duplicate (sometimes quadruplicate), and test standards were included in all analyses. 
One possibility for the variability between the tonsil sections was due to each epithelial 
section having a different amount of lymphoid tissue attached to it as a result of the 
dissection i.e. the samples were not homogeneous. As such it could be argued that the 
AMP expression data was biased by the proportion of epithelial and lymphoid tissue. 
However the results of the study presented in Chapter 4, did not support this as the 
epithelial and lymphoid tissues appeared to express AMPs at a similar levels within the 
control (non-RAT) and RAT groups. None the less the effects of either necrotic or 
scarred tissue on the AMP expression data, or perhaps the presence of a lymphoid 
follicle on the AMP expression levels could not be excluded entirely. The length of 
time from the excision of a tonsil to dissection was also considered as influencing AMP 
gene expression, but this was unlikely as all the tonsils were immersed in tonsil medium 
within one hour of excision. 
It is acknowledged that the surgery to excise the tonsils, the dissection of the epithelium 
from the tonsils and the sectioning of the tonsil per se may have caused inflammatory 
re~ponses that affected the expression of the AMP genes. While it has been reported that 
the APC derived cytokines IL-12, IL-23 and IL-27 enhance HBD2 secretion and mRNA 
expression in keratinocytes functioning through NF-KB, STAT3 and STATI signalling 
pathways (Kanda and Watanabe 2008), the effects of other inflammatory factors on 
AMP gene expression are not known. For this reason it could be argued that the ex vivo 
model, while mimicking the moisture lined airways where the tonsils are situated, and 
an excellent model for investigating the mechanisms by which streptococci bind to 
tonsil, was not as ideal for studying the tonsil AMP responses resulting from such 
binding. However, a superior tonsil model has yet to be reported. 
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Following challenge of the control (non-RAT) and RAT tonsil sections with S. 
pyogenes, a statistically significant increase in HBD 1 gene expression and a decrease in 
HBD2 gene expression were observed in the control (non-RAT) tonsils. No comparable 
statistically significant changes were identified in the RAT tonsils although there was 
the suggestion of a reduction in HBD2 expression. These data therefore highlight 
differences between the AMP expression profiles of the control (non-RAT) and RAT 
tonsils in response to a S. pyogenes Ml challenge. Although speculative these data 
indicate that the RAT tonsils were less able to respond to the S. pyogenes challenge, 
which may in part help to explain the susceptibility of RAT patients to infection. 
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Figure 6.17: LEAP-2 Gene Expression: Real-time PCR data showing LEAP-2 mRNA expression in human tonsil incubated for two, four and six 
hours with S. pyogenes Ml serotype using the ex vivo model. Control samples were incubated in normal tonsil media (C) and all tonsils (TA-J) were 
infected with S. pyogenes. Data was normalised to GAPDH and expressed as a percentage of control. n = number of samples analysed in total from 3 
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with Group A Streptococcus (G) for 2 (2H) or 4 (4H) hours. Data is normalised to GAPDH and expressed as a percentage of control. n = number 
of tonsil sections analysed from a total of 4 control (non-RAT) tonsils. Statistical analysis was performed by a one way ANOVA followed by a 
Bonferroni post-test. All values represent mean ± SEM. Real-time PCR analysis was performed once, each samples was assayed in duplicate 
except for LL-37 which was assayed in quadruplicate. 
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Figure 6.20: Real-time PCR data showing (a) HBDI and (b) HBD2 mRNA expression in all human tonsils incubated for 2 and 4 hours (2H and 
4H) with S. pyogenes M2 serotype (wild-type) using the ex vivo tonsil model. Expression is shown in control (C) and cells infected with Group A 
Streptococcus (G). Data is normalised to GAPDH and expressed as a percentage of control. n= number of tonsil sections analysed in total from 4 
control (non-RAT) tonsils. Statistical analysis was performed by a one way ANOV A followed by a Bonferroni post-test. All values represent 
mean ± SEM. Real-time PCR analysis was performed once. Each sample was assayed in duplicate. 
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Figure 6.21: LL-37 Gene Expression: Real-time PCR data showing LL-37 mRNA expression in human tonsil incubated for (a) two and (b) four hours with 
-.) S. pyogenes M2 serotype using the ex vivo model. Control samples were incubated in normal tonsil media (C) and all tonsils (M2TCI-4) were infected with S. 
t pyogenes. Data was normalised to GAPDH and expressed as a percentage of control. n = number of samples analysed in total from 4 control (non-RAT) 
tonsils. Statistical analysis was performed by a one way ANOV A followed by a Bonferroni post-test. All values represent mean ±SEM where appropriate. 
Real-time PCR analysis was performed once, each sample was assayed in quadruplicate. 
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Figure 6.22: HBDI Gene Expression: Real-time PCR data showing HBDI mRNA expression in human tonsil incubated for (a) two and (b) four hours with 
S. pyogenes M2 serotype using the ex vivo model. Control samples were incubated in normal tonsil media (C) and all tonsils (M2TCl-4) were infected with S. 
pyogenes. Data was normalised to GAPDH and expressed as a percentage of control. n = number of samples analysed in total from 4 control (non-RAT) 
tonsils. Statistical analysis was performed by one way ANOV A followed by a Bonferroni post-test. All values represent mean ±SEM where appropriate. Real-
time PCR analysis was performed once, each sample was assayed in duplicate. 
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Figure 6.23: HBD2 Gene Expression: Real-time PCR data showing HBD2 rnRNA expression in human tonsil incubated for (a) two and (b) four hours with 
S. pyogenes M2 serotype using the ex vivo model. Control samples were incubated in normal tonsil media (C) and all tonsils (M2TCl-4) were infected with S. 
pyogenes. Data was normalised to GAPDH and expressed as a percentage of control. n = number of samples analysed in total from 4 control (non-RAT) 
v tonsils. ~tistical analysis was performed by a one way ANOV A followed by a Bonferroni post-test. All values represent mean ± SEM where appropriate. 
~ Real-time'l>CR analysis was performed once, each sample was assayed in duplicate. 
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Figure 6.24: LEAP-2 Gene Expression: Real-time PCR data showing LEAP-2 mRNA expression in human tonsil incubated for (a) two and (b) four hours 
with S. pyogenes M2 serotype using the ex vivo model. Control samples were incubated in normal tonsil media (C) and all tonsils (M2TCI-4) were infected 
with S. pyogenes. Data was normalised to GAPDH and expressed as a percentage of control. n = number of samples analysed in a total of 4 control (non-RAT) 
tonsils. Statistical analysis was performed by one way ANOVA followed by a Bonforroni post-test. All values represent mean ± SEM where appropriate. 
Real-time PCR analysis was performed once, each sample was assayed in duplicate. 
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Humans are constantly exposed to an array of micro-organisms, some of which are 
innocuous but others can cause infection and death. Therefore the ability of the host 
to sense pathogenic microbes and to respond appropriately to control infection is 
pivotal to survival. Indeed delayed detection and killing of pathogens contributes to 
overwhelming infections, inflated systemic responses, tissue damage and in many 
cases organ dysfunction. A better understanding of the disease process may therefore 
be achieved by studying and comparing the immune response of subjects either 
susceptible or resistant to specific diseases. 
The innate immune system has evolved as the first line of defence against invading 
pathogens. It plays a critical role in destroying pathogens by not only pinpointing the 
location of a potential infection, instigating the host challenge but also signalling to 
the adaptive immune response. The recognition of potential pathogenic micro-
organisms is through receptors on eukaryote cells that recognise conserved pathogen-
associated molecular patterns shared by different classes of micro-organisms. One 
consequence of the triggering of such receptors is the production of host defence 
peptides of which cationic antimicrobial peptides (AMPs) are part. These small, 
structurally diverse, molecules function as the body's 'natural antibiotics,' displaying 
broad spectrum antimicrobial activity against a range of microbes including Gram-
positive and negative bacteria. Their cationic charge targets them specifically to 
microbes and their hydrophobicity allows them to integrate into the microbial 
membrane causing depolarisation and death. This killing mechanism ensures that 
microbes are killed rapidly, thus preventing the onset of infection. Moreover these 
molecules have evolved to play a role in mediating inflammation through the 
stimulation of chemotaxis and wound repair (Bowdish, Davidson et al. 2006). 
The human palatine tonsils play important roles in host immunity and provide a 
barrier against invading pathogens. However the Gram-positive bacterium, 
Streptococcus pyogenes often penetrates these defences resulting in the disease 
tonsillitis, in which sufferers present with swollen and painful palatine tonsils. 
Moreover the infection is often recurrent. Despite tonsillitis being relatively common, 
the immunological factors that allow this infection to perpetuate remain obscure, and 
in particular the roles of the AMPs in tonsillitis are not well documented. Thus the 
results of the studies presented in this thesis were designed to test the hypothesis that 
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a defect in the innate immune response involving host AMPs, IS a cause or 
contributory factor to recurrent acute tonsillitis (RAT). 
To address this, the first study, AMP gene expression patterns in palatine tonsils 
excised from patients undergoing tonsillectomy for RATto those of control subjects 
whose tonsils were excised for conditions such as snoring were compared (Chapter 4). 
It was the largest investigation of its kind to date and used over ninety tonsils. The 
data indicated that all the AMP genes examined i.e. LL-37, HBDl, HBD2 and LEAP-
2, were expressed, but disappointingly that the mean AMP expression levels between 
the RAT and control groups were not statistically different. However considerable 
variability was detected between the AMP expression levels of individual subjects 
and as the AMP expression data was pooled this meant that any patterns relating to 
actual individuals were lost. 
Allelic variants of genes involved in the innate response have been shown to influence 
an individual's susceptibility to infection (Hill 2001). In the future it would be of 
interest to take each individual RAT and control tonsil, and to examine and compare 
the LL-37, HBD1, HBD2 and LEAP-2 AMP profiles. This, possibly, would allow 
patterns between individuals in the RAT and control groups to be revealed e.g. a 
group of RAT patients may present with reduced HBD2 and LL-37 gene expression 
but HBD 1 and LEAP-2 mRNA levels comparable to those of the control. If so this 
may indicate, potentially, the synergistic activities of peptides in protecting against a 
S. pyogenes infection. The real-time assay to quantify HBD3 gene expression was at 
the time of these analyses not working efficiently. As HBD3 has been shown to have 
streptococcal killing activities (Harder, Bartels et al. 2001), it would be valuable to 
have the HBD3 gene expression data, however as RNA samples from each of the 
tonsils are available this is still feasible. 
In addition it would be practical to genotype the patient samples to explore potential 
single nucleotide polymorphisms (SNPs) in the AMP genes and their promoters that 
might increase the susceptibility of certain individuals to RAT. In humans it is also 
known that polymorphisms in the TLRs, which attenuate receptor signalling, can also 
enhance the risk of infection (Bochud, Hawn et al. 2003). As mentioned previously 
the RNA samples from each of the RAT and control tonsils are still available so it 
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would also be valuable to analyse the TLR gene expression patterns, particularly 
those relating to TLR2 and TLR4, in these samples. Again in future analyses it would 
be beneficial to genotype for TLR polymorphisms and establish whether populations 
with increased susceptibility to RAT are characterised particularly by specific 
polymorphisms in genes encoding molecules involved in the innate immune response. 
It could be argued that the patient study, as presented, was flawed as it was conducted 
using tonsils excised from RAT patients at the time of their surgery when they were 
probably not suffering a streptococcal infection. Thus at this time it might be 
predicted that no differences in AMP gene expression between RAT and control 
tonsils would be revealed. Therefore, to answer the question of whether RAT was 
due to a failure of the AMP genes to up-regulate expression in response to infection, 
an in vitro model was adopted. The HaCaT cell model was selected as interactions 
observed between the HaCaT cells and S. pyogenes mimicked those of the tonsil and 
the bacterium (Abbot, Smith et aI, 2007). Moreover it was found that the HaCaT 
AMP expression profile was similar to tonsil, although characteristically of 
keratinocyte derived cells, the LL-37 gene expression levels were very low. 
The results of the experiments using this model cell line, described in Chapter 5, 
indicated that HBD 1 gene expression was reduced following a S. pyogenes challenge, 
suggesting that the pathogen was inhibiting or down-regulating AMP gene 
expreSSiOn. The mechanisms by which this occurred is not known but investigations 
to unravel the signalling pathways would naturally be the next stage for this work. 
Such analyses could be performed using either chemical and/or immunological 
inhibitors of components of known signalling pathways. This work could be carried 
out in a model cell line first, therefore only one cell type would be encountered 
initially making results clearer to analyse. 
Previous observations have indicated that pili are necessary for S. pyogenes to bind to 
tonsils. The studies reported in this thesis with the pili-defective mutants indicated 
that binding and colonisation is not necessary for an antimicrobial peptide response to 
take place and that it is the proximity of the streptococci to the cells that causes an 
immune response rather than direct binding through pili. This is exciting and it 
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suggests that additional investigations using such mutants are essential to explore this 
further. 
The HaCaT cells, although an appropriate model for the in vitro studies, were not 
derived from tonsil. To further investigate streptococcal-tonsil AMP responses the ex 
vivo tonsil model developed here in Newcastle was used (Abbot, Smith et al. 2007). 
The data from these studies described in Chapter 6, highlighted differences between 
the AMP expression profiles of the control (non-RAT) and RAT tonsils in response to 
as. pyogenes Ml challenge. Although speculative these data suggested that the RAT 
tonsils were less able to respond to the S. pyogenes challenge, which may in part help 
to explain the susceptibility of RAT patients to infection. However the data was very 
variable and raised questions as to whether the model, as is, provided a good enough 
in vitro system for studying the tonsil AMP responses in response to streptococci. 
The reasons for the variability have already been discussed in Chapter 6, and include 
the fact that the AMP expression data between actual individuals is very different. 
Thus as the model does allow the responses of actual tonsil tissue to be studied in 
response to a live streptococcal infection, and as a superior tonsil model has not been 
reported, it can be argued that it provides a unique, and suitable system for our 
investigations. However in future it is possible that primary or indeed immortalised 
tonsil derived cell lines will be established to facilitate such investigations. 
In the studies reported in Chapter 6, only AMP gene expressIOn profiles were 
examined. However AMPs are only a part of the tonsil innate defences and do not 
work in isolation. As RNA from the streptococcal challenge experiments is stored it 
would be possible to analyse the nucleic acid material for other immune responses, for 
example, using the Applied Biosystems TaqMan immune array. This array includes 
96 gene targets associated with the immune response and inflammation, and profiling 
the data from RAT and control tonsils may allow the recognition of unique transcripts 
encoding proteins playing key roles in the tonsil defence pathways. 
It is acknowledged that gene expression relates only to what is happening at a 
molecular level. However the results of previous studies in Newcastle (Ball, Siou et 
ai, 2007), using tonsil sections and immunohistochemical analyses suggested that the 
amounts of the HBDI and 3, and LL-37 peptide were reduced in the tonsils of RAT 
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patients compared to control subjects. Thus potential future investigations should also 
aim to quantify actual peptide concentrations either through ELISA and/or 
immunohistochemistry. 
The studies reported in this thesis have focused specifically on S. pyogenes. Using the 
ex vivo model it would also be of interest to challenge the tonsils with other potential 
oral pathogens and investigate the innate responses. This in turn may allow us a 
better understanding of the disease process operating in recurrent acute tonsillitis. 
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